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ABSTRACT 
 
 
 Health-related quality of life is an important phenomenon to measure in children 
undergoing treatment for cancer. However, the effects of different treatment modalities 
and cancer related factors over the duration of treatment have not been explored. To 
assess the effects of different child-, cancer-, and treatment-related factors, we analyzed a 
large sample of children undergoing curative treatment for 5 different childhood cancer 
diagnoses. These diagnostic groups were Hodgkin Lymphoma (HL), Acute 
Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Osteosarcoma (OS ), 
and Melanoma. We analyzed a sample of 710 patients across the five diagnostic groups 
over four time-points in treatment. These time-points reflected significant clinical events 
that reflected change in the intensity or modality of treatments.  
 
Our analysis identified significant changes across different diagnostic groups and 
over time in HRQOL of children undergoing curative cancer treatments. Time in 
treatment was a significant predictor of change in HRQOL, with children reporting 
higher HRQOL scores at the end of treatment in comparison to the beginning of 
treatment. Demographic variables including age, gender, and race predicted significant 
changes over time in children. Other treatment related variables including risk group and 
surgery predicted change in HRQOL domains and cancer-related symptoms in children 
undergoing curative cancer treatment.  
 
Multiple cancer-related symptoms have been identified to significantly predict 
HRQOL in children across the different diagnostic groups.  These symptoms were also 
predicted by different demographic, treatment, and cancer related factors. Some of these 
symptoms including pain and hurt, and nausea did not regain the same level at the end of 
treatment in comparison to the beginning of treatment, indicating residual effects of 
treatment on children with cancer even at the end of treatment. 
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CHAPTER 1.    INTRODUCTION 
 
 
 Problem  
 
Health-related quality of life (HRQOL) is a complex phenomenon measuring 
domains of the person’s general health and well-being. The aim of studying HRQOL is to 
specifically identify and quantify subjective aspects of social, emotional, physical, and 
psychological well-being.1 Measurement of HRQOL among patients during an illness 
experience is an important means of evaluating the quality and outcomes of healthcare.2–5 
Since the introduction of the concept, researchers have defined, conceptualized, and 
measured HRQOL in various patient populations. Measurement of HRQOL has led to the 
identification of factors that impact the patient reported outcome (PRO) and HRQOL. 
However, progress in understanding and measuring HRQOL has been hindered by the 
ambiguous use of the term in describing the phenomena. HRQOL has been measured as a 
representation of an individual’s health status, physical functioning, symptoms, 
psychosocial adjustment, well-being, life satisfaction, and happiness. In addition, 
measurement of HRQOL across diseases and treatment modalities make it difficult to 
draw comparisons between populations. As a result of disease and treatment variability, 
comparing HRQOL findings across studies or making implications to clinical practice is 
difficult.6 
 
The illness experience in children with cancer varies across cancer diagnoses due 
to different treatment modalities associated with disease risk and biology. Numerous 
factors have been identified as impacting HRQOL in children with cancer and include 
demographic, socio-economic status, cancer diagnosis, biology, treatment intensity and 
duration of treatment. Therefore, in assessing the illness experience of children 
undergoing curative cancer treatment, there is a need to consider aspects that extend 
beyond the measures of treatment response and survivorship. The modalities and 
intensity of treatment make it important to also measure the subjective experience of the 
child undergoing cancer treatment. This subjective cancer experience can best be 
measured through HRQOL measures. In addition, treatment modalities impact the 
patient’s general well-being and health, both short term during curative treatment and 
long term into adult survivorship. Thus, children who undergo multiple or more intensive 
treatment modalities generally report decreased well-being and lower HRQOL.7–9 
 
Time is an important variable that impacts HRQOL during treatment. Therefore, 
HRQOL should be measured over time, as children and adolescents progress in treatment 
and into survivorship. While evidence from childhood cancer survivors’ studies describe 
stable HRQOL throughout the survivorship trajectory,10 results from HRQOL studies in 
children undergoing curative treatment describe variability by diagnosis and time. The 
association of HRQOL and time has been measured inconsistently, with studies 
measuring HRQOL at variable time points during and after the completion of treatment. 
Many HRQOL studies are limited to a cross-sectional design, only measuring HRQOL at 
a single time point in therapy within a specific cancer diagnostic group. These studies 
also included a limited number of factors that were measured with variable scales and 
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instruments, leading to an incomplete and inconsistent understanding of the effect of time 
on the HRQOL experience.  
 
Given the current state of knowledge, the overall aim of this study is to address 
some limitations of HRQOL research in children with cancer by measuring longitudinal 
trends of change in HRQOL within a large sample, across diagnoses and time, using a 
widely used and valid instrument. Through this study, we also aim to identify and 
quantify the factors affecting HRQOL across diagnoses and time.  
 
 
Background 
 
 
Childhood Cancer 
 
Cancer is the leading cause of death from disease among children in developed 
countries. An estimated 12,060 new cases were expected to occur among children ages 0 
to 14 in 2012. The most common childhood cancer is acute lymphoblastic leukemia 
(ALL), followed by cancers of the brain and central nervous system (CNS). Together, 
these cancers account for more than 50% of the new cases of childhood cancer in the US, 
with consistent trends in the European Union and most other countries.11  
 
Over the last decades, there has been a marked improvement in the cure and 
survival rates, with mortality rates declining by 66% over the past four decades to a 2.2 
per 100,000 in 2008.11 This decline in mortality is due to the development of highly 
specific diagnostic tests and improvement in treatment modalities and supportive care. 
However, children with cancer continue to develop severe side effects from intensive 
treatments including manifestation of physical, cognitive, emotional, psychological and 
social changes, either during treatment or later in life.12 More specifically symptoms 
within these domains may include nausea, vomiting, pain, fatigue, anxiety, cancer worry, 
and body image. Measuring these patient reported outcomes requires the use of self-
reported measures in addition to the objective diagnostic indicators of tumor and 
treatment burden, thus allowing capture of the subjective and objective illness 
experience. Therefore, the utilization of HRQOL instruments to assess the subjective 
patient reported outcomes is important during the illness experience.  
 
 
Health-Related Quality of Life in Children with Cancer 
 
The measurement of HRQOL in children with cancer has evolved over several 
decades; from measurement of the patients’ physical limitations to now include measures 
of physical, social, emotional, and psychological functioning.  
 
However, the need to capture the child’s self-reported firsthand experience 
remains the preferred method of HRQOL outcomes research. The utilization of reliable 
and valid instruments for measuring HRQOL among age groups allows researchers to be 
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confident that the concepts of interest are being consistently measured through the child’s 
self-report of HRQOL during treatment, thus resulting in an improved understanding of 
factors that affect HRQOL during the illness experience across time. These factors 
include demographic, socio-economic status, diagnosis, treatment intensity and time in 
treatment.13–15 The identification of these factors allowed the development of 
interventions mediating these factors in children with cancer.1,14,16 
 
 Despite progress in improving HRQOL in children with cancer, most published 
studies provide incomplete information describing the impact of time and treatment. The 
majority of studies only assess single diagnostic groups of children with cancer, include 
small sample sizes, utilize a cross sectional design, measure a limited number of 
treatment factors, which limits the ability to report change in HRQOL over time. Most 
treatment regimens extend for months to years; however, the current HRQOL evidence 
does not describe the change in HRQOL through these treatments. The lack of evidence 
of factors impacting HRQOL over time leads to an incomplete understanding of the 
illness experience of children with cancer, and thus hinders the development of 
interventions that can address HRQOL mediating factors in real-time.  
 
 
Significance 
 
The assessment of HRQOL describes the subjective experience of the patient 
during an illness experience. HRQOL data have been shown to provide significant 
predictive power of survival in some patient groups and is comparable to the traditional 
indicators of tumor burden, tumor response, and other clinical factors.17,18 In a study of 
patients with advanced lung cancer, global HRQOL scores obtained immediately before 
diagnosis were the most significant predictors of the length of survival, even after 
adjusting for known prognostic factors.18,19  
 
The measurement of HRQOL offers a unique perspective on the benefit-burden 
ratio from the patient’s view. Successful treatments have led to the development of 
neuropsychological, physical, social, and emotional late effects that continue with 
survivors through their lives.20 In addition, research on HRQOL provides evidence to 
support policymakers allocation of health care resources and mandated reimbursement 
policies.4,21 
 
The need for HRQOL assessment and measurement can also be recognized when 
two treatment regimens have equal outcomes. Such situations may lend weight to the 
treatment regimen that yields the higher HRQOL during treatment.17 This may be 
especially beneficial in children with cancer in which the overall survival is excellent and 
the differences in survival between treatment regimens are not significantly different. As 
a result, HRQOL information may add value when one treatment produces higher 
survival rates than another, but is more toxic, particularly when the average survival time 
is short.17 Furthermore, treatments that extend life while impairing HRQOL may not be 
worthwhile from the patient’s perspective. Therefore, an important reason to assess 
HRQOL is to understand how an existing or novel treatment impacts an individual’s 
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functioning in the context of improvement in long-term survival. Similarly, if a new 
treatment is being compared with an existing standard of care (SOC), inclusion of a 
measure of HRQOL allows for comparison, especially if there is existing knowledge of 
the impact the SOC has on HRQOL.20  
 
These findings reinforce the importance of collecting HRQOL data, and have led 
clinicians and researchers to consider HRQOL of patients with cancer as essential when 
measuring patients’ response to treatments. The mounting evidence supporting the 
importance of collecting and measuring HRQOL in patients, along with a growing patient 
advocacy movement, led the National Cancer Institute (NCI) as well as other funding 
agencies to strongly recommend that outcome measures for cancer treatment include 
measuring HRQOL.22,23 The US Food and Drug Administration (FDA) has named 
patient-reported outcomes (PROs) including HRQOL as an important end point for 
approval of new anticancer drugs, which led most cooperative groups to integrate 
HRQOL research into hundreds of treatment protocols. The pharmaceutical industry has 
also started to include HRQOL end points in phase II to phase IV trials.20 These findings 
and recommendations support the call for enhanced utilization and collection of HRQOL 
information as an important end-point and outcome of treatment. 
 
 
Conceptual Framework 
 
An important limitation in HRQOL is the lack of consensus on a conceptual 
framework to guide the researchers’ understanding and study of HRQOL in children.24 
This limitation may explain the variation in items and domains measured in pediatric 
HRQOL instruments. To overcome these obstacles, literature from both adult oncology 
and the childhood epilepsy field was synthesized to develop the conceptual model for this 
HRQOL study in children undergoing cancer treatment. This model explains the 
relationship between factors that will be explored in this study. Figure 1-1 presents the 
inclusive HRQOL conceptual model that identifies all proposed factors affecting HRQOL 
in children under treatment. It also presents the abbreviated model that describes factors 
measured and included in this study. This study examined the biomedical/treatment 
factors as independent factors, and the child factors as mediating factors. 
 
The inclusive conceptual model (Figure 1-1) identifies four domains that define 
HRQOL in children with cancer. These domains are a) the biomedical/treatment, b) 
environmental, c) child, and d) outcome. The biomedical/treatment domain is represented 
by two sets of factors, the cancer variable and the treatment variable. These factors 
represent the first insult to the child’s HRQOL. The child’s perception of change in 
HRQOL may be positively or negatively affected by the environmental domain which 
includes factors from the family and community. Depending on these variable 
characteristics, the child may find a strong support system of family and friends, or face 
uncertainty and stress due to lack of such support. The last domain is the child domain. 
This domain describes the understanding that children interact and perceive their illness 
in a unique and different perspective than their family or community and this perspective 
is influenced by the child’s age, gender, and ethnicity.  
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Figure 1-1. Conceptual model of HRQOL in children with cancer 
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For this study, the final adapted model is depicted in solid lines. This model 
includes three domains: 1) biomedical treatment, 2) child, and 3) outcome. While the 
larger conceptual model identifies the importance of the environmental domain on 
HRQOL of children, our study did not include collection of data that would describe this 
domain.  
 
 
The Biomedical/Treatment Domain 
 
The factors within the biomedical/treatment domain impact the disease risk stage 
and define the modality of treatments used, thus impacting the child’s HRQOL. This 
domain is further categorized into cancer and treatment factors.  
 
Cancer Factors. Cancer factors in the proposed model include cancer diagnosis, 
and cancer stage or risk. Relapsed disease is not included within the model, as patients 
with relapse were taken off study. 
 
Treatment Factors. Treatment factors include treatment side effects or cancer-
related symptoms, time in treatment, treatment intensity, and type of treatment. Time in 
treatment was measured at specific important treatment time points dictated by the 
treatment modality and length of treatment protocol. The data for this study were 
collected from patients over multiple time points (from the initiation of treatment through 
treatment and at the completion of treatment). In addition, the modality of treatments 
used (i.e., radiotherapy, chemotherapy, surgery, immunotherapy and stem cell 
transplantation) were identified for each diagnostic group.  
 
 
Child Domain 
 
The Child Domain included age, gender, and ethnicity. Age was measured as 
child age in years at the time of diagnosis. Ethnicity was self-reported and included 
Asian, Caucasian, Black, Hispanic, and Other. However, the categorization of ethnicity 
was divided to White versus other ethnicities due to the small sample size of ethnic 
groups outside of white. For descriptive purposes, Black ethnicity will be listed but will 
be included within the other ethnicities for analysis. 
 
 
Outcome Domain 
 
The outcome domain was assessed using the Pediatric Quality of Life Scale-
Generic core scale (PedsQL-Generic) and the Pediatric Quality of Life Scale-Cancer 
(PedsQL-Cancer) modules. These instruments measured three categories of HRQOL 
outcomes: physical, emotional, and social functioning. All three outcome categories were 
measured using content items within the instrument.  
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Specific Aims 
 
 
Aim 1   
 
To identify longitudinal trends in HRQOL change in diagnostic groups of 
children undergoing curative cancer treatment. 
 
? Research Question 1-1: What is the self-reported HRQOL of children 
undergoing curative cancer treatment within each diagnostic group at each time 
point? 
 
? Research Question 1-2: What is the difference in self-reported HRQOL of 
children undergoing curative cancer treatment at each time point within each 
diagnostic group? 
 
 
Aim 2   
 
To identify the differences in HRQOL among different diagnostic groups of 
children undergoing curative cancer treatment. 
 
? Research Question 2-1: What is the difference in self-reported HRQOL of 
children undergoing curative cancer treatment between different diagnostic 
groups at each time point? 
 
 
Aim 3   
 
To identify correlates with HRQOL of children undergoing curative cancer 
treatment over time within each diagnostic group. 
 
? Research Question 3-1: Is there an association between cancer and treatment 
factors and self-reported HRQOL of children undergoing curative cancer 
treatment over time?  
 
? Research Question 3-2: What is the combined effect of cancer and treatment 
factors on the self-reported HRQOL of children undergoing curative cancer 
treatment in each diagnostic group? 
 
? Research Question 3-3: What are the associations between each variable and the 
change in self-reported HRQOL of children undergoing curative cancer 
treatment? 
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Assumptions 
 
 Study assumptions are made regarding the sample and the efficacy of the 
collected data included: 
 
1. Children are able to adequately and accurately provide an assessment of their 
HRQOL.  
 
2. A child’s self-report of their HRQOL is the most accurate report of their 
perceived HRQOL during an illness experience. 
 
3. Other factors not included in the conceptual framework have a negligible effect 
on the child’s HRQOL during treatment. 
 
 
Limitations  
 
Study limitations include: 
 
1. The study was a retrospective analysis of existing data which leads to an inability 
to assess the integrity of the data collection and data entry methods. However, the 
team that collected the data was adequately trained in data collection and data 
storage. The data collection team was trained and prepared to identify and 
respond to potential questions and problems that may have risen through data 
collection.  
 
2. The PI did not contribute to the study design nor data collection, thus limiting the 
PI’s knowledge of potential problems that may have occurred with the data 
collection. The faculty advisor was part of the original study team.  
 
3. Data collected and utilized in the current study did not include socio-demographic 
or socio-economic status information. This limitation impacts our ability to 
measure all these domains within our conceptual framework and prevents the 
consideration of these important factors. This poses a limitation in assessing the 
associated factors and the impact on HRQOL in children undergoing curative 
cancer treatment. However, this limitation does not affect the internal validity of 
the measures and the results reported from our sample. 
 
4. Our sample included cancer diagnosis with varying treatment durations, 
modalities, and intensities, making comparison across diagnoses and time 
difficult. 
 
5. HRQOL interviews for patients were administered using instrument modules 
based on the age at diagnosis, even if patients progressed in age through their 
treatment, each child continued to be interviewed using the same module at 
diagnosis. While this can assist with the statistical analysis, it does not consider 
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the child’s development as they progress in treatment. However, this limitation 
did not affect the content of questions that were asked to patients, the number of 
items or the validity of the responses. 
 
6. Limitations in patient and treatment selection may have affected the final outcome 
of HRQOL. The study enrollment excluded children with relapsed or progressive 
disease. In addition, it is not known if patients who agreed to participate had a 
higher HRQOL than those that refused participation. Thus, the study was not able 
to determine how a relapse, progressive disease, or refusal to participate affected 
their HRQOL outcome compared to children who participated in the study. While 
the exclusion of relapsed patients reduced our understanding of HRQOL in those 
children, it allowed for higher validity of responses that adequately reflects 
HRQOL in our target population, children receiving curative treatment.  
 
 
Definitions 
 
 
Health-Related Quality of Life 
 
Health-related quality of life was defined as a complex concept with multiple 
domains that are affected by the person’s illness and health. These domains included: 
cognitive functioning, emotional functioning, psychological well-being, general health, 
physical functioning, physical symptoms and toxicity, role functioning, social well-being 
and functioning, and spiritual domains. Operationally, it was defined as the outcome 
measure of physical, emotional, psychosocial, and illness-related domains as determined 
by the PedsQL-Generic v4.0 and the PedsQL-Cancer v3.0. 
 
 
Diagnosis 
 
Diagnosis is defined as the cancer that was identified through examination of the 
patient history, signs, symptoms, and diagnostic data. The diagnosis was defined 
operationally as the identifying disease or illness as determined by entry onto a specific 
disease protocol. 
 
 
Time Point 
 
Time was defined as a particular instance or period of time covering a defined set 
of treatments for a patient under treatment in a certain diagnostic group. Operationally, it 
was defined as the time at which data were collected from each child during the treatment 
protocol as determined by the original study team. 
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Stage (Risk) 
 
Cancer stage was defined as the severity and subsequent side-effects experienced 
by the child during treatment. Operationally, it was defined as the treatment group for 
which each child was assigned based on disease-specific biological and diagnostic 
measures according to the treatment protocol and documented for each patient. 
 
 
Treatment Intensity 
 
Treatment intensity is defined as the extent of severity and subsequent side-effects 
experienced by the child during treatment. It was operationally defined as the sum of 
single or combined treatment modalities that included surgery, chemotherapy, 
immunotherapy, and radiotherapy. 
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CHAPTER 2.    REVIEW OF LITERATURE 
 
 
Introduction 
 
HRQOL is a dynamic concept that is affected by the changing image of self and 
numerous factors that impact the individual’s perception of self. Programs of research 
continue to explore this dynamic phenomena, as well as factors that contribute to the 
continuous transformation of HRQOL within an illness experience. However, significant 
gaps remain in the pediatric oncology HRQOL literature, specifically related to factors 
that affect HRQOL during the treatment process, including the effect of time and duration 
of therapy. While multiple studies have successfully identified factors of HRQOL among 
selected diagnostic groups of childhood cancers, many of these studies have reported 
conflicting results that preclude the identification of other HRQOL factors in childhood 
cancer.14 Most studies have measured HRQOL at a single time point in treatment and 
included a single diagnostic group.1 Thus, it is difficult to draw conclusions on the 
HRQOL changes over time and across cancer diagnoses.  Evidence is further hindered by 
the lack of studies measuring intensity or treatment factors and the impact on HRQOL 
during cancer treatment.25,26  
 
This chapter includes a systematic review of the literature regarding the current 
status of HRQOL studies in children undergoing curative cancer treatment. This review 
focused in particular on factors examined by HRQOL studies in children undergoing 
curative cancer treatment. Additionally, these studies address concerns related to the 
HRQOL measurement and conceptual problems related to the definition and meaning of 
HRQOL. 
 
 
Quality of Life and Health-Related Quality of Life 
 
As the concept of health evolved to include a wider spectrum of psychological, 
social, and spiritual domains, so did the concept of quality of life (QoL).27 QoL was 
originally introduced as a measure of individual and community well-being.  Thus, 
description of QoL among individuals during an illness experience required a new 
conceptual definition, health-related quality of life. Health-related quality of life was 
defined as an individual’s impact by illness and health. Operationally, it was defined as 
the outcome measure of physical, emotional, psychosocial, and illness-related domains. 
 
 
Factors, Measurement, and Conceptual Definition of HRQOL in Children with 
Cancer 
 
Numerous studies have explored factors that affect the HRQOL among survivors 
of childhood cancer; however, few studies have explored factors and their impact on 
HRQOL in children during curative cancer treatment. In order to identify relevant studies 
that have described HRQOL and associated factors among children during curative 
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cancer treatment, a structured review of the literature was performed to synthesize 
evidence and identify factors of interest. To achieve this goal, the conceptual model for 
this study (Figure 2-1) was used as a framework for categorizing and listing identified 
factors.  
 
 
Types of Childhood Cancer Groups 
 
This study aimed to measure HRQOL in five diagnostic groups of childhood 
cancer. The diagnostic groups included Acute Lymphoblastic Leukemia (ALL), Acute 
Myeloid Leukemia (AML), Hodgkin Lymphoma (HL), Osteosarcoma (OS), and 
Melanoma (MEL).  
 
Acute Lymphoblastic Leukemia (ALL). ALL is a hematological cancer and is 
the most common pediatric cancer. In the United States, approximately 3,000 children are 
diagnosed with ALL annually. ALL affects slightly more boys than girls and more whites 
than blacks, with peak incidence 2 to 5 years of age. Siblings of children with cancer 
have a slightly higher risk of developing the disease; however, the incidence is relatively 
low. ALL is treated with combined rotational chemotherapy, with radiation reserved for 
those with a central nervous system relapse.  Hematopoietic stem cell transplantation may 
be a treatment option for very high-risk cases or those who develop an early relapse. The 
intensity of ALL treatment varies over time and is dependent upon the patient risk 
group.28 About 98-99% of children with newly diagnosed ALL attain  a 
complete remission in four to six weeks, with approximately 90% having event-free 
survival.28,29 
 
Acute Myeloid Leukemia (AML). Approximately 500 children are diagnosed 
with AML in the United States each year, comprising approximately 20% of the children 
diagnosed with leukemia. AML may occur as a secondary malignancy after the treatment 
of another malignancy. Although approximately 80-90% of children with AML attain 
remission, 70% will attain long-term remission with chemotherapy or stem cell 
transplantation.30 
 
Hodgkin Lymphoma (HL). In the United States and northern Europe, HL is rare 
before five years of age, with increased incidence in adolescence with a peak in the 
second and fifth decade of life. Associated risk factors are male gender, having a sibling 
diagnosed with the disease, and Epstein-Barr virus. Chemotherapy alone or combined 
with low-dose radiation therapy is the standard treatment for young patients and patients 
with advanced disease; however, radiation significantly impairs the growth of bones and 
soft tissues in children and increases the risk of heart disease and secondary 
malignancies. Current event-free survival is 90%. 
 
Melanoma. Melanoma is the most common skin cancer in children. Of the 
estimated 55,000 cases of melanoma diagnosed in the United States each year, fewer than 
5% occur in patients under 20 years of age and only 0.3% are younger than 11 years.  
Thus, melanoma accounts for only 1-2% of all pediatric cancers.31 
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Children with dysplastic nevus syndrome, giant congenital nevi, DNA repair 
disorders or immunodeficiency states have an increased risk of developing melanoma. 
The most common cause of skin cancer is exposure to the ultraviolet rays, but may also 
be secondary to cancer-causing chemicals and ionizing radiation. Individuals with a 
family history of melanoma are at increased risk.32 
 
Thickness of a tumor has been shown to predict the likelihood of tumor spread 
(metastases) or recurrence. Optimal treatment for melanoma is complete surgical removal 
and is dependent upon the size, site, level of invasion into the skin and stage of the 
tumor.33 Prognosis for resected superficial melanomas is approximately 90%, with 
patients surviving 10 years from diagnosis. Survival is decreased if the melanoma has 
spread to distant organs. 
 
Osteosarcoma (OS). Osteosarcoma is the most common bone tumor in children 
and adolescents. The most common sites of this tumor are the femur, tibia, and humerus. 
It most commonly arises from the metaphysis of the bone. Each year in the United 
States, osteosarcoma is diagnosed in approximately 400 children and adolescents younger 
than 20 years of age. The peak incidence of osteosarcoma is in the second decade of life, 
during the adolescent growth spurt. It is extremely rare in children before the age of 5 
years of age and is  more frequent in the male gender and black race.34 
 
Osteosarcoma may occur in long-term survivors of cancer who were treated with 
radiation therapy. The interval between radiation and the appearance of osteosarcoma 
ranges from 4 to 40 years (median, 12-16 years). Two suppressor genes, p53 and Rb1 
genes have major roles in tumor genesis in osteosarcoma, with approximately 3-4% of 
children with osteosarcoma having a germ line mutation in p53. The majority of patients 
with germ line p53 mutations have a strong family history of cancer suggestive of the Li-
Fraumeni syndrome (a familial cancer syndrome) or multiple cancers.35 
 
Patients with osteosarcoma may present with pain, swelling, and sometimes 
decreased joint motion. Occasionally, a patient may present with a fracture at the tumor 
site. Symptoms are usually present for several months prior to diagnosis, with 15-20% of 
the patients having lung or bony metastatic disease at the time of diagnosis. Treatment 
of osteosarcoma includes surgery and chemotherapy. Surgical removal of all gross and 
microscopic tumors is required to prevent local tumor recurrence. The majority of 
patients (95%) with localized osteosarcoma of the extremity are candidates for limb-
salvage surgery. The use of multi-agent chemotherapy has markedly improved the 
outcome of patients with osteosarcoma.36–38 
 
The over-all estimated 5-year survival for patients with osteosarcoma is 65%, 
with the presence of metastasis at diagnosis having a significant impact on outcome. The 
estimated survival rate for patients with localized osteosarcoma is about 75% compared 
to 30% for patients with metastatic disease.36  
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Review of HRQOL Studies in Children under Cancer Treatment 
 
To assess the current HRQOL literature in children undergoing curative cancer 
treatment, a systematic review of the literature was completed. The review identified 
relevant factors that significantly impact HRQOL in children as outlined by the 
conceptual model and instruments utilized in measuring HRQOL in children undergoing 
curative cancer treatment. In addition, we reviewed studies that identified issues in 
measuring and conceptualizing the definition of HRQOL. 
 
 
Procedure for Review of Literature 
 
A literature search of PubMed, CINAHL, and PsycINFO was performed using the 
terms “health-related quality of life” and “quality of life’ as mesh terms. The term 
HRQOL was combined with a subject heading for cancer, and limited to children.  
Articles were initially scanned for eligibility based on title, followed by an abstract scan, 
and finally through a full text scan. Full text articles were also scanned for relevant 
literature that was not found during the literature search.  
 
Inclusion Criteria. Study titles and abstracts were examined and screened for 
relevancy to the review. The remaining full text articles were screened using the 
following inclusion and exclusion criteria: 
 
• Study subjects were limited to children under 18 years of age.  
• Publication date was January 1st 2005, through March 1st 2013. 
• Published in English. 
• Study subjects were under curative cancer treatment with a curative intent.  
• Study outcome or dependent factors were health-related quality of life or quality 
of life. 
 
Exclusion Criteria. Studies were excluded from this report if they examined: 
 
• Cancer survivors, or included cancer survivors with no separate analysis for 
groups under treatment and survivors. 
• Children undergoing palliative care with no realistic chances of survival. 
 
 
Findings 
 
A total of 1333 articles were identified during the initial search and articles were 
scanned based on titles. Articles were excluded if the abstract included any of the 
exclusion criteria. The review resulted in the evaluation of 88 full-text articles, with 28 
articles meeting the eligibility criteria for review. 
 
The final 28 studies included in this review represented work conducted in 16 
countries, with a majority of studies (17) occurring in the United States. Study sample 
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size ranged from 8 to 411. Using the conceptual framework, the factors were categorized 
into five categories: cancer, treatment, child, family, and community. 
 
 
Cancer Factors Considered in the Systematic Review 
 
Type of Cancer. The impact of cancer diagnosis has been found to alter HRQOL 
in children when compared to healthy norms. Most studies in our review were diagnosis 
specific, making it difficult to draw HRQOL comparisons between diagnostic groups. 
Studies that have assessed the impact of cancer diagnosis on HRQOL have conflicting 
results, with some studies showing a significant effect of diagnosis on HRQOL, and 
others reporting the cancer diagnosis as having little impact on HRQOL.7,8,13,15,16,39–47 
Two studies found that children with ALL tend to report higher HRQOL than children 
with solid tumors or central nervous system (CNS) tumors,13,15,39 while another study 
reported that children with ALL experience a lower HRQOL than other groups.8 The 
poorest HRQOL was reported in children with AML and solid tumors,15,48 while other 
studies reported finding no correlation between the type of cancer and HRQOL of 
children.7,13,16,39–42,46,49 Most of these studies measured HRQOL in a mixed sample of 
multiple, small diagnostic groups, thus proving difficult to interpret the effects of cancer 
type on the HRQOL outcome.  
 
Cancer Stage. Only three studies in the review attempted to measure cancer stage 
or risk as a variable of HRQOL in children under curative treatment.9,49,50 Of those 
studies, only one could establish cancer stage as a significant variable.50 Thus, the 
influence of cancer stage or risk on HRQOL is not well understood.  
 
 
Treatment Factors Considered in the Systematic Review 
 
Type of Treatment. Treatment modality and treatment impact on HRQOL is 
frequently evaluated among diagnostic groups. Studies that explored the treatment 
modality as a variable affecting HRQOL found a significant decrease in HRQOL in 
children receiving radiotherapy, chemotherapy, or surgery.7,13,51,52 Radiotherapy was 
measured in a total of three studies; however, radiotherapy was not compared to other 
modalities and all of these studies measured HRQOL among patients with a brain 
tumor.7,53 Two of the studies described HRQOL of children undergoing a new method of 
radiotherapy treatment (proton beam) without drawing any comparisons with other 
methods.7,53 These studies reported that children reported higher HRQOL scores after 
being treated with proton beam therapy in comparison to previous studies that reported 
on HRQOL in children receiving conventional radiotherapy treatment.7,53 Another study 
identified radiotherapy as a significant variable impacting HRQOL in children with brain 
tumors at the first year of diagnosis.49 As for chemotherapy, two out of three eligible 
studies identified chemotherapy as a significant predictor of lower HRQOL in children 
undergoing curative cancer treatment.7,49 One study found surgery to significantly lower 
HRQOL.13 Other studies in this review found no significant association between type of 
treatment and HRQOL in adolescents and children with cancer.13,40  
 17 
Treatment Intensity. Treatment intensity is another variable that has been 
assessed as impacting HRQOL and was measured in five studies in our systematic 
review.7–9,13,40 Of those studies, three established a significant association between 
intensity of treatment and HRQOL in children receiving radiotherapy,7 and children with 
leukemia.8,9 No other studies could establish a significant association between intensity 
and type of treatment or other diagnostic group.13,40 Thus, this review supports the need 
to explore a possible association between treatment intensity and HRQOL in all 
diagnostic groups. 
 
Time in Treatment. A generally low HRQOL was reported following diagnosis, 
and this trend continued during intensification or changes in treatment.13,15,46,49 Children 
with ALL receiving maintenance treatment reported significantly lower HRQOL as 
compared to children at the completion of treatment.54 However, there was a consensus 
among these studies that HRQOL steadily improved as children progressed in treatment, 
with highest HRQOL immediately after completion of treatment.41,49,53 
 
Longitudinal HRQOL during cancer treatment was explored once in children with 
(ALL) receiving curative cancer treatment. 96 patients treated for ALL were followed 
over three time points during treatment in a study by Peeters et al.55 The child’s HRQOL 
improved over time during treatment, especially in physical and mental functions. The 
study also noted a significant improvement in both patient and parent responses as time 
progressed. These findings were not correlated with age, and showed that HRQOL of 
children with ALL was lower than the general population of the same age. 
 
Time is perhaps one of the least understood factors of HRQOL in children 
undergoing curative cancer treatment. Most studies assessing HRQOL in children 
undergoing curative cancer treatment use inconsistent time points across studies, making 
it difficult to infer HRQOL according to time in therapy. The cross-sectional designs of 
most studies further hinder understanding the change with time. For example, two 
reviewed studies assessed HRQOL at the time of diagnosis,15,16 while others chose a time 
point that was significant for the diagnostic group under study.46,50,56 The fact that each 
diagnostic group had variability in treatment modality, intensity and timing made it 
difficult to draw comparisons or make assumptions regarding HRQOL across diagnoses.  
 
Complications and Relapse. A noticeable limitation in most studies was the 
exclusion of patients who were experiencing complications or relapse.15,40 Only one study 
measured complications,8 and one other study measured relapse status as factors of 
HRQOL.13 In general, children who progress under curative treatment were taken off 
curative study protocols and put on either palliative or experimental regimens.48 This 
explains the lack of studies that assess curative patients that relapse. Complications 
during treatment are not included as a HRQOL variable and may be attributed to 
difficulties in tracking and documenting complications during curative cancer treatment. 
Most patients who relapse or progress during treatment are removed from the curative 
treatment protocol and usually transferred to a hospice or palliative care setting in many 
occasions requiring a change of primary clinician and institute. 
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Child Factors Considered in the Systematic Review 
 
Age. Results from studies assessing age show limited evidence to support the role 
of age as a variable of HRQOL. Age was one of the frequently mentioned factors 
measured in children with cancer.7–9,13,16,39,40,42,44–47,49,50 However, of the 17 studies that 
measured age as a variable of HRQOL, only four identified age as having a significant 
impact on HRQOL during treatment.9,13,44,46 Young children generally reported lower 
procedural anxiety and treatment anxiety than adolescents,9 while older children reported 
better social HRQOL and communication that younger children.57 Overall, HRQOL has 
been found to improve with age,9,40 while another study found younger age to be 
associated with an improved HRQOL.21 Others reported no association between age and 
HRQOL in children.7,8,39,42,47,50,58 These studies reported that differences between parent 
proxy-reports and child self-reports of HRQOL were influenced by the child’s 
age.7,25,40,49,59 Parsons et al.25 reported that the highest degree of difference between the 
child and parent report was seen in the physical functioning domain and the lowest for 
social functioning domain. This degree of difference was more evident in adolescents 
than in children with cancer.15,25 
 
Gender. Gender is another frequently measured variable impacting HRQOL in 
children with cancer. However, of the 16 studies that examined gender as a variable of 
HRQOL, only four identified gender as a significant variable. In these studies, female 
gender was consistently associated with a lower HRQOL.8,13,44,45 
 
Ethnicity. Few studies describe variations in HRQOL among ethnic groups and 
most of the studies were conducted among samples that included predominately white 
children. Only three studies examined ethnicity as a variable of HRQOL.7,39,45 Of these 
studies, Shankar et al. described the association of ethnicity on HRQOL of children 
undergoing curative cancer treatment, with non-white children reporting lower HRQOL 
than their white peers.45  
 
 
Family Factors Considered in the Systematic Review 
 
Few studies assessed the impact of family factors on the child’s HRQOL during 
curative therapy; however, two studies found higher family functioning and involved 
parental care and bonding predicted higher physical HRQOL.40,49 Family resources were 
the strongest predictors of psychosocial HRQOL.40 Mothers with higher rated QoL were 
found to be predictive of the child’s having higher HRQOL.16 In addition, parental 
overprotection was significantly related to a child’s HRQOL;40,42 higher parental 
overprotection and perceived child vulnerability were related to lower parent-proxy 
report of child HRQOL.40,42,46 Perceived child vulnerability mediated the effect of 
parental overprotection on children’s HRQOL negatively. Higher family socio-economic 
status and annual income were also significant factors related to higher HRQOL in 
children with cancer.13,42 
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Community Factors Considered in the Systematic Review 
 
A limited number of studies within our review addressed the association between 
community factors and HRQOL. Two studies attempted to measure the HRQOL 
difference in children treated in their home environment as opposed to being treated at a 
hospital.46,60 In these studies, both the child and parent reported a higher HRQOL when 
treated in a home environment as compared to a hospital environment.59 However, 
Stevens et al.60 described children as reporting more distress during treatment progression 
when at home. Tremolada et al.46 also found that when parents developed a trusting 
relationship with the hospital staff, the child reported a higher HRQOL. 
 
 
HRQOL Measurement Issues in Subject Studies 
 
Currently, there are numerous instruments that measure HRQOL in children.61 
Additionally, there are disease-specific instruments that measure HRQOL in children 
with cancer,44,62 and instruments which measure HRQOL specific to the outcomes of a 
cancer diagnoses such as brain tumors.63 These instruments vary in the scope of domains 
measured, and the length and format of the questions.64 HRQOL instruments may be 
categorized as generic, disease-specific, and modular depending on their intended 
outcomes and disease population.65  
 
The Pediatric Quality of life Scale (PedsQL) was found to be the most used 
generic module in the assessment of HRQOL in children with cancer (Figure 2-2).14,66 
Other generic instruments by order of frequency include the Health Utility Index (HUI), 
and the Child Health Questionnaire (CHQ).  
 
As for cancer-specific instruments, the PedsQL Cancer module was the most 
widely used cancer specific instrument in our review (Figure 2-3), followed by the 
Pediatric Oncology Quality of Life Scale (POQOLS). These findings were consistent 
with the systematic review based on Figure 2-1 and described earlier in this chapter.  
 
Despite the reported variation of findings between studies using different 
instruments, most studies that utilized the PedsQL generic and cancer specific modules 
have reported similar findings. Studies that did not report consistent findings were more 
likely to have low sample size that impeded the power to reach conclusions with 
associated factors.41,49,50,67  
 
These findings support the utilization of the most frequently used instruments in 
measuring HRQOL to identify and establish factors that significantly affect HRQOL of 
children with cancer. 
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Figure 2-2. Generic HRQOL instruments used in the systematic review 
 
PedsQL-Generic: Pediatric Quality of Life –Generic Scale; CHQ: Child Health 
Questionnaire; DISABKIDS: DISABKIDS instrument; Lansky: Lansky 
Performance Scale; TACQOL: TNO-AZL Child Quality of Life; CBCL: Child 
Behavior Checklist. 
 
 
 
 
 
Figure 2-3. Cancer-specific scales used in the systematic review 
 
PedsQL-Cancer: Pediatric Quality of Life – Cancer Module; EORTC QLQ C-30: 
European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire Cancer 30; MMQL: Minneapolis-Manchester Quality of Life; EFI-
c: Ecocultural Family Interview – cancer.   
13 
3 
2 
1 1 1 
PedsQL
Generic
CHQ DISABKIDS Lansky TACQOL CBCL
11 
2 2 
1 1 
PedsQL-Cancer PedsQL-Brain EORTC QLQ C-
30
MMQL EFI-c
 21 
Conceptual Limitations of HRQOL Measurement 
 
Instruments measuring HRQOL in children with cancer have limitations due to 
lack of conceptual clarity in defining HRQOL. The concept of QoL was first introduced 
in the early 70’s, as a means to measure the general satisfaction of healthy populations.20 
Early in QoL research, the concept of QoL was viewed as an embodiment of change or 
interruption in health and well-being. At the time, health was widely viewed as a 
reflection of the physical aspects and domains of function. Thus, early HRQOL 
definitions corresponded with change and deterioration in physical health. This idea of 
limiting HRQOL definition to the functional domain is evident in earlier instruments that 
attempted to only measure aspects of functional physical activities.68 It is generally 
agreed, however, that the current scope of HRQOL measurement in children with cancer 
should include aspects of physical, social, emotional, psychological, and spiritual 
domains,1 most instruments fail to capture all these domains within their questions.66 
Most notably, the domain of spiritual well-being is usually neglected due to the complex 
nature of this domain, exceeding the young children’s cognitive development and ability 
to think abstractly.69,70  
 
 
Conclusion from the Systematic Review of Literature 
 
This review presents the current state of the science on the measurement and 
assessment of HRQOL in children undergoing curative cancer treatment. In addition to 
demographic and family factors, many treatment and cancer related factors significantly 
impact the HRQOL of children under curative cancer treatment. This review found time 
to be an important variable impacting HRQOL. Most studies of children under curative 
treatment were cross-sectional in nature and varied considerably in their sample size. Our 
review found limitations of the current research on HRQOL in children undergoing 
curative cancer treatment. These limitations can affect our understanding of the dynamic 
nature of HRQOL and the factors that impact the change in HRQOL over time.  
 
The evidence from this review indicates a significant gap in comparing the impact 
of treatment types and treatment intensities on diagnostic groups. In addition, there is a 
lack of time-series studies that consider the dynamic change of HRQOL over time during 
curative cancer treatment. This review also points to wide variability in reporting and 
identifying factors impacting HRQOL in children with cancer. This variability can be 
explained by cross-sectional designs, small sample sizes, differences in instruments used 
to measure HRQOL as an outcome, and the dynamic nature of the HRQOL phenomenon. 
 22 
CHAPTER 3.    METHODOLOGY 
 
 
Study Design 
 
 This retrospective study analyzed HRQOL data collected from a convenience 
sample of children undergoing treatment for acute Lymphoblastic leukemia (ALL), acute 
myeloid leukemia (AML), Hodgkin’s lymphoma (HL), osteosarcoma (OS), and 
melanoma (MEL). Data were collected from children and adolescents using two HRQOL 
instruments: The Pediatric Quality of Life Generic Core Scale version 4.0 (PedsQL 
Generic v4.0) and the Pediatric Quality of Life Cancer Module version 3.0 (PedsQL 
Cancer v3.0). The use of the same instruments in all groups allowed for comparisons 
between diagnostic groups. Reponses to these instruments were collected from patient 
self-report over multiple time points. These diagnostic groups varied in treatment 
modality, treatment intensity and treatment duration. In addition, diagnostic groups 
differed within groups according to stage of disease and treatment intensity. The overall 
aim of this study was to describe the HRQOL across time points within and between the 
diagnostic groups and to identify factors that impact the change in HRQOL over time.  
 
 
Sample and Setting  
 
Across the diagnostic groups, 720 patients were included in our HRQOL 
analyses. The sample included HRQOL data collected from children and adolescents 
treated on front-line (initial line of treatment) St. Jude Children’s Research Hospital 
(SJCRH) protocols. SJCRH is a tertiary care hospital specialized in treating and caring 
for children with cancer and hematological disease. In addition to clinical care, the 
hospital has a research infrastructure that focuses on scientific advancement and 
improvement utilization of new treatment regimens for the treatment of childhood cancer. 
Patients at SJCRH are referred by an outside physician, and nearly all have a disease 
under clinical study, making them eligible for a research protocol. About 7,800 active 
patients are seen at SJCRH yearly; most are treated on a continuing outpatient basis as 
participants in ongoing research treatment protocols. The hospital has 78 hospital beds 
with admissions for chemotherapy or supportive care. Patients included in this study were 
between 5-18 years of age. Younger children were excluded as we could only obtain 
parent proxy reports of their HRQOL.  
 
 
Acute Lymphoblastic Leukemia (ALL) 
 
The SJCRH TOTALXV Protocol objective was to improve cure and health 
outcomes of children and adolescents diagnosed with acute lymphoblastic leukemia. The 
therapeutic aims of the protocol were to estimate the overall survival of children who 
were treated with a risk directed therapy and to monitor molecular remission induction 
rate. It also aimed to determine if CNS irradiation could be safely omitted in the context 
of the protocol’s systematic therapy. In addition, it aimed to assess prognostic values of 
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biological markers in childhood ALL. HRQOL data was collected from children and 
adolescents at designated time points during treatment. Protocol eligible patients were 
ages 1-18 years, diagnosed with precursor B cell or T cell leukemia and with no more 
than a week of prior therapy that is limited to glucocorticoids, vinca alkaloids, emergence 
radiation therapy and one dose of intrathecal chemotherapy. 
 
At the time of diagnosis, patients were assigned to risk groups (low, standard, or 
high) according to genetic and molecular markers of their leukemia. Genetic and 
molecular markers predict treatment response and determine therapy intensity. Protocol 
Treatment for ALL consisted of three phases, Remission Induction (first 6-7 weeks), 
Consolidation (8weeks), and Continuation (120 weeks for girls and 146 weeks for boys).  
 
HRQOL information was collected from patients on the treatment protocol at 4 
time points in treatment: At day 40 of induction (T1), at week 7 of consolidation (T2), at 
week 48 of the treatment continuation phase (T3), and at the end of treatment. Since the 
treatment protocol differed in length based on gender, the end point of treatment (T4) was 
collected at week 120 for females, and week 146 for males which accounted for the end 
of treatment for each gender. 
 
 
Acute Myeloid Leukemia (AML) 
 
The AML02 was a frontline therapeutic protocol for the treatment of acute 
myeloid leukemia and aimed to compare immunologic and molecular remission induction 
rates in patients receiving two different induction therapy regimens. It also aimed to 
estimate the event-free survival (EFS) of AML patients who undergo risk-adapted and 
genotype-directed therapy, to assess the prognostic value of biological markers in 
childhood AML. 
 
Patients were admitted to this treatment protocol if they had a confirmed 
diagnosis of AML, were less than 21 years, with no prior history of therapy for AML 
except for one dose of intrathecal chemotherapy. HRQOL data were collected from 
patients at baseline (T1), prior to induction II (T2), prior to consolidation III (T3), and at 
the completion of therapy (after count recovery following consolidation III) (T4). Patients 
enrolled in this protocol were categorized to 3 risk categories (low, standard, and high), 
based on cytogenetic and molecular characteristics, morphology, and response to therapy.  
 
 
Hodgkin Lymphoma (HL) 
 
Two protocols provided the HRQOL data for children and adolescents diagnosed 
with Hodgkin Lymphoma. Both HOD99 and HOD05 protocols utilized a risk adapted 
therapy approach to treat HL. The primary protocol objective was to estimate the event 
free survival distribution in intermediate risk Hodgkin’s disease treated with Stanford V 
chemotherapy plus or minus low-dose, tailored-field radiation therapy. The protocols also 
aimed to determine patterns of treatment failure for children treated with or without 
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tailored field radiation therapy and to describe patient quality of life during and after 
treatment from the patient and parent perspective. Eligible patients had histologically 
confirmed untreated Hodgkin's disease. Patients who were 21 years of age or younger, 
receiving limited emergent radiation therapy or steroid therapy because of 
cardiopulmonary decompensation or spinal cord compression were eligible for protocol 
enrollment. 
 
Children and adolescents were assigned to one of three risk groups according to 
the extent of disease and biological subset. The risk groups were categorized as 1) 
Favorable; 2) Intermediate; and 3) Unfavorable groups. The groups varied in the intensity 
of chemotherapy and radiotherapy was delivered according to disease staging and 
response to treatment. Patients on the favorable risk arm did not receive radiotherapy. 
Therapy included 12 weeks of chemotherapy, followed by radiation therapy for 
intermediate and unfavorable risk groups. The dose to individual nodal sites was based on 
response after 8 weeks of chemotherapy: 15 Gy for patients achieving a complete 
response and 25.5 Gy achieving less than a complete response. 
 
 HRQOL data were obtained at baseline before the first treatment (T1); after 8 
weeks of Stanford V (T2); after 12 weeks of chemotherapy and prior to or in the first few 
days of beginning radiation (T3); and at 3 to 6 months after completion of therapy 
follow-up evaluation (T4). The PedsQL-Cancer module was not required from patients at 
the beginning of treatment (T1). This step was taken as children who have not started 
treatment yet cannot give responses to many of the items on the PedsQL-Cancer module 
as they have not experienced the side-effects of cancer treatment.  
 
 
Melanoma (MEL) 
 
The primary treatment protocol aim for melanoma (MEL08) was to estimate the 
tumor response between two treatment arms assigned according to disease extent, in 
addition to identifying the impact of these therapies on patients’ HRQOL. On this 
protocol, all patients with initial presentation of melanoma were treated with primary 
wide local excision with a minimum of 1 cm margin surrounding the primary lesion or 
biopsy scar. Patients with sentinel lymph node positive for disease underwent complete 
lymph node dissection of the involved nodal basin. 
 
Patients were enrolled on MEL 08 if they had a histologic diagnosis of cutaneous 
malignant melanoma, were no more than 21 years of age, had adequate performance 
status and organ function, and did not receive any prior therapy for melanoma except for 
surgical resection of local and regional lymph nodes. Patients with localized disease must 
have undergone sentinel lymph node biopsy for positive disease. In cases of positive 
disease the patient had complete lymph node dissection of the involved nodal basin. 
Patients were excluded if they had prior therapy with dacarbazine or temozolomide, had a 
history of myocardial infarction, hypo or hyperthyroidism, diabetes mellitus, auto 
immune hepatitis, an uncontrolled infection, depression or other psychotic disorders, or 
were taking steroids. 
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The MEL08 protocol required assignment to Stratum A or Stratum B. Patients 
assigned to Stratum A had a resected Stage IIC, IIIA and IIIB. Treatment included two 
phases of chemotherapy: Induction therapy over 4 weeks, receiving recombinant 
interferon α-2b weekly. This was followed by Maintenance Therapy from week 5 to 
week 52. Patients enrolled on stratum B presented with Stage IIIC, Metastatic, 
Unresectable Stage III or Recurrent Disease and further divided into two groups based on 
the presence (Stratum B1) or absence (Stratum B2) of measurable disease. The dose and 
schedule of peginterferon α-2b and temozolomide were the same for both groups. 
Patients receive 8 weekly doses of peginterferon α-2b in combination with temozolomide 
daily for 6 weeks followed by a 2 week break. In the absence of recurrent disease or 
toxicity, patients in Stratum B2 received 7 courses of temozolomide in combination with 
peginterferon. Data were collected from children with melanoma at baseline before the 
start of treatment (T1); at week 4, the end of induction treatment (T2); at week 24 of 
treatment (T3); and at the end of treatment, at about 48 weeks from the beginning of 
treatment (T4). 
 
 
Osteosarcoma (OS) 
 
The aim of the Osteosarcoma protocol was to evaluate the feasibility of 
combining bevacizumab, a humanized monoclonal antibody against vascular endothelial 
growth factor with cisplatin, doxorubicin, and high-dose methotrexate (HDMTX) in 
patients with localized resectable osteosarcoma, and bevacizumab with cisplatin, 
doxorubicin, HDMTX, ifosfamide, and etoposide in patients with unresectable or 
metastatic osteosarcoma. The protocol also aimed to study the effect of adding 
bevacizumab to chemotherapy comprised of cisplatin, doxorubicin, and HDMTX on the 
event-free survival (EFS) in patients with localized resectable osteosarcoma compared to 
historical controls treated with cisplatin, doxorubicin, and HDMTX without 
bevacizumab. Thus, patients on this protocol were treated on one of two different arms 
according to the extent of tumor resection and metastatic status. 
 
Patients were eligible for treatment if they: were younger than 30 years at 
diagnosis; had a newly diagnosed osteosarcoma; had adequate performance and organ 
function measures and had no previous chemotherapy or radiation therapy. Patients were 
excluded if they had a surgical procedure with serious or non-healing wounds, known 
bleeding disorders or coagulopathy, a deep vein thrombosis, cardiac disease or 
hypertension, proteinuria, central nervous system disease, or gastrointestinal perforation. 
 
Children’s and adolescents’ disease was categorized according to the extent of 
tumor metastasis, i.e., localized, localized unresectable, or metastatic disease. Both 
treatment arms included chemotherapy, followed by radiotherapy, and additional 
chemotherapy after surgery recovery. The duration of treatment, however, differed 
between both groups; children with a resectable tumor were treated for a total of 31 
weeks, while children with an unresectable tumor were treated for 39 weeks. 
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HRQOL data was assessed for both arms of treatment at 4 time points: at 
diagnosis (T1), at week 8 and after cycle 2 of chemotherapy (T2), prior to radiation 
therapy or after cycle 4 of chemotherapy (T3), and at the end of radiation therapy (T4). 
 
 
Instruments 
 
 This study measured HRQOL using the Pediatric Quality of Life Scale (PedsQL) 
Generic Core Scale v 4.071 and the PedsQL Cancer Module v 3.0 (Appendix A).72 These 
PedsQL scales are the most widely used quality of life scales in pediatric cancer research 
and include Generic and Cancer specific scales.14 The instruments have high reliability 
and validity and have been utilized extensively as outcome measures in research and 
clinical practice.66,72–74  
 
 
PedsQL Generic Core Scale (PedsQL-Generic) 
 
The 23-item multidimensional PedsQL 4.0 Generic Core Scales includes four 
domains: physical functioning (8 items), emotional functioning (5 items), social 
functioning (5 items), and school functioning (5 items). Child self-report includes ages 5–
7 years (young child), ages 8–12 years (child), and ages 13–18 years (adolescent). A 5-
point Likert response scale is utilized across child self-report for ages 8–18 years. That is, 
0=never a problem; 1=almost never a problem; 2=sometimes a problem; 3=often a 
problem; 4=almost always a problem.  
 
To further increase the ease of use for the young child self-report (ages 5–7 
years), the Likert scale is reworded and simplified to a 3-point scale. That is, 0=not at all 
a problem; 2=sometimes a problem; 4=a lot of a problem; with each response choice 
anchored to a happy to sad faces scale.72 Items are reverse-scored and linearly 
transformed to a 0–100 scale so that higher PedsQL 4.0 scores indicate better HRQOL 
(Appendix A).72 PedsQL v 4.0 Generic core scales have been heavily tested on different 
child population groups and have been shown to be valid and reliable.61,71  
 
The PedsQL Generic scale internal consistency generally exceeds the standard of 
0.70 for group comparisons.71 The Total Scale Score Cronbach alpha was 0.88 for child 
report, making the Total Scale Score suitable as a summary score for the primary analysis 
of HRQOL outcomes in clinical trials and other group comparisons.  
 
The Physical Health (α=0.8) and Psychosocial Health (α=0.83) Summary Scores 
achieved high reliability scores as recommended for secondary analyses. The school 
functioning subscale for ages 5 to 7 was the only subscale that did not approach or exceed 
0.70.71 Considering that the physical health score is the same as physical summary score, 
and since the psychosocial summary score is a combination of emotional, social, and 
school scores, we reported in this study on 5 HRQOL domains: physical, emotional, 
social, and school domains, in addition to the total HRQOL summary score. 
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PedsQL Cancer Module (PedsQL-Cancer) 
 
The 27-item multidimensional PedsQL 3.0 Cancer Module Acute Version 
includes 8 domains: pain and hurt (2 items), nausea (5 items), procedural anxiety (3 
items), treatment anxiety (3 items), worry (3 items), cognitive problems (5 items), 
perceived physical appearance (3 items), and communication (3 items). The format, 
instructions, Likert response scale, and scoring method are identical to the PedsQL 4.0 
Generic Core Scales Acute Version, with higher scores indicating fewer problems and 
symptoms or better HRQOL.72 The PedsQL 3.0 Cancer Module Scales internal 
consistency reliabilities generally exceeded the recommended minimum alpha coefficient 
standard of 0.70 for group comparisons for child self-report ages 8–18 years.72  
 
 
Data Management Procedure 
 
Data for this study were previously collected as a secondary objective within each front-
line treatment protocol at SJCRH. Approvals to conduct this retrospective analysis were 
obtained from both SJCRH and University of Tennessee Health Science Center 
Institutional Review Boards (Appendix B). Approval to use and collect the instruments 
was obtained (Appendix C).The primary investigator and faculty sponsor obtained 
necessary permission to access de-identified data for the purpose of this study.  
 
Data were collected at specified time-points for each treatment protocol during 
face-to-face interviews. These data were collected by trained research nurses. The 
assigned research nurse followed the child’s appointment and scheduled an interview at 
the designated time point for HRQOL data collection. The research nurse would remain 
with the family as they completed the questionnaires should the family or children have 
questions or concerns.  
 
 
Statistical Analysis 
 
Patient demographics were summarized for each diagnostic group by descriptive 
statistics (frequency and percent, mean and standard deviation, and median and range). 
HRQOL data were scored using the algorithm provided by the instrument manual.75 
Internal consistency for each instrument domain was evaluated by Cronbach’s alpha 
coefficients within each diagnostic group. The minimum standard of 0.70 for Cronbach’s 
alpha coefficients was assumed for adequate internal reliability.72 HRQOL scores were 
summarized for each diagnostic group by domain at each time point in treatment using 
descriptive statistics (mean and standard deviation). HRQOL domains were scored using 
the instruction manual authored by James Varni (version 5: updated March 2014). Items 
were reverse scored and linearly transformed to a 0-100 scale (0=100, 1=75, 2=50, 3=25, 
4=0), so that higher scores indicate better HRQOL. Domain scores were computed as the 
sum of the items answered divided by the number of items answered. If more than 50% 
of the items in the domain are missing, then the domain score was not computed.75 Time 
at treatment was based on previously selected time points during data collection for each 
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diagnostic group. For each diagnostic group, a time point representing the beginning of 
treatment (T1), two time points representing significant clinical incidents that correspond 
with treatment changes (T2, T3) and a time-point at the end of treatment (T4) were 
selected to represent changes over time in each diagnostic group, and to compare 
HRQOL between different diagnostic groups. 
 
 
Aim 1 
 
Aim 1 was to identify longitudinal trends in HRQOL change in diagnostic groups 
of children undergoing curative cancer treatment. The following research questions were 
related to this aim: 
 
? Research Question 1-1: What is the self-reported HRQOL of children 
undergoing curative cancer treatment within each diagnostic group at each time 
point? 
 
? Research Question 1-2: What is the difference in self-reported HRQOL of 
children undergoing curative cancer treatment at each time point within each 
diagnostic group? 
 
To address these questions, HRQOL scores were summarized for each diagnostic 
group by domain at each time point using descriptive statistics (mean and standard 
deviation). Plots were also used to represent the data. The mixed effects linear model for 
repeated measures was used to assess change in HRQOL over time within each 
diagnostic group. An appropriate correlation structure was used to account for the 
correlation among repeated measurements made on the same patient.  
 
 
Aim 2  
 
Aim 2 was to identify the differences in HRQOL among different diagnostic 
groups of children undergoing curative cancer treatment. One question was related to this 
aim: 
 
? Research Question 2-1: What is the difference in self-reported HRQOL of 
children undergoing curative cancer treatment between different diagnostic 
groups at each time point?  
 
The mixed effects linear model for repeated measures was used to compare 
HRQOL over time between different diagnostic groups. An appropriate correlation 
structure was used to account for the correlation among repeated measurements made on 
the same patient. The model included the diagnostic group and time. 
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Aim 3  
 
Aim 3 was to identify correlates with HRQOL of children undergoing curative 
cancer treatment over time within each diagnostic group. Three questions were related to 
this aim: 
 
? Research Question 3-1: Is there an association between cancer and treatment 
factors and self-reported HRQOL of children undergoing curative cancer 
treatment over time? 
 
? Research Question 3-2: What is the combined effect of cancer and treatment 
factors on the self-reported HRQOL of children undergoing curative cancer 
treatment in each diagnostic group? 
 
? Research Question 3-3: What are the associations between each variable and the 
change in self-reported HRQOL of children undergoing curative cancer 
treatment? 
 
To answer these three questions, the following statistical procedures were 
undertaken accordingly: 
 
Univariate Analysis. The mixed effects linear model for repeated measures was 
used to examine the relationship of demographic variables and cancer and treatment 
factors to HRQOL. An appropriate correlation structure was used to account for the 
correlation among repeated measurements made on the same patient.  
 
The following demographic and cancer and treatment factors were considered: 
gender, age at enrollment (child: age<13 years, teen: age≥13 years), race (white, other), 
time point in treatment, blocks of radiation received (none, 1 block, >1 block), and risk 
group (favorable, intermediate, unfavorable). 
 
Multivariate Analysis. The criterion of p<0.1 was used to select factors from the 
univariate model to include in the multivariable model. The mixed effects linear model 
for repeated measures was used to examine the effects of all selected factors on HRQOL.  
 
An appropriate correlation structure was used to account for the correlation 
among repeated measurements made on the same patient. The multivariate model 
included main effects only (i.e., no interaction). A two-sided significance level of p<0.05 
was used for all statistical tests unless otherwise stated. Statistical analyses were 
conducted using SAS 9.3 (SAS Institute, Cary, NC). 
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Human Studies Protection 
 
 
Potential Risk to Participants 
 
Many concerns and consideration arise when conducting research in a vulnerable 
population such as children. These issues include the compromised state of the child’s 
ability to process and consent to research.76 These issues are inherent in most research 
involving children and were addressed in this study. Data collection policies in this study 
dictated that in addition to parental consent to participate, the child was also asked to give 
assent. This question was asked verbally of any child who was developmentally capable 
of responding to the items on the questionnaires, and was required to be written at age 14. 
Children were also given the option to answer the questionnaire at a later time, to choose 
not to respond at a later stage in their treatment trajectory, or to opt out of participation at 
any time they wanted. While this issue can compromise the completeness of the data, it 
ensures that no coercion was used to influence the child’s and parent’s participation in 
research.  
 
Despite the minimally invasive approach in this study (responding to 
questionnaires), the use of questionnaire and interview questions can cause emotional 
discomfort and unpleasant feelings.77,78 In this case, the child could have decided not to 
answer such questions and would have been referred to a psychological service as 
instructed in the data collection protocol. 
 
 
Benefits to Participants and Society 
 
This study has potential benefit to children undergoing curative cancer treatment. 
Through the identification of treatment related factors that impact HRQOL change in 
children undergoing curative cancer treatment, interventions can be developed to 
specifically target diagnostic groups with lower HRQOL. The identification of domains 
of lower HRQOL allows researchers and clinicians to identify and intervene on these 
domains in an attempt to improve HRQOL and the illness experience of children 
undergoing curative cancer treatment. This allows for improved screening and 
management of symptoms that result in lower HRQOL in children and adolescents with 
cancer. Furthermore, identifying critical time points within diagnostic groups allows for 
targeting children at these time points with interventions that specifically address factors 
impacting HRQOL changes in children under curative cancer treatment. 
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CHAPTER 4.    RESULTS 
 
 
Description of the Sample 
 
The study sample included 710 participants across five diagnoses, including 
children and adolescents with Hodgkin lymphoma, acute lymphoblastic leukemia, acute 
myeloid leukemia, osteosarcoma, and melanoma. A study participant was defined as a 
child who had undergone and completed treatment at St. Jude Children’s Research 
Hospital (SJCRH). The demographic data of the participants by diagnostic group are 
shown in Table 4-1.  
 
Some of the demographic descriptions provided in the description tables are 
intended for thorough descriptive purposes. For statistical analysis purposes, age was 
categorized into two categories instead of three (Children ages 5-12 vs. Teenagers ages 
13-18). Race was also categorized into White vs. Other races.  
 
 
Acute Lymphoblastic Leukemia 
 
The study included 234 participants with acute lymphoblastic leukemia (ALL). 
Table 4-2 presents the demographics of the ALL participants by gender, age, and 
ethnicity across risk group. A greater percentage of this diagnostic group was male, and 
most of the sample was of white race. 
 
 
Acute Myeloid Leukemia 
 
The study included 86 participants with acute myeloid leukemia (AML).  
Table 4-3 presents the demographics of the AML participants by gender, age, and 
ethnicity across risk group. 
 
 
Hodgkin Lymphoma 
 
 The study included 251 participants with HL. Table 4-4 presents the 
demographics of HL participants by gender, age, and ethnicity across risk group. 
 
 
Melanoma 
 
The study included 23 participants with Melanoma. The small sample size didn’t 
allow for meaningful description of the effect of different variables on the HRQOL of the 
group, thus only a univariate analysis was performed on children with melanoma.  
Table 4-5 presents the demographics of the Melanoma group. 
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Table 4-1. Demographics of study participants by diagnostic group 
Factor 
Diagnostic Group  
ALL (n=234) 
 
AML (n=86) 
 
HL (n=251) 
 MEL 
(n=23) 
 
OS (n=116) 
 
Total (N=710) 
n %  n %  n %  n %  n %  N % 
Gender 
88 38 
 
39 45 
 
133 52 
 
11 48 
 
50 43 
 
321 45 Female      
Male 146 62  47 55  118 48  12 52  66 57  389 55 
Age 
84 36 
 
10 11 
 
8 3 
 
3 13 
 
9 8 
 
114 16 
Young child 
(ages 5-7) 
     
Child (ages 8-
12) 84 36 
 
33 38 
 
46 18 
 
5 22 
 
39 34 
 
207 29 
Teen(ages 13-
18) 66 28 
 
43 51 
 
197 79 
 
15 65 
 
68 58 
 
389 55 
Ethnicity                  
White 188 80  57 68  192 76  16 70  76 66  529 75 
Black 37 16  19 24  49 20  2 9  28 24  135 19 
Other 9 4  10 8  10 4  5 21  12 10  46 6 
 
ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; HL: Hodgkin lymphoma; MEL: melanoma; OS: 
osteosarcoma. 
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Table 4-2. Demographics of patients with acute lymphoblastic leukemia by risk group 
Factor 
Risk 
All (n=234) 
Low 
(n=94) Standard (n=130) 
High 
(n=10) 
n % n % n % n % 
Gender         
Female 44 47 41 32 3 30 88 38 
Male 50 53 89 68 7 70 146 62 
Age         
Young child (ages 5-
7) 53 56 26 20 5 50 84 36 
Child (ages 8-12) 32 34 49 38 3 30 84 36 
Teen (ages 13-18) 9 10 55 42 2 20 66 28 
Ethnicity         
White 81 86 102 78 5 50 188 80 
Black 10 11 23 18 4 40 37 16 
Other 3 3 5 4 1 10 9 4 
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Table 4-3. Demographics of patients with acute myeloid leukemia by risk group 
 
 Risk Group  
 Low (n=29) Standard (n=25) High (n=32) Total (n=86) 
Factor n % n % n % n % 
Gender 
Female 15 52 10 40 14 44 39 45 
Male 14 48 15 60 18 56 47 55 
Age         
Young child 
(ages 5-7) 3 10 1 4 6 19 10 12 
Child (ages 8-
12) 13 45 10 40 10 31 33 38 
Teen (ages 13-
18) 13 45 14 56 16 50 43 50 
Ethnicity         
White 19 65 16 64 22 68 57 66 
Black 8 28 6 24 5 16 19 22 
Other 2 7 3 12 5 16 10 12 
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Table 4-4. Demographics of patients with Hodgkin lymphoma by risk group 
 
 Risk Group  
 Favorable (n=48) Intermediate (n=108) Unfavorable (n=95) Total (n=251) 
Factor n % n % n %   
Gender 
Female 20 41 64 59 49 52 133 53 
Male 28 58 44 40 46 48 118 47 
Age         
Young child 
(ages 5-7) 4 8 2 2 2 2 8 3 
Child (ages 8-
12) 10 20 18 17 18 19 46 18 
Teen (ages 13-
18) 34 70 88 81 75 79 197 79 
Ethnicity         
White 40 83 88 81 64 67 192 77 
Black 5 10 16 15 28 30 49 19 
Other 3 6 4  4 3 3 10 4 
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Table 4-5. Demographics of patients with melanoma  
 Total (n=23) 
Factor n % 
Gender   
Female 11 48 
Male 12 52 
Age   
Young child (ages 5-7) 3 13 
Child (ages 8-12) 5 22 
Teen (ages 13-18) 15 65 
Ethnicity   
White 16 69 
Black 2 9 
Other 5 22 
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Osteosarcoma 
 
The study included 116 participants with Osteosarcoma (OS) treated across two 
protocols, OS99 and OS08. Table 4-6 presents the demographics of the OS participants 
by gender, age, and ethnicity across the two study groups. 
 
 
Aim 1  
 
Aim 1 was to identify longitudinal trends in HRQOL change in diagnostic groups 
of children undergoing curative cancer treatment. Two research questions were proposed 
to address this aim. The research questions to answer this aim were: 
 
? Research Question 1-1: What is the self-reported HRQOL of children 
undergoing curative cancer treatment within each diagnostic group at each time 
point? 
 
? Research Question 1-2: What is the difference in self-reported HRQOL of 
children undergoing curative cancer treatment at each time point within each 
diagnostic group? 
 
To address these questions, HRQOL scores were summarized for each diagnostic 
group by domain at each time point using descriptive statistics (mean and standard 
deviation). The results are presented according to the domains of the PedsQL-Generic 
scale (physical, emotional, social, school), and the PedsQL-Cancer specific module (pain 
and hurt, nausea, procedural anxiety, treatment anxiety, cancer worry, cognitive 
problems, perceived physical appearance, communication). 
 
For consistency, results in each diagnostic group are presented separately. Higher 
scores indicate fewer problems and symptoms or better HRQOL on the PedsQL-Generic 
and the PedsQL-Cancer modules. The results for each group are presented alphabetically 
in the same order they were presented in the demographic description section; acute 
lymphoblastic leukemia (ALL), acute myelocytic leukemia (AML), Hodgkin lymphoma 
(HL), melanoma, and osteosarcoma (OS). 
 
 Demographic descriptions are provided for each group in addition to the scores of 
each domain and cancer-related symptom in that particular group. In this section, a brief 
overview of the self-reported HRQOL in each group in addition to identifying differences 
in these self-reported HRQOL scores within each diagnostic group will be presented as 
well to give an overview of the longitudinal trends within each diagnostic group. These 
results pertain to each group separately and do not present comparisons with other 
diagnostic groups.  
 
 
 
 
 38 
Table 4-6. Demographics of patients with osteosarcoma by study 
 
 Study  
 OS99 (n=75) OS08 (n=41) Total (n=116) 
Factor n % n % n % 
Gender       
Female 32 43 18 44 50 43 
Male 43 57 23 56 66 57 
Age       
Young child 
(ages 5-7) 7 9 2 5 9 8 
Child (ages 8-12) 21 28 18 44 39 34 
Teen (ages 13-
18) 47 63 21 51 68 58 
Ethnicity       
White 54 72 22 54 76 66 
Black 14 19 14 34 28 24 
Other 7 9 5 12 12 10 
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Acute Lymphoblastic Leukemia 
 
At day 40 of after the beginning of treatment (T1), participants with ALL had a 
mean HRQOL score of 68. This score steadily improved during treatment to an average 
score of 75 at the last time point (T4).All domains of HRQOL in children with ALL were 
less than 80 except for the social functioning domain at T2 (80.01) and T4 (82.21). 
Physical functioning was the lowest scoring domain at T1 (60.70); however, it improved 
at T2 through T4. The lowest domain across time was school, with the exception of T1, 
while social function was the highest scoring domain across all time-points. 
 
As for cancer symptoms, all symptoms scored lower than 80 except for treatment 
anxiety. Procedural anxiety was the lowest scoring symptom, reflecting poorer HRQOL 
outcomes and more symptoms, at T1 (54.67), however, it improved over time reaching 
highest score at T4 (76.71). The lowest symptom scores at the end of treatment (T4) were 
for pain and hurt (70.57) and nausea (71.65). Procedural anxiety being the lowest domain 
at the initial time point. As treatment progressed, nausea became the lowest domain, with 
poorest outcomes, at both T2 and T3. 
 
Physical Functioning. The physical functioning domain started as the lowest 
scoring domain in children with ALL, lower than all other domains. However, physical 
functioning improved at T2 and a stable score was maintained through treatment, 
achieving an increase from T1 to T4. 
 
Emotional Functioning. Emotional functioning started at a mean score of 71 at 
T1, this score improved at T2, however, it dipped again at T3, and it eventually regained 
a higher score at T4 in comparison to T1. 
 
Social Functioning. Social functioning was the highest mean score domain in 
children with ALL across all time points in treatment. It started at a mean score of 79.6 at 
T1, plateaued at T2 and T3, and reached a high score of 82.2 at T4.  
 
School Functioning. School functioning maintained a steady score throughout 
treatment for children with ALL. School functioning was the lowest scoring domain at all 
time-points except for beginning of treatment (T1), where it was the second lowest 
domain after the physical functioning domain. 
 
Total Score. Children with ALL reported an increase in their total HRQOL score 
at T2 in comparison to T1. The total score then decreased at T3, but increased again at 
the end of treatment (T4) to comparable levels of T2. In general, the total HRQOL score 
at the end of treatment (T4) is higher than at the beginning of treatment (T1).  
 
Table 4-7 presents the HRQOL outcomes collected using the PedsQL-Generic 
and PedsQL-Cancer scales for the ALL group across all time points and domains.  
Figure 4-1 presents the plotting of different HRQOL domain average scores across time 
on the PedsQL-Generic and the PedsQL-Cancer scales. Higher scores on the PedsQL-
Generic and PedsQL-Cancer indicate fewer symptoms and better HRQOL. 
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Table 4-7. Domains and symptoms of HRQOL outcomes over time in ALL 
 
 T1  T2  T3  T4 
HRQOL  n Mean StdDev  n Mean StdDev  n Mean StdDev  n Mean StdDev 
PedsQL-Generic Domains                
Total Score 209 68.66 17.19  203 75.14 16.04  169 73.55 14.75  158 75.70 14.35 
Physical Functioning 209 60.70 25.99  203 73.89 19.90  169 73.09 18.89  158 75.18 18.89 
Emotional Functioning 209 71.06 20.19  202 76.07 19.20  169 73.59 17.85  158 77.34 18.17 
Social Functioning 207 79.61 18.47  202 80.01 17.73  169 79.41 18.57  158 82.21 16.74 
School Functioning 156 67.27 23.22  167 70.10 22.16  156 68.17 19.60  150 68.10 18.81 
PedsQL-Cancer Domains                
Pain and Hurt 206 67.17 27.80  200 79.38 22.62  168 68.75 25.81  158 70.57 28.92 
Nausea 206 72.96 19.55  200 63.44 20.19  167 68.77 18.27  158 71.65 17.36 
Procedural Anxiety 206 54.67 30.77  199 64.15 28.44  166 71.99 28.44  158 76.71 27.13 
Treatment Anxiety 205 82.87 23.02  200 86.42 19.86  167 89.97 16.90  157 91.03 16.89 
Cancer Worry 203 73.21 24.13  198 72.47 24.31  167 75.85 22.88  158 81.38 19.35 
Cognitive Problems 200 75.25 21.13  197 75.53 20.84  167 76.27 20.33  158 75.24 20.42 
Perceived Physical Appearance 206 78.64 23.65  200 78.96 24.34  167 75.85 24.61  159 80.45 23.19 
Communication 204 76.08 23.75  201 77.03 22.46  167 79.09 21.60  159 83.44 18.06 
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Figure 4-1. HRQOL domain average scores across time on the PedsQL-Generic 
and the PedsQL-Cancer scales for the ALL group 
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Acute Myeloid Leukemia 
 
All HRQOL domains in children with AML domains scored well below 80, 
except for the social functioning domain (85.56). The lowest scoring domains at T1 are 
the emotional functioning domain (65.07) and the physical functioning domain (65.41). 
During treatment at T2, the physical functioning domain experiences a significant drop 
(60.05), this trend is also experienced in the school functioning domain (67.51) and is 
reflected by a non-significant decrease in the total score (69.33). This trend is gradually 
resolved at T3, where all domains experience a gradual increase in their scores, and this 
trend carries over to the end of treatment (T4), where all domains are s higher than at the 
beginning of treatment (T1). Data related to cancer symptoms were not reported for 
children with AML at the beginning of treatment (T1). Throughout treatment (T2, T3), 
the lowest scoring cancer-related symptoms were nausea (T2, 59.86; T3, 65.33) and 
procedural anxiety (T2, 60.75; T3, 66.76). Over time, children with AML report an 
improvement in all cancer-related symptom scores at the end of treatment (T4) in 
comparison to the beginning of treatment (T1).  
 
Table 4-8 presents the HRQOL outcomes for the AML group across all time 
points and domains collected using the PedsQL-Generic and the PedsQL-Cancer scales. 
Higher scores on the scales indicate better HRQOL and fewer symptoms. Figure 4-2 
presents the plotting of different HRQOL domain average scores across time on the 
PedsQL-Generic and the PedsQL-Cancer scales.  
 
Physical Functioning. Physical functioning at T1 averaged at 65.41 for children 
with AML. This score dropped further at T2 to reach 60. However, it slowly improved at 
T3 and at T4 reaching a maximum score of 85 at the end of treatment (T4). 
 
Emotional Functioning. Emotional functioning was the lowest scoring domain at 
the beginning of treatment at T1. However, emotional functioning was found to have 
trending improvement through treatment, reaching a mean score of 84.85 at T4. 
 
Social Functioning. Social function was the highest mean score domain across all 
domain and time points in children with AML. The mean score for the social domain 
started at 85.6, reaching a high score of 92.5 at T4. 
 
School Functioning. School functioning in children with AML experienced a 
decrease at T2 (67.4) in comparison to T1 (73.18); this decrease is corrected at T3 
(72.36). At the end of treatment (T4), children with AML reported higher school 
functioning scores (81.99) in comparisons to the beginning of treatment (T1, 73.18).  
 
Total Score. As a reflection of the general trend in all HRQOL domains in 
children with AML, the total HRQOL score indicated a decrease at T2 (69.33), in 
comparison to the beginning of treatment (T1, 71.29). This trend is, however, reversed at 
T3 (74.90) and at T4 (86.57). The total HRQOL at the end of treatment (T4) is higher in 
comparison to the beginning of treatment (T1), indicating improved HRQOL. 
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Table 4-8. Domains and symptoms of HRQOL outcomes over time in AML 
 
 T1  T2  T3  T4 
HRQOL n Mean StdDev  n Mean StdDev  n Mean StdDev  n Mean StdDev 
PedsQL-Generic Domains                
Total Score 73 71.29 16.72  74 69.33 16.33  45 74.90 16.58  33 86.57 10.06 
Physical Functioning 73 65.41 24.41  74 60.05 27.02  45 67.74 25.77  33 85.51 14.57 
Emotional Functioning 73 65.07 24.74  74 69.31 21.74  45 76.00 19.90  33 84.85 13.20 
Social Functioning 72 85.56 15.64  72 84.74 14.85  45 87.72 14.40  33 92.53 10.58 
School Functioning 67 73.18 19.11  59 67.51 23.03  36 72.36 17.50  28 81.99 16.58 
PedsQL-Cancer Domains                
Pain and Hurt     75 69.67 27.20  45 71.39 24.08  30 85.00 17.18 
Nausea     75 59.86 21.94  45 65.33 20.10  30 82.67 17.31 
Procedural Anxiety     74 60.75 32.26  45 66.76 31.31  30 74.17 25.37 
Treatment Anxiety     75 82.50 24.34  45 91.67 16.95  30 93.61 13.43 
Cancer Worry     74 67.62 24.43  45 70.56 23.48  30 80.00 23.53 
Cognitive Problems     74 78.38 18.29  45 82.97 18.19  30 84.83 17.44 
Perceived Physical Appearance     74 78.49 23.65  45 85.19 20.33  30 88.61 18.24 
Communication     75 77.06 24.23  45 86.11 19.70  30 86.53 19.07 
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Figure 4-2. HRQOL domain average scores across time on the PedsQL-Generic 
and the PedsQL-Cancer scales for the AML group 
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Hodgkin Lymphoma 
 
At the initiation of therapy (T1) and during treatment (T2, T3), all HRQOL 
domains were less than 80 except social functioning (range 88.33-87.56). Emotional 
functioning (69.45) at the initiation of therapy was the lowest domain, followed by school 
functioning (70.76). During therapy (T2, T3) school functioning remained low (67.98, 
70.67), followed by physical functioning (70.82, 72.63) and emotional functioning 
(71.54, 74.18). All HRQOL domains were 80 or higher at the completion of therapy time 
point, with social functioning remaining the highest (91.58). Symptom reports were only 
collected at T2, T3, and T4. During the two time points in treatment (T2, T3), nausea (T2, 
60.70; T3, 59.31) was reported as the lowest scoring symptom in children with HL. 
However, at the end of treatment (T4), cancer worry became the lowest scoring symptom 
in children with HL. Table 4-9 presents the HRQOL outcomes collected using the 
PedsQL-Generic and PedsQL-Cancer scales for the HL group across all time points and 
domains. The PedsQL Cancer scale was not collected at the beginning of treatment (T1). 
Figure 4-3 presents the plotting of different HRQOL domain average scores across time 
on the PedsQL-Generic and the PedsQL-Cancer scales. 
 
Physical Functioning. The Physical functioning domain is relatively high at T1. 
However, at T2 and T3, the domain significantly dropped, becoming the lowest at T3 and 
the second lowest at T2. At T4, the physical domain improved at T4 from T3 and T1, 
achieving a higher score than at the beginning of treatment (T1). 
 
Emotional Functioning. The emotional functioning domain is the lowest scoring 
domain for children with HL at the beginning of treatment, with a score of 69.5 at T1. 
However, this domain demonstrated a steady improvement during treatment and reaching 
a higher mean score of 80.16 at T4.  
 
Social Functioning. The social functioning domains maintain the highest mean 
score across all time points in children with HL. This domain also show stable scores 
across all time points, starting with a mean score of 88.3 at T1 and ending with a mean 
score of 91.6 at T4. 
 
School Functioning. Children with HL reported higher school functioning scores 
at the end of treatment (T4) in comparison to the beginning of treatment. This domain 
showed a decrease as children receive treatment at (T2, T3). School functioning was the 
lowest scoring domain during treatment (T2, T3) and the second lowest at the beginning 
of treatment (T1, 70.76) and end of treatment (T4, 80.20). 
 
Total Score. As a reflection of the consistent trend of decreased HRQOL scores 
during treatment, the total HRQOL score indicated a decrease during treatment (T2, T3). 
However, the total HRQOL score for children with HL was higher at the end of treatment 
(T4) in comparison to the beginning of treatment (T1). 
 
 
 46 
Table 4-9. Domains and symptoms of HRQOL outcomes over time in HL 
 
 T1  T2  T3  T4 
HRQOL n Mean StdDev  n Mean StdDev  n Mean StdDev  n Mean StdDev 
PedsQL-Generic Domains                
Total Score 197 77.21 14.72  194 74.04 15.54  181 76.51 15.95  164 84.47 14.31 
Physical Functioning 217 78.38 21.22  216 70.82 21.44  204 72.63 22.48  177 84.79 15.90 
Emotional Functioning 217 69.45 18.04  216 71.54 20.20  204 74.18 20.80  177 80.16 22.07 
Social Functioning 218 88.33 14.73  216 87.56 14.04  204 87.72 14.16  177 91.58 13.01 
School Functioning 199 70.76 18.08  194 67.98 20.82  181 70.67 21.74  164 80.20 18.81 
PedsQL-Cancer Domains                
Pain and Hurt     212 65.92 25.56  196 69.39 26.04  174 84.91 21.43 
Nausea     212 60.70 23.05  196 59.31 24.47  170 77.92 22.45 
Procedural Anxiety     211 71.05 27.93  195 72.39 29.08  174 78.35 25.66 
Treatment Anxiety     212 85.36 19.16  196 82.57 22.55  174 84.77 21.31 
Cancer Worry     211 65.92 24.12  196 66.50 24.79  170 69.88 26.97 
Cognitive Problems     211 77.42 19.24  194 78.85 20.37  174 80.77 20.95 
Perceived Physical Appearance     212 77.00 22.95  196 78.23 23.19  172 80.81 23.90 
Communication     212 78.89 19.68  196 81.63 20.71  172 85.56 19.28 
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Figure 4-3. HRQOL domain average scores across time on the PedsQL-Generic 
and the PedsQL-Cancer scales for the HL group 
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Melanoma 
 
The melanoma group experienced HRQOL scores that were below or around 80. 
School functioning was the lowest scoring domain in children with melanoma across all 
time points in treatment. The highest scoring HRQOL domain at the beginning of 
treatment (T1) in children with Melanoma was the social functioning domain (82.95). 
However, at the end of treatment (T4), the highest scoring HRQOL domain was the 
physical functioning domain (83.53) followed closely by the social functioning domain 
(83.13).As for cancer-related symptoms , the highest scoring symptom across all time 
points was treatment anxiety, while the lowest scoring symptom across all time points 
was the procedural anxiety. Nausea improved gradually over time in children with 
melanoma from T1 (73.48) to the second highest domain at the end of treatment (T4, 
87.50).Table 4-10 presents the HRQOL outcomes for the melanoma group across all 
time points and domains collected using the PedsQL-Generic and the PedsQL-Cancer 
scales. Figure 4-4 presents the plotting of different HRQOL domain average scores 
across time on the PedsQL-Generic and the PedsQL-Cancer scales. 
 
Physical Functioning. Children with melanoma reported a high physical score at 
beginning of treatment (T1, 79.39). This score slightly declined at T2 (77.19), but 
improved gradually to a mean physical functioning score of 83.5 at the end of treatment 
(T4). At the end of treatment (T4) physical functioning was the highest mean domain 
score in children with melanoma. 
 
Emotional Functioning. Emotional functioning was the second lowest domain in 
children with melanoma, with a mean score of 73.5 at T1. This domain gradually 
increased throughout treatment (T2, 83.26; T3, 82.06), but decreased at the end of 
treatment (T4, 78.4).  
 
Social Functioning. Social functioning was the highest mean scoring domain 
across all time points except at the end of treatment (T4) in children with melanoma and 
remained relatively stable over time. Children with melanoma reported a mean social 
score of 82.9 at T1. This score was the same at T2, increased to 87 at T3, and decreased 
to the same level at T4, reaching a mean score of 83.1 at T4. 
 
School Functioning. School functioning was the lowest scoring domain at all 
time-points in children with melanoma. However, it showed improvement during 
treatment (T2, 72.00; T3, 74.71) in comparison to the beginning of treatment (T1, 68.82). 
At the end of treatment (T4), school functioning decreased again (69.64). 
 
Total Score. The total HRQOL score at the beginning of treatment (T1, 76.56) 
experienced a trend of increase throughout treatment points. During treatment, (T2, T3), 
the total score increased (78.99, 81.33) in comparison to at the beginning of treatment 
(T1, 76.56). However, at the end of treatment (T4, 79.59), the total HRQOL score is 
lower than in comparison to the previous time point (T3). The total HRQOL score at the 
end of treatment (T4) remains higher than at the beginning of treatment (T1). 
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Table 4-10. Domains and symptoms of HRQOL outcomes over time in melanoma 
 
 T1 T2 T3 T4 
HRQOL n Mean StdDev N Mean StdDev n Mean StdDev n Mean StdDev 
PedsQL-Generic Domains             
Total Score 23 76.56 18.02 23 78.99 15.63 17 81.33 16.00 16 79.59 16.06 
Physical Functioning 23 79.39 20.82 23 77.19 18.21 17 81.43 17.42 16 83.53 14.11 
Emotional Functioning 23 73.53 21.73 23 83.26 16.96 17 82.06 21.51 16 78.44 20.71 
Social Functioning 22 82.95 24.04 23 83.91 24.86 17 87.06 24.75 16 83.13 24.55 
School Functioning 17 68.82 25.16 20 72.00 34.12 17 74.71 23.55 14 69.64 18.65 
PedsQL-Cancer Domains             
Pain and Hurt    23 79.35 21.52 16 83.59 19.75 14 80.36 21.21 
Nausea    23 73.48 23.86 16 81.25 17.94 16 87.50 14.49 
Procedural Anxiety    23 72.10 28.82 16 67.19 33.12 16 68.75 31.70 
Treatment Anxiety    23 90.22 16.60 16 89.06 15.13 16 91.67 14.91 
Cancer Worry    23 77.17 21.35 16 77.60 27.17 16 79.17 28.22 
Cognitive Problems    23 82.07 25.51 16 80.94 24.17 16 80.00 17.77 
Perceived Physical Appearance    23 80.43 27.02 16 74.48 30.35 16 72.92 30.81 
Communication    23 82.61 25.49 16 82.81 20.06 16 77.08 28.79 
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Figure 4-4. HRQOL domain average scores across time on the PedsQL-Generic 
and the PedsQL-Cancer scales for the melanoma group  
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Osteosarcoma 
 
The OS group reported HRQOL domain scores well below 80 at all HRQOL 
domains. The physical functioning domain (46.81) was the lowest scoring domain at the 
beginning of treatment (T1) and throughout the other time points (T2, T3); it also was the 
lowest scoring domain at the end of treatment (T4, 62.46). The highest scoring domain at 
the beginning of treatment (T1) was the social functioning domain (77.35). The social 
functioning domain was the only domain that scored lower at the end of treatment (T4) in 
comparison to the beginning of treatment. All the remaining domains reported an 
increase over time and reported highest scores at the end of treatment (T4). However, at 
the end of treatment (T4), the highest scoring domain was the social functioning domain 
(76.55). 
 
As for cancer-related symptoms in the OS group, the lowest scoring symptom, 
indicating more problems, at the beginning of treatment (T1) was cancer worry (52.18) 
followed closely by pain and hurt (52.55). Cancer worry improved gradually over time in 
treatment to a highest score (69.82) at the end of treatment (T4). The highest scoring 
symptom across all time points was treatment anxiety. At the beginning of treatment the 
nausea score was 67.29, however, during treatment (T2, T3), nausea scores decreased to 
become the lowest scoring symptom reported by the OS group (T2, 50.73; T3, 48.54). 
Nausea improved again at the end of treatment (T4) to achieve a higher mean score than 
at the start of treatment (T1).Table 4-11 presents the HRQOL outcomes for the OS group 
across all time points and domains collected using the PedsQL-Generic and the PedsQL-
Cancer scales. Figure 4-5 presents the plotting of different HRQOL domain average 
scores across time on the PedsQL-Generic and the PedsQL-Cancer scales. 
 
Physical Functioning. Children with OS started with a considerably low physical 
functioning score, with a mean score of 46.81. This score only slightly improved during 
treatment and reached the highest score of 62.46 at T4. 
 
Emotional Functioning. Children with OS reported the lowest emotional mean 
score at T1 compared to the other groups. The mean emotional score at T1 was 60.66. 
This domain, however, showed gradual improvements, reaching a highest score (76.10) 
at T4. 
 
Social Functioning. Social functioning domain started as the highest scoring 
domain at the first three time points in children with OS; however, children with OS were 
the only diagnostic group who reported lower social mean scores at the end of treatment 
T4 in comparison to baseline T1. 
 
School Functioning. School functioning in children with OS reflected a trend of 
gradual improvement over time. At the beginning of treatment (T1), children with OS 
reported the lowest school functioning score (63.80), this score improved at T2 (68.64) 
and maintained a relatively stable score at T3 (67.54). At the end of treatment (T4), 
children with OS reported a higher school functioning score (74.31) than all previous 
time points.
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Table 4-11. Domains and symptoms of HRQOL outcomes over time in OS 
 
T1 T2 T3 T4 
HRQOL n Mean StdDev n Mean StdDev n Mean StdDev n Mean StdDev 
PedsQL-Generic Domains             
Total Score 110 59.91 17.91 100 63.82 17.12 89 62.86 16.14 84 70.69 17.04 
Physical Functioning 110 46.81 27.98 100 51.75 24.80 89 48.77 21.59 84 62.46 21.83 
Emotional Functioning 110 60.66 22.75 100 66.40 22.10 89 69.66 22.64 82 76.10 18.84 
Social Functioning 110 77.35 18.18 99 79.39 15.52 89 74.94 17.83 82 76.55 17.14 
School Functioning 98 63.80 22.70 77 68.64 24.03 77 67.54 23.80 74 74.31 19.16 
PedsQL-Cancer Domains             
Pain and Hurt 108 52.55 30.08 101 76.24 22.74 89 72.89 23.55 82 71.80 24.04 
Nausea 107 67.29 26.25 101 50.73 23.49 89 48.54 22.83 80 73.88 22.09 
Procedural Anxiety 108 59.57 34.50 100 72.71 28.74 89 73.69 28.48 81 76.23 30.19 
Treatment Anxiety 107 74.57 28.33 101 86.30 19.31 88 89.30 17.73 82 88.92 19.42 
Cancer Worry 105 52.18 32.18 100 58.17 30.95 89 64.98 28.18 82 69.82 25.41 
Cognitive Problems 107 74.57 20.81 101 75.86 18.81 89 77.75 17.44 82 79.92 17.49 
Perceived Physical Appearance 108 75.00 25.39 100 76.29 24.01 89 79.87 20.83 82 81.30 21.38 
Communication 107 73.01 24.38 99 76.26 25.35 89 81.09 20.44 81 82.92 20.54 
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Figure 4-5. HRQOL domain average scores across time on the PedsQL-Generic 
and the PedsQL-Cancer scales for the OS group 
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Total Score. The total score corresponded with the trend of the previous domains. 
The total HRQL score is lower at the beginning of treatment (T1, 59.91). HRQOL total 
score then increased gradually at T2 (63.82) and T3 (74.9). The Total score at the end of 
treatment (T4, 70.69) was higher than the previous time point during treatment (T3), or at 
the beginning of treatment (T1). 
 
 
Aim 2  
 
Aim 2 was to identify the differences in HRQOL among different diagnostic 
groups of children undergoing curative cancer treatment. 
 
? Research Question 2-1: What is the difference in child self-reported HRQOL of 
children undergoing curative cancer treatment between different diagnostic 
groups at each time point? 
 
 
Physical Functioning 
 
Physical Functioning scores were lowest in the OS group across all time points 
and highest for the melanoma groups across all time points except at T4 where the AML 
group scored the highest on the physical functioning domain (M=85.51). All diagnostic 
groups reported a significantly higher physical domain score at the end of treatment at T4 
in comparison to T1 (p<.0001) except for the melanoma group which reported higher, but 
not significant, increase in the physical domain score (p=.3278). Table 4-12 presents the 
mean physical functioning scores over time in each diagnostic group. 
 
 
Emotional Functioning 
 
 Emotional functioning scores were lowest in children with OS (M=60.66), and 
highest in children with melanoma (M=73.53) at T1. The emotional functioning domain 
shows consistent increase over time in all diagnostic groups except for the melanoma 
group where emotional function reaches high levels during treatment at T2 (M=83.26) 
and T3(M=82.06) but lower scores at T4 (M=78.44). At T4, the highest emotional 
domain score across groups is for the AML group (M=84.85), followed closely by the 
HL group (M=80.38). All diagnostic group showed significant increases in emotional 
functioning at T4 in comparison to T1 (p<.0001) except for the melanoma group which 
achieves non-significant increase in the emotional score domain (p=.3064). Table 4-13 
presents the mean emotional functioning score over time in each diagnostic group. 
 
 
Social Functioning 
 
 The social functioning domain scores were generally higher than most other 
domains across all diagnostic groups. The OS group scored the lowest social functioning  
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Table 4-12. Physical HRQOL scores across diagnostic groups and over time 
 
Time Point 
T1  T2  T3  T4 
Diagnosis n Mean  n Mean  n Mean  n Mean 
ALL 209 60.70  203 73.89^  169 73.09^  158 75.18^ 
AML 73 65.41  74 60.05  45 67.74  33 85.51^ 
HL* 218 78.30  216 70.82^  205 72.53^  177 84.85^ 
MEL 23 79.39  23 77.19  17 81.43  16 83.53 
OS 110 46.81  100 51.75  89 48.77  84 62.46^ 
 
ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia; HL: Hodgkin 
lymphoma; MEL: melanoma; OS: osteosarcoma. 
*:p<0.05 between diagnostic groups in comparison to acute lymphoblastic leukemia; 
^:p<0.05 within group over time in comparison to first time point of measurement.  
 
 
 
Table 4-13. Emotional HRQOL scores across diagnostic scores and over time 
 
Time Point 
T1  T2  T3  T4 
Diagnosis n Mean  n Mean  n Mean  n Mean 
ALL 209 71.06  202 76.07^  169 73.59  158 77.34^ 
AML 73 65.07  74 69.31  45 76.00^  33 84.85^ 
HL 218 69.40  216 71.66  205 74.26^  177 80.38^ 
MEL 23 73.53  23 83.26  17 82.06  16 78.44 
OS 110 60.66  100 66.40^  89 69.66^  82 76.10^ 
 
ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; HL; Hodgkin 
lymphoma; MEL: melanoma; OS: osteosarcoma. 
*:p<0.05 between diagnostic groups in comparison to acute lymphoblastic leukemia; 
^:p<0.05 within group over time in comparison to first time point of measurement.  
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score among all other groups across all time points (T1, M=77.35; T2, M=79.39; T3, 
M=74.94; T4, M=76.55). The OS group was also the only group that reported a lower 
social functioning at T4 in comparison to T1 (p=.8874), while all other groups reported 
an increase. The HL and AML were the highest scoring diagnostic groups, with the HL 
group scoring highest at T1 (M=88.14), T2 (87.42), and T3 (87.49), and the AML group 
scoring the highest average social functioning score at T4 (92.53). All diagnostic groups 
except for the OS group reported higher, but not significant increases in social 
functioning at T4 in comparison to T1. Table 4-14 describes the change in social 
functioning scores over time in each diagnostic group. 
 
 
School Functioning 
 
 School functioning maintained a relatively stable outcome over time. The lowest 
school functioning score at the beginning of treatment (T1) was for the OS group 
(M=63.80), indicating poorer outcomes. However, at the end of treatment (T4), children 
with ALL (M=68.10) reported the lowest school functioning among all groups.  
 
There was also a noticeable different between school functioning at the end of 
treatment (T4) in children with AML (81.99) and HL (80.21), and the OS (74.31), 
melanoma (69.64), and ALL (68.1) groups. Children with HL and OS reported 
significantly higher school functioning scores (p<0.0001) at the end of treatment (T4) in 
comparison to the beginning of treatment (T1). Table 4-15 describes the change in school 
functioning scores over time in each diagnostic group. 
 
 
Total Score 
 
With the exception of children with melanoma, all other diagnostic groups 
reported significant increases (p<.0001) in total HRQOL scores at the end of treatment 
(T4) in comparison to the beginning of treatment (T1). The HRQOL total score was 
lowest for the OS group over all time points.  
 
The highest mean HRQOL total scores at T1 were 77.00 for the HL and 76.56 for 
the melanoma diagnostic groups. The melanoma group maintained the highest total score 
through treatment at T2 (M=78.99) and T3 (M=81.33). However, at T4, the highest total 
HRQOL score was for the AML (86.57) group which experienced the most significant 
change in HRQOL total score from T1 to T4 (p<.0001).  
 
Table 4-16 presents the change in total HRQOL scores diagnostic groups and 
over time. Figure 4-6 presents the plotting of total HRQOL scores over time in each 
diagnostic group. It demonstrates the variation within different diagnostic groups across 
time. 
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Table 4-14. Social HRQOL scores across diagnostic groups and over time 
 
Time Point 
T1  T2  T3  T4 
Diagnosis n Mean  n Mean  n Mean  n Mean 
ALL 207 79.61  202 80.01  169 79.41  158 82.21 
AML* 72 85.56  72 84.74  45 87.72  33 92.53 
HL* 218 88.14  216 87.42  205 87.49  177 91.58^ 
MEL 22 82.95  23 83.91  17 87.06  16 83.13 
OS 110 77.35  99 79.39  89 74.94  82 76.55 
 
ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia; HL: Hodgkin 
lymphoma; MEL: melanoma; OS: osteosarcoma. 
*:p<0.05 between diagnostic groups in comparison to acute lymphoblastic leukemia; 
^:p<0.05 within group over time in comparison to first time point of measurement. 
 
 
 
Table 4-15. School HRQOL scores across diagnostic groups and over time 
 
Time Point 
T1  T2  T3  T4 
Diagnosis n Mean  n Mean  n Mean  n Mean 
ALL 156 67.27  167 70.10  156 68.17  150 68.10 
AML 67 73.18  59 67.51  36 72.36  28 81.99 
HL 202 70.41  197 68.14  182 70.76  165 80.21^ 
MEL 17 68.82  20 72.00  17 74.71  14 69.64 
OS 98 63.80  77 68.64^  77 67.54  74 74.31^ 
 
ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia; HL: Hodgkin 
lymphoma; MEL: melanoma; OS: osteosarcoma. 
*:p<0.05 between diagnostic groups in comparison to acute lymphoblastic leukemia; 
^:p<0.05 within group over time in comparison to first time point of measurement. 
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Table 4-16. Total HRQOL scores across diagnostic groups and over time 
 
Time Point 
T1  T2  T3  T4 
Diagnosis n Mean  n Mean  n Mean  n Mean 
ALL 209 68.66  203 75.14^  169 73.55^  158 75.70^ 
AML 73 71.29  74 69.33  45 74.90  33 86.57^ 
HL 218 77.00  216 74.15^  205 75.77  177 84.35^ 
MEL 23 76.56  23 78.99  17 81.33  16 79.59 
OS 110 59.91  100 63.82^  89 62.86  84 70.69^ 
 
ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia; HL: Hodgkin 
lymphoma; MEL: melanoma; OS: osteosarcoma. 
*:p<0.05 between diagnostic groups in comparison to acute lymphoblastic leukemia; 
^:p<0.05 within group over time in comparison to first time point of measurement. 
 
 
 
 
 
Figure 4-6. HRQOL outcomes on PedsQL-Total domain across diagnostic groups 
 
ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia; HL: Hodgkin 
lymphoma; MEL: melanoma; OS: osteosarcoma. 
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Pain and Hurt 
 
No information were collected on Pain and hurt at T1 for the AML, HL, and 
melanoma groups as patients did not experience cancer-related symptoms before 
beginning treatment. At the 3 time points following T1, two groups could be identified by 
the differences in pain and hurt scores. Children with AML (p=.7586) and HL (p=.5031) 
experienced lower but not significantly different pain and hurt scores in comparison to 
children with ALL. Children with melanoma reported significantly better pain and hurt 
scores (p=.0371), and children with OS reported a significantly lower pain and hurt 
scores (p=.0741), in comparison to the ALL group.  
 
In general, diagnosis was a significant predictor of change in pain and hurt scores 
(p=.033). Overall, pain and hurt symptoms improved significantly between the beginning 
of treatment (T1) and the end of treatment (T4) in children with AML, HL, and OS, but 
not in children with ALL and melanoma, where pain and hurt scores improved but not 
significantly. Table 4-17 presents the change in Pain and hurt scores over time and across 
the different diagnostic groups.  
 
 
Nausea 
 
 Nausea symptoms were significantly predicted by diagnosis. All groups reported 
significantly lower nausea scores (p<.1) in comparison to the ALL group, except for the 
melanoma group, which reported significantly higher scores (p<.0045) in comparison to 
the ALL group. Over time, nausea scores significantly improved in the overall sample 
(p<.005). However, by examining each group separately, we found that all groups 
reported significantly improved nausea scores (p<.05) at the end of treatment (T4) in 
comparison to the beginning of treatment (T1), except for the ALL group (p=.4048). 
Table 4-18 presents the change in nausea scores over time and across the different 
diagnostic groups in the study. 
 
 
Procedural Anxiety 
 
 Across diagnostic groups and over time, children with ALL reported the lowest 
procedural anxiety scores at T1 (M=54.67), indicating high burden of symptom. At the 
end of treatment (T4), children with HL reported the highest procedural anxiety scores, 
indicating less symptom burden.  
 
Over time, children reported a significantly improved procedural anxiety scores 
(p<.05) at the end of treatment in comparison to the beginning of treatment (T1), except 
for children with melanoma, where procedural anxiety scores improved but not 
significantly (p=.7634). Table 4-19 presents the change in procedural anxiety scores over 
time and across the different diagnostic groups. 
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Table 4-17. Pain and hurt scores across diagnostic groups and over time 
 
Time Point 
T1  T2  T3  T4 
Diagnosis n Mean  n Mean  n Mean  n Mean 
ALL 206 67.17  200 79.38^  168 68.75  158 70.57 
AML . .  75 69.67  45 71.39  30 85.00^ 
HL . .  212 65.92  196 69.39  174 84.91^ 
MEL* . .  23 79.35  16 83.59  14 80.36 
OS 108 52.55  101 76.24^  89 72.89  82 71.80^ 
 
ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia; HL: Hodgkin 
lymphoma; MEL: melanoma; OS: osteosarcoma. 
*:p<0.05 between diagnostic groups in comparison to acute lymphoblastic leukemia; 
^:p<0.05 within group over time in comparison to first time point of measurement. 
 
 
 
Table 4-18. Nausea scores across diagnostic groups and over time 
 
Time Point 
T1  T2  T3  T4 
Diagnosis n Mean  n Mean  n Mean  n Mean 
ALL 206 72.96  200 63.44^  167 68.77  158 71.65 
AML . .  75 59.86  45 65.33  30 82.67^ 
HL . .  212 60.70  196 59.31  170 77.92^ 
MEL* . .  23 73.48  16 81.25  16 87.50^ 
OS 107 67.29  101 50.73^  89 48.54^  80 73.88^ 
 
ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia; HL: Hodgkin 
lymphoma; MEL: melanoma; OS: osteosarcoma. 
*:p<0.05 between diagnostic groups in comparison to acute lymphoblastic leukemia; 
^:p<0.05 within group over time in comparison to first time point of measurement. 
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Table 4-19. Procedural anxiety scores across diagnostic groups and over time 
 
Time Point 
T1  T2  T3  T4 
Diagnosis n Mean  n Mean  n Mean  n Mean 
ALL 206 54.67  199 64.15^  166 71.99^  158 76.71^ 
AML . .  74 60.75  45 66.76  30 74.17^ 
HL . .  211 71.05  195 72.39  174 78.35^ 
MEL . .  23 72.10  16 67.19  16 68.75 
OS 108 59.57  100 72.71^  89 73.69^  81 76.23^ 
 
ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia; HL: Hodgkin 
lymphoma; MEL: melanoma; OS: osteosarcoma. 
*:p<0.05 between diagnostic groups in comparison to acute lymphoblastic leukemia; 
^:p<0.05 within group over time in comparison to first time point of measurement. 
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Treatment Anxiety 
 
 Treatment anxiety was generally not predicted by the different diagnoses in the 
overall sample. Table 4-20 presents the change in treatment anxiety scores over time and 
across the different diagnostic groups. Children with HL reported significantly lower 
treatment anxiety scores, indicating higher symptom burden in comparison to children 
with ALL (p<.0432). Over time in the overall sample, children reported higher treatment 
anxiety scores, indicating better outcomes, at the end of treatment (T4) in comparison to 
T1 (p<.0001). This trend was not significant, however, in children with HL (p=.8591), 
and melanoma (p=.5752).  
 
 
Cancer Worry 
 
 Table 4-21 presents the change in cancer worry scores across different diagnostic 
groups and over time. The lowest cancer worry score at the beginning of treatment was 
for the OS groups (M=74.57). At the end of treatment (T4), children with AML reported 
the highest cancer worry score. Symptoms of cancer worry were significantly predicted 
by diagnosis and time in treatment in the overall sample (p<.0001). There were no 
significant differences in cancer worry scores among different diagnostic groups over 
time in our sample.  
 
 
Cognitive Problems 
 
 Cognitive problems scores maintained relatively stable scores over time. The 
group with the lowest cognitive fatigue scores was the OS group at T1 (M=74.57). 
Overall in the general sample, cognitive fatigue scores improved significantly at the end 
of treatment (T4) in comparison to the beginning of treatment (T1, p=.002). This trend, 
however, was not observed in all diagnostic groups, only children with HL (p<.0123) and 
OS (p<.0023) reported significant improvement in cognitive problems at T4 in 
comparison to T1. There were no significant differences between diagnostic groups over 
time in our sample. Table 4-22 presents the change in cognitive problems’ scores across 
different diagnostic groups and over time. 
 
 
Perceived Physical Appearance 
 
 Perceived physical appearance was a relatively stable symptom that significantly 
improved over time in children within our overall sample. Children reported significantly 
higher perceived physical appearance scores (p<.0089) at the end of treatment (T4) in 
comparison to the beginning of treatment (T1). However, the trend of improvement over 
time was not significant in all diagnostic groups. Diagnosis was not a predictor of 
perceived physical appearance scores, indicating that children across all diagnostic 
groups experienced similar effects. Table 4-23 presents the change in perceived physical 
appearance scores across different diagnostic groups and over time. 
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Table 4-20. Treatment anxiety scores across diagnostic groups and over time 
 
Time Point 
T1  T2  T3  T4 
Diagnosis n Mean  n Mean  n Mean  n Mean 
ALL 205 82.87  200 86.42^  167 89.97^  157 91.03^ 
AML . .  75 82.50  45 91.67  30 93.61 
HL* . .  212 85.36  196 82.57  174 84.77 
MEL . .  23 90.22  16 89.06  16 91.67 
OS 107 74.57  101 86.30^  88 89.30^  82 88.92^ 
 
ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia; HL: Hodgkin 
lymphoma; MEL: melanoma; OS: osteosarcoma. 
*:p<0.05 between diagnostic groups in comparison to acute lymphoblastic leukemia; 
^:p<0.05 within group over time in comparison to first time point of measurement. 
 
 
 
Table 4-21. Cancer worry scores across diagnostic groups and over time 
 
Time Point 
T1  T2  T3  T4 
Diagnosis n Mean  n Mean  n Mean  n Mean 
ALL 205 82.87  200 86.42  167 89.97  157 91.03^ 
AML . .  75 82.50  45 91.67  30 93.61 
HL . .  212 85.36  196 82.57  174 84.77^ 
MEL . .  23 90.22  16 89.06  16 91.67 
OS 107 74.57  101 86.30^  88 89.30^  82 88.92^ 
 
ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia; HL: Hodgkin 
lymphoma; MEL: melanoma; OS: osteosarcoma. 
*:p<0.05 between diagnostic groups in comparison to acute lymphoblastic leukemia; 
^:p<0.05 within group over time in comparison to first time point of measurement. 
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Table 4-22. Cognitive problems scores across diagnostic groups and over time 
 
Time Point 
T1  T2  T3  T4 
Diagnosis n Mean  n Mean  n Mean  n Mean 
ALL 200 75.25  197 75.53  167 76.27  158 75.24 
AML . .  74 78.38  45 82.97  30 84.83 
HL . .  211 77.42  194 78.85  174 80.77^ 
MEL . .  23 82.07  16 80.94  16 80.00 
OS 107 74.57  101 75.86  89 77.75^  82 79.92^ 
 
ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia; HL: Hodgkin 
lymphoma; MEL: melanoma; OS: osteosarcoma. 
*:p<0.05 between diagnostic groups in comparison to acute lymphoblastic leukemia; 
^:p<0.05 within group over time in comparison to first time point of measurement. 
 
 
 
Table 4-23. Perceived physical appearance scores across diagnostic groups and 
over time 
 
Time Point 
T1  T2  T3  T4 
Diagnosis n Mean  n Mean  n Mean  n Mean 
ALL 206 78.64  200 78.96  167 75.85  159 80.45 
AML . .  74 78.49  45 85.19  30 88.61 
HL . .  212 77.00  196 78.23  172 80.81^ 
MEL . .  23 80.43  16 74.48  16 72.92 
OS 108 75.00  100 76.29  89 79.87  82 81.30^ 
 
ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia; HL: Hodgkin 
lymphoma; MEL: melanoma; OS: osteosarcoma. 
*:p<0.05 between diagnostic groups in comparison to acute lymphoblastic leukemia; 
^:p<0.05 within group over time in comparison to first time point of measurement. 
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Communication 
 
 Communication scores generally improved over time in the overall sample.  
Table 4-24 presents the change in communication scores across different diagnostic 
groups and over time. The lowest communication score was for the OS group at the 
beginning of treatment (T1, M=73.01). Examining each diagnostic group separately, only 
children with ALL (p=.0003), HL (p<.0001), and OS (p<.0001) experienced a significant 
increase in their communication scores at the end of treatment (T4) in comparison to the 
beginning of treatment (T1). In the overall sample, diagnosis was not a predictor of 
communication scores (p=.2209).  
 
 
Aim 3  
 
Aim 3 was to identify correlates with HRQOL of children undergoing curative 
cancer treatment over time within each diagnostic group.  
 
? Research Question 3-1: Is there an association between cancer and treatment 
factors and self-reported HRQOL of children undergoing curative cancer 
treatment over time? 
 
? Research Question 3-3: What are the associations between each variable and the 
change in self-reported HRQOL of children undergoing curative cancer 
treatment? 
 
 
Table 4-24. Communication scores across diagnostic groups and over time 
 
Time Point 
T1  T2  T3  T4 
Diagnosis n Mean  n Mean  n Mean  n Mean 
ALL 204 76.08 
 201 77.03  167 79.09  159 83.44^ 
AML . . 
 75 77.06  45 86.11  30 86.53 
HL . . 
 212 78.89  196 81.63  172 85.56^ 
MEL . . 
 23 82.61  16 82.81  16 77.08 
OS 107 73.01 
 99 76.26^  89 81.09  81 82.92^ 
 
ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia; HL: Hodgkin 
lymphoma; MEL: melanoma; OS: osteosarcoma. 
*:p<0.05 between diagnostic groups in comparison to acute lymphoblastic leukemia; 
^:p<0.05 within group over time in comparison to first time point of measurement. 
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Acute Lymphoblastic Leukemia 
 
A univariate model to identify predictors of the PedsQL-Generic domain scores 
identified age, gender, race, risk group, and time as significant predictors of HRQOL 
domains on the PedsQL-Generic scale (Table 4-25). A multivariate analysis of the 
PedsQL-Generic domain scores which included the significant factors from the univariate 
analysis for each domain identified age, gender, race, risk group, and time as significant 
predictors of the physical, emotional and total HRQOL scores. No included factors were 
identified to predict the social functioning and school functioning domains on the 
multivariate analysis (Table 4-26).On the PedsQL-Cancer module, age, gender, race, risk 
group and time were also significant predictors of different cancer-related symptoms in 
children with ALL (Table 4-27). A multivariate analysis of the PedsQL-Cancer symptom 
scores which included the significant factors from the univariate analysis for each 
symptom identified age, gender, race, risk group, and time as significant predictors of the 
cancer-related symptoms (Table 4-28).  
 
 In multivariate models, age was a significant predictor of HRQOL in children 
with ALL only on the physical domain score (p<.0001). Children (5-12 years) reported 
significantly better physical functioning score. Age was also a predictor of cancer-related 
symptoms, including pain and hurt, nausea, procedural anxiety, and communication. 
Children (ages 5-12 years) reported significantly better pain and hurt (p=.0003), and 
nausea (p=.0003) scores, and reported significantly lower, indicating worse outcomes, 
procedural anxiety (p<.0001) and communication (p=.0009) scores than adolescents.  
 
Gender was a significant predictor of physical (p=.0003), emotional (p<.0001), 
and total (p=.0005) scores of HRQOL. In all these domains, being female was associated 
with a significantly lower HRQOL. Female gender was also associated with lower pain 
and hurt (p=.0104), nausea (p=.0104), procedural anxiety (p=.0074), cancer worry 
(p<.0001), and perceived physical appearance scores (p=.0002). 
 
Ethnicity was also a predictor of HRQOL in children with ALL, non-white 
children reported significantly lower physical functioning (p<.0001), and total HRQOL 
(p=.0016) scores. Non-white race was also a predictor of lower, and worse pain and hurt 
(p=.0002), nausea (p=.0002), and treatment anxiety (p=.0184) scores. 
 
Time predicted higher physical, emotional, and total HRQOL scores. Children 
reported significantly higher (p<.0001) HRQOL scores on these domains at the end of 
treatment (T4) in comparison to the beginning of treatment (T1). This significance was 
also reported for procedural anxiety, treatment anxiety, and cancer worry (p<.0001). 
 
Risk predicted HRQOL domains and cancer symptoms in children with ALL. 
Children on the Low risk arm of therapy reported higher physical (p=.01), emotional 
(p=.0253) and total (p=.01) HRQOL scores than children on the Standard/High risk 
group. Children on the Standard/High risk arm also reported lower pain and hurt 
(p=.0102), nausea (p=.0102), cancer worry (p=.0239), and cognitive problems (p=.0081) 
scores, indicating higher symptom burden.  
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Table 4-25. Univariate model results investigating predictors of PedsQL-Generic domain scores in ALL 
 
Physical Functioning 
Emotional 
Functioning Social Functioning School Functioning Total Score 
Factor  B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P 
Age (Child vs. 
Teen) 
12.78 
(2.41) <.0001 1.26 (2.14) 0.5566 -2.5 (1.92) 0.1937 4.66 (2.33) 0.0465 5.06 (1.85) 0.0063 
Gender (Male vs. 
Female) 6.4 (2.36) 0.0068 7.77 (1.93) <.0001 2.61 (1.79) 0.1463 2.13 (2.17) 0.3282 4.95 (1.72) 0.0042 
Ethnicity (Other 
vs. White) 
-10.54 
(2.9) 0.0003 
-3.53 
(2.49) 0.1565 
-3.58 
(2.23) 0.1087 
-3.54 
(2.72) 0.1935 
-5.94 
(2.15) 0.0059 
Risk Group (Low 
vs. Standard/High) 7.66 (2.3) 0.0010 3.26 (1.97) 0.0983 1.69 (1.77) 0.3406 4.01 (2.11) 0.0585 4.43 (1.71) 0.0097 
Time <.0001 0.0003 0.3331 0.4867 <.0001 
T1 vs. T2 
-13.35 
(1.58) <.0001 -5.12 (1.5) 0.0007 
-0.74 
(1.49) 0.6183 
-3.08 
(2.07) 0.1373 
-6.66 
(1.16) <.0001 
T1 vs. T3 
-12.44 
(1.67) <.0001 
-2.82 
(1.58) 0.0749 0.06 (1.58) 0.9682 
-0.99 
(2.11) 0.6405 
-5.09 
(1.23) <.0001 
T1 vs. T4 
-14.07 
(1.71) <.0001 
-6.42 
(1.61) <.0001 
-2.62 
(1.61) 0.1035 
-0.83 
(2.14) 0.6994 
-6.94 
(1.25) <.0001 
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Table 4-26. Multivariate model results investigating predictors of PedsQL-Generic domain scores in ALL 
 
  Physical Functioning Emotional Functioning School Functioning Total Score 
Factor  B (SE) P B (SE) P B (SE) P B (SE) P 
Age (Child vs. 
Teen) 10.48 (2.41) <.0001 . 3.54 (2.49) 0.1553 3.38 (1.88) 0.0732 
Gender (Male vs. 
Female) 7.79 (2.13) 0.0003 8.5 (1.94) <.0001 . 5.81 (1.67) 0.0005 
Ethnicity (Other 
vs. White) -11.24 (2.65) <.0001 . . -6.56 (2.07) 0.0016 
Risk Group (Low 
vs. 
Standard/High) 5.87 (2.27) 0.0100 4.3 (1.92) 0.0253 2.88 (2.26) 0.2016 4.59 (1.77) 0.0100 
Time . . . . 
T1 vs. T2 -13.39 (1.57) <.0001 -5.15 (1.49) 0.0006 . -6.67 (1.16) <.0001 
T1 vs. T3 -12.38 (1.67) <.0001 -2.7 (1.58) 0.0885 . -5.03 (1.23) <.0001 
T1 vs. T4 -13.92 (1.7) <.0001 -6.26 (1.61) 0.0001 . -6.82 (1.25) <.0001 
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Table 4-27. Univariate model results investigating predictors of PedsQL-Cancer domain scores in ALL 
 
 
Pain and Hurt Nausea 
Procedural 
Anxiety 
Treatment 
Anxiety Cancer Worry 
Cognitive 
Problems 
Perceived 
Physical 
Appearance 
Communica-
tion 
Factor 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
Age (Child 
vs. Teen) 
12.99 
(2.76) 
<.000
1 
2.11 
(2.08) 0.3102 
-16.64 
(3.28) 
<.000
1 
-3.95 
(2.23) 0.0772 
2.23 
(2.63) 0.3964 
5.33 
(2.37) 0.0249 
2.27 
(2.69) 0.3997 
-7.02 
(2.18) 
0.001
4 
Gender 
(Male vs. 
Female) 
5.03 
(2.69) 0.0617 
5.15 
(1.92) 0.0076 
8.68 
(3.18) 0.0066 
2.66 
(2.1) 0.2058 
9.43 
(2.39) 
<.000
1 
0.27 
(2.25) 0.9037 
9.32 
(2.45) 0.0002 
3.37 
(2.06) 
0.102
8 
Ethnicity 
(Other vs. 
White) 
-10.81 
(3.23) 0.0009 
-4.93 
(2.35) 0.0365 
-2.71 
(3.94) 0.4913 
-5.41 
(2.54) 0.0336 
0.05 
(3.01) 0.9865 
-2.23 
(2.74) 0.4146 
-1.75 
(3.07) 0.5703 
-2.46 
(2.54) 
0.332
8 
Risk Group 
(Low vs. 
Standard/
High) 
7.9 
(2.59) 0.0025 
2.18 
(1.9) 0.2529 
-3.83 
(3.16) 0.2271 
0.44 
(2.06) 0.8325 
4.6 
(2.4) 0.0564 
7.11 
(2.15) 0.0010 
3.72 
(2.46) 0.1318 
0.6 
(2.04) 
0.768
9 
Time 
<.000
1 
<.000
1 
<.000
1 
<.000
1 
<.000
1  0.9325  0.2502  
0.002
1 
T1 vs. T2 
-12.19 
(2.17) 
<.000
1 
9.73 
(1.57) 
<.000
1 
-10.25 
(2.1) 
<.000
1 
-3.75 
(1.53) 0.0148 
0.53 
(1.81) 0.7706 
-0.71 
(1.61) 0.6623 
-0.46 
(1.92) 0.8102 
-1.03 
(1.93) 
0.592
5 
T1 vs. T3 
-1.84 
(2.29) 0.4221 
3.97 
(1.67) 0.0175 
-18.57 
(2.23) 
<.000
1 
-7.26 
(1.62) 
<.000
1 
-2.9 
(1.91) 0.1291 
-1.05 
(1.7) 0.5387 
2.47 
(2.03) 0.2247 
-3.14 
(2.04) 
0.123
6 
T1 vs. T4 
-3.25 
(2.33) 0.1643 
1.41 
(1.69) 0.4048 
-23.37 
(2.26) 
<.000
1 
-8.51 
(1.65) 
<.000
1 
-8.2 
(1.94) 
<.000
1 
-0.32 
(1.73) 0.8544 
-1.73 
(2.06) 0.4016 
-7.5 
(2.07) 
0.000
3 
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Table 4-28. Multivariate model results investigating predictors of PedsQL-Cancer domain scores in ALL 
 
Pain and Hurt Nausea 
Procedural 
Anxiety 
Treatment 
Anxiety Cancer Worry 
Cognitive 
Problems 
Perceived 
Physical 
Appearance 
Communica-
tion 
Factor 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
Age (Child 
vs. Teen) 
10.39 
(2.86) 0.0003 
10.39 
(2.86) 0.0003 
-17.6 
(3.24) 
<.000
1 
-4.27 
(2.21) 0.0538 . 
2.94 
(2.51) 0.2419  . 
-7.25 
(2.18) 0.0009 
Gender 
(Male vs. 
Female) 
6.42 
(2.5) 0.0104 
6.42 
(2.5) 0.0104 
8.14 
(3.03) 0.0074 . 
10.32 
(2.4) 
<.000
1  . 
9.32 
(2.45) 0.0002  . 
Ethnicity 
(Other vs. 
White) 
-11.47 
(3.1) 0.0002 
-11.47 
(3.1) 0.0002 . 
-5.96 
(2.52) 0.0184 .       
Risk Group 
(Low vs. 
Standard/H
igh) 
6.88 
(2.67) 0.0102 
6.88 
(2.67) 0.0102 . . 
5.37 
(2.37) 0.0239 
6.13 
(2.31) 0.0081  .  . 
Time . . . . .  .  .  . 
T1 vs. T2 
-12.35 
(2.17) 
<.000
1 
-12.35 
(2.17) 
<.000
1 
-10.36 
(2.1) 
<.000
1 
-3.74 
(1.53) 0.0149 .  .  . 
-7.63 
(2.06) 0.0002 
T1 vs. T3 . . 
-18.7 
(2.22) 
<.000
1 
-7.39 
(1.62) 
<.000
1 .       
T1 vs. T4 . . 
-23.83 
(2.26) 
<.000
1 
-8.65 
(1.65) 
<.000
1 
-8.08 
(1.94) 
<.000
1       
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Acute Myeloid Leukemia 
 
A univariate model to identify predictors of the PedsQL-Generic domain scores 
identified age, risk group, and time as significant predictors of HRQOL on the PedsQL-
Generic scale (Table 4-29). A multivariate analysis of the PedsQL-Generic domain 
scores which included the significant factors from the univariate analysis for each domain 
identified risk group and time as the only significant predictors of the physical 
functioning domain, emotional functioning domain and total HRQOL scores  
(Table 4-30). None of the factors that have been included in our analysis were significant 
predictors of the social functioning domain or the school functioning domain in children 
with AML. 
 
On the PedsQL-Cancer module, age, risk group and time were also significant 
predictors of HRQOL in children with AML (Table 4-31). A multivariate analysis of the 
PedsQL-Cancer symptom scores which included the significant factors from the 
univariate analysis for each domain identified age and time as the only significant 
predictors of cancer-related symptoms (Table 4-32).  
 
Most cancer-related symptoms in children with AML, including treatment 
anxiety, cancer worry, cognitive problems, perceived physical appearance, and 
communication were not significantly correlated with any of the factors included in our 
study. 
 
 Fewer predictor factors were identified in children with AML. Time in treatment 
was the only significant predictor of HRQOL in children with AML on our PedsQL-
Generic multivariate linear model. Children reported significantly higher (p=.0001) on 
the physical, emotional, and total HRQOL scores at the end of treatment (T4) in 
comparison to the beginning of treatment (T1).Other factors considered in our analysis, 
including ethnicity and risk had no significant effect on HRQOL in our sample of 
children with AML.  
 
The remaining cancer-related symptoms of pain and hurt, nausea, and procedural 
anxiety were correlated with time in treatment, while procedural anxiety was the only 
symptom correlated with age. Children with AML reported improved pain and hurt 
(p=.0077), nausea (p<.0001), and procedural anxiety (p=.0247) at the end of their 
treatment (T4) in comparison to the first point where cancer-related symptoms were 
collected at T2. Age was not a significant predictor of HRQOL domains. However, it was 
a significant predictor of cancer-related symptoms. Children (ages 5-12 years) reported 
significantly more issues related to procedural anxiety (p=.018) than adolescents (ages 
13-18 years). Ethnicity, risk, and gender were not correlated with any of the HRQOL 
domain scores on the PedsQL-Generic scale and were also not correlated with any of the 
cancer-related symptoms on the PedsQL-Cancer scale. 
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Table 4-29. Univariate model results investigating predictors of PedsQL-Generic domain scores in AML 
 
Physical Functioning Emotional Functioning Social Functioning School Functioning Total Score 
Factor  B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P 
Age (Child 
vs. Teen) 8.63 (4.64) 0.0649 -1.64 (4.15) 0.6936 -4.36 (2.65) 0.1022 0.08 (3.92) 0.9836 1.83 (3.18) 0.5661 
Gender 
(Male vs. 
Female) -1.53 (4.8) 0.7503 3.12 (4.15) 0.4528 -0.51 (2.71) 0.8498 -4.46 (3.95) 0.2619 -0.46 (3.21) 0.8869 
Ethnicity 
(Other vs. 
White) -0.08 (5.06) 0.9882 -3.01 (4.39) 0.4943 0.33 (2.85) 0.9074 5.8 (4.11) 0.1610 0.08 (3.38) 0.9820 
Risk Group 0.2886 0.0292 0.0529 0.0378 0.0586 
High vs. Low -8.79 (5.61) 0.1193 -8.46 (4.77) 0.0782 -6.73 (3.13) 0.0337 -8.71 (4.45) 0.0530 -7.95 (3.68) 0.0324 
High vs. 
Standard -3.29 (5.89) 0.5777 -13.18 (5.01) 0.0095 -6.84 (3.28) 0.0391 -11.67 (4.78) 0.0162 -7.61 (3.87) 0.0511 
Time <.0001 0.0001 0.0883 0.0185 <.0001 
T1 vs. T2 3.78 (2.99) 0.2089 -5.09 (2.66) 0.0581 0.46 (1.95) 0.8149 4.87 (2.74) 0.0783 0.73 (1.87) 0.6953 
T1 vs. T3 -0.02 (3.54) 0.9947 -8.41 (3.15) 0.0085 -0.75 (2.27) 0.7423 2.59 (3.27) 0.4294 -1.28 (2.22) 0.5634 
T1 vs. T4 -16.12 (3.98) <.0001 -16.38 (3.54) <.0001 -5.79 (2.55) 0.0247 -6.42 (3.6) 0.0777 -12.21 (2.49) <.0001 
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Table 4-30. Multivariate model results investigating predictors of PedsQL-Generic domain scores in AML 
 
  Physical Functioning Emotional Functioning Social Functioning School Functioning Total Score 
Factor  B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P 
Age (Child 
vs. Teen) 7.86 (4.46) 0.0800 . . . . 
Time . . . . . 
T1 vs. T4 -15.82 (3.99) 0.0001 -15.66 (3.56) <.0001 -5.05 (2.56) 0.0505 -5.48 (3.62) 0.1336 -11.65 (2.51) <.0001 
T1 vs. T2 . -4.96 (2.66) 0.0639 . 4.74 (2.73) 0.0852 . 
T1 vs. T3 . -7.68 (3.17) 0.0169 . . . 
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Table 4-31. Univariate model results investigating predictors of PedsQL-Cancer domain scores in AML 
 
 
Pain and Hurt Nausea 
Procedural 
Anxiety 
Treatment 
Anxiety Cancer Worry 
Cognitive 
Problems 
Perceived 
Physical 
Appearance 
Communica-
tion 
Factor  B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P 
Age 
(Child 
vs. Teen) 
6.79 
(4.86) 0.1664 
9.19 
(3.97) 0.0235 
-12.93 
(6.1) 0.0374 
-0.24 
(4.78) 0.9601 
8.5 
(5.17) 0.1042 
1.18 
(3.86) 0.7613 
6.73 
(4.77) 0.1629 
1.83 
(5.1) 0.7201 
Gender 
(Male vs. 
Female) 
-0.63 
(4.94) 0.8996 
1.23 
(4.12) 0.7672 
5.67 
(6.29) 0.3698 
-1.34 
(4.75) 0.7780 
7.1 
(5.24) 0.1796 
-2.9 
(3.87) 0.4568 
5.04 
(4.76) 0.2925 
1.14 
(5.14) 0.8246 
Ethnicity 
(Other 
vs. 
White) 
-1.62 
(5.19) 0.7558 
-1.57 
(4.34) 0.7191 
4.81 
(6.63) 0.4703 
-5.48 
(5.03) 0.2798 
-3.37 
(5.56) 0.5460 
-0.36 
(4.1) 0.9297 
-7 
(5.09) 0.1735 
-7.54 
(5.34) 0.1621 
Risk 
Group 0.5750 0.2837 0.0920 0.0255 0.1431  0.1105  0.1905  0.2774 
High vs. 
Low 
-6.03 
(6.02) 0.3198 
-0.61 
(5.01) 0.9027 
-16.44 
(7.44) 0.0301 
-14.89 
(5.54) 0.0089 
-4.92 
(6.2) 0.4302 
-9.58 
(4.54) 0.0383 
-9.43 
(5.78) 0.1073 
-8.89 
(6.06) 0.1468 
High vs. 
Standard 
-5.12 
(6.24) 0.4143 
-7.24 
(5.19) 0.1675 
-7.82 
(7.7) 0.3133 
-11.29 
(5.74) 0.0531 
-12.74 
(6.42) 0.0509 
-3.75 
(4.7) 0.4271 
-9.32 
(5.98) 0.1236 
-8.25 
(6.27) 0.1928 
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Table 4-31. (Continued)  
 
 
Pain and Hurt Nausea 
Procedural 
Anxiety 
Treatment 
Anxiety Cancer Worry 
Cognitive 
Problems 
Perceived 
Physical 
Appearance 
Communica-
tion 
Factor B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P 
Time 0.0192 <.0001 0.0564 0.0817 0.1634  0.4523  0.0967  0.2791 
T2 vs. T3 -0.52 
(4.1) 0.8989 
-4.77 
(3.53) 0.1812 
-4.34 
(4.66) 0.3543 
-5.43 
(2.91) 0.0663 
-0.03 
(3.06) 0.9924 
-1.84 
(2.28) 0.4228 
-5.33 
(2.87) 0.0674 
-4.19 
(2.77) 0.1353 
T2 vs. T4 -13.08 
(4.77) 0.0077 
-21.39 
(4.1) <.0001 
-13.28 
(5.43) 0.0169 
-6.56 
(3.4) 0.0578 
-6.33 
(3.57) 0.0810 
-3.25 
(2.67) 0.2272 
-6.1 
(3.35) 0.0731 
-3.61 
(3.24) 0.2681 
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Table 4-32. Multivariate model results investigating predictors of PedsQL-Cancer domain scores in AML 
 
Pain and Hurt Nausea Procedural Anxiety Treatment Anxiety Cancer Worry 
Cognitive 
Problems 
Perceived 
Physical 
Appearance 
Factor B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P 
B 
(SE) P 
B 
(SE) P 
Age 
(Child 
vs. 
Teen) . 7.4 (3.77) 0.0537 -14.39 (5.94) 0.0180 . .     
Risk 
Group . . . . .  .  . 
Time . . . . .  .  . 
T2 vs. 
T3 . . . -4.18 (2.91) 0.1556 .  . 
-5.33 
(2.87) 0.0674 
T2 vs. 
T4 -13.08 (4.77) 0.0077 -20.7 (4.1) <.0001 -12.73 (5.55) 0.0247 -5.32 (3.39) 0.1205 -5.79 (3.6) 0.1121  . 
-6.1 
(3.35) 0.0731 
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Hodgkin Lymphoma 
 
A univariate model to identify predictors of the PedsQL-Generic domain scores 
identified gender, age, risk group, and time as significant factors is presented in  
Table 4-33. Ethnicity and radiation dose were not significant predictors of HRQOL on 
the PedsQL-Generic scale. Table 4-34 presents the results of the multivariate analysis of 
PedsQL-Generic domain scores.  
 
A multivariate analysis of the PedsQL-Generic domain scores which included the 
significant factors from the univariate analysis identified gender, risk, and time as 
significant predictors of HRQOL domains. On the PedsQL-Cancer module, age, gender, 
and time were significant predictors of HRQOL. As for cancer-related symptoms, age, 
gender, and time were significant predictors of HRQOL over time Table 4-35 presents 
the results of the univariate analysis. Table 4-36 presents the results of the multivariate 
analysis for the PedsQL-Cancer module. 
 
In the HL group, gender was a significant predictor of HRQOL in children with 
HL. Gender was identified as a predictor of HRQOL in our univariate analysis on all 
domains of HRQOL except for the social functioning domain. Gender predicted physical 
(p=.0021), emotional (p=.0036), and total score (p=.0019) on the multivariate model. It 
was also found to be a predictor of pain and hurt (p=.0054), procedural anxiety 
(p=.0029), and perceived physical appearance (p<.0001) from the cancer-related 
symptoms. On all these domains and symptoms, females consistently reported lower 
scores, indicating worse outcomes, in comparison to male children. 
 
As for risk group, it was only a predictor of the physical functioning domain, with 
higher (unfavorable) risk groups reporting a significantly lower physical functioning 
score than the lower (favorable) risk group. The group with the highest physical 
functioning HRQOL domain was the favorable risk group, while the group with the 
lowest physical HRQOL was the unfavorable risk group. Risk, however, was not a 
predictor of any cancer-related symptoms in the HL group on the multivariate analysis. 
 
Time was also a significant predictor of HRQOL in the HL when comparing the 
beginning of treatment (T1) in comparison to the end of treatment (T4). This significance 
was observed at all HRQOL domains. The significant differences in HRQOL cancer-
related symptoms, however, can be observed in comparing T2, the first time point for 
collecting PedsQL-Cancer score, to T4, where symptoms of pain and hurt (p<.0001), 
nausea (p<.0001), procedural anxiety (p<.0001), cancer worry (p=.0138), cognitive 
problems (p=.0129), perceived physical appearance (p<.0110) and communication 
(p<.0001) were found to be significantly higher at T4 in comparison to T2.Ethnicity was 
not correlated with any HRQOL domain or cancer-related symptom in our sample of 
children with HL across all time points in treatment.  
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Table 4-33. Univariate model results investigating predictors of PedsQL-Generic domain scores in HL 
  Physical Functioning Emotional Functioning Social Functioning School Functioning Total Score 
Factor  B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P 
Age (Child vs. 
Teen) 4.43 (2.64) 0.0942 2.44 (2.57) 0.3428 -3.01 (1.74) 0.0831 3.28 (2.56) 0.2013 1.83 (2.05) 0.3736 
Gender (Male 
vs. Female) 6.83 (2.12) 0.0014 5.67 (2.07) 0.0063 -0.11 (1.43) 0.9364 3.96 (2.09) 0.0591 4.81 (1.66) 0.0039 
Ethnicity 
(Other vs. 
White) 0.19 (2.57) 0.9400 1.48 (2.5) 0.5531 1.01 (1.69) 0.5488 2.09 (2.5) 0.4020 1.42 (2.01) 0.4799 
Radiation (Yes 
vs. No) -1.57 (3.43) 0.6473 1.91 (3.32) 0.5661 0.88 (2.26) 0.6968 -0.45 (3.33) 0.8928 0.05 (2.65) 0.9849 
Risk Group 0.0364 0.7998 0.4530 0.1695 0.2314 
Favorable vs. 
Intermediate 3.26 (2.99) 0.2769 -1.51 (2.93) 0.6063 -1.47 (1.99) 0.4598 -1.06 (2.94) 0.7173 0.28 (2.35) 0.9039 
Favorable vs. 
Unfavorable 7.44 (3.04) 0.0148 -0.14 (2.98) 0.9626 0.46 (2.02) 0.8201 3.24 (3) 0.2798 3.15 (2.39) 0.1880 
Time <.0001 <.0001 0.0012 <.0001 <.0001 
T1 vs. T2 7.33 (1.42) <.0001 -2.25 (1.4) 0.1081 0.62 (1.03) 0.5488 3.2 (1.5) 0.0333 3.01 (1.04) 0.0041 
T1 vs. T3 6.01 (1.45) <.0001 -4.79 (1.42) 0.0008 0.71 (1.04) 0.4971 -0.05 (1.53) 0.9727 0.94 (1.06) 0.3784 
T1 vs. T4 -5.79 (1.51) 0.0001 -11.18 (1.49) <.0001 -3.16 (1.09) 0.0040 -9.24 (1.59) <.0001 -6.92 (1.1) <.0001 
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Table 4-34. Multivariable model results investigating predictors of PedsQL-Generic domain scores in HL 
 Physical Functioning Emotional Functioning Social Functioning School Functioning Total Score 
Factor B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P 
Age (Child 
vs. Teen) 2.92 (2.6) 0.2617 . -2.97 (1.73) 0.0875 -2.97 (1.73) 0.0875 . 
Gender 
(Male vs. 
Female) 6.57 (2.13) 0.0021 6.04 (2.07) 0.0036 . . 5.11 (1.64) 0.0019 
Risk 
Group 
(Favorable 
vs. 
Unfavorabl
e) 6.25 (2.97) 0.0354 . . . . 
Time . . . . . 
T1 vs. T2 7.23 (1.42) <.0001 . . . 3.02 (1.04) 0.0039 
T1 vs. T3 5.91 (1.45) <.0001 -4.85 (1.43) 0.0007 . . . 
T1 vs. T4 -5.93 (1.51) <.0001 
-11.28 
(1.49) <.0001 -3.14 (1.09) 0.0042 -3.14 (1.09) 0.0042 -6.99 (1.1) <.0001 
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Table 4-35. Univariate model results investigating predictors of PedsQL-Cancer domain scores in HL 
  
Pain and Hurt Nausea 
Procedural 
Anxiety 
Treatment 
Anxiety Cancer Worry 
Cognitive 
Problems 
Perceived 
Physical 
Appearance 
Communica-
tion 
Factor B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P 
Age 
(Child vs. 
Teen) 
4.5 
(3.39) 0.1857 
3.26 
(3.34) 0.3293 
-19.19 
(3.95) <.0001 
-3.42 
(2.94) 0.2457 
7.42 
(3.72) 0.0469 
6.96 
(2.87) 0.0158 
4.52 
(3.38) 0.1826 
-0.08 
(2.85) 
0.97
62 
Gender 
(Male vs. 
Female) 
6.75 
(2.65) 0.0111 
-0.72 
(2.65) 0.7866 
6.66 
(3.25) 0.0412 
3.22 
(2.32) 0.1659 
4.98 
(2.96) 0.0940 
3.5 
(2.3) 0.1279 
12.59 
(2.56) <.0001 
1.98 
(2.24) 
0.37
78 
Ethnicity 
(Other 
vs. 
White) 
0.16 
(3.17) 0.9607 
3.37 
(3.11) 0.2791 
3.46 
(3.86) 0.3704 
1.91 
(2.74) 0.4860 
5.27 
(3.49) 0.1321 
-1.08 
(2.72) 0.6904 
-5.84 
(3.14) 0.0642 
2.51 
(2.64) 
0.34
14 
Radiatio
n (Yes vs. 
No) 
1.13 
(4.47) 0.8006 
7.77 
(4.36) 0.0755 
6.17 
(5.36) 0.2509 
5.26 
(3.84) 0.1710 
4.41 
(4.89) 0.3681 
-2.96 
(3.79) 0.4360 
2.53 
(4.4) 0.5664 
5.59 
(3.69) 
0.13
01 
Risk 
Group 0.7056 0.8338 0.9010 0.7717 0.5552  0.7700  0.7223  
0.09
38 
Favorable 
vs. 
Intermedi
ate 
-2.96 
(3.94) 0.4530 
-2.17 
(3.88) 0.5768 
0.43 
(4.81) 0.9286 
-0.93 
(3.41) 0.7856 
-4.53 
(4.36) 0.2989 
-1.74 
(3.38) 0.6061 
-2.67 
(3.93) 0.4974 
-7.1 
(3.26) 
0.03
03 
Favorable 
vs. 
Unfavora
ble 
-1.19 
(4.01) 0.7661 
-2.22 
(3.94) 0.5738 
-1.18 
(4.88) 0.8084 
-2.27 
(3.47) 0.5127 
-2.4 
(4.42) 0.5876 
-0.1 
(3.43) 0.9775 
-3.16 
(3.99) 0.4284 
-5.66 
(3.31) 
0.08
85 
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Table 4-35. (Continued) 
 
  
Pain and Hurt Nausea 
Procedural 
Anxiety 
Treatment 
Anxiety Cancer Worry 
Cognitive 
Problems 
Perceived 
Physical 
Appearance 
Communica-
tion 
Factor B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
Time 
<.0001 <.0001 <.0001 0.1528 
0.039
3  
0.043
4  
0.048
8  
0.000
1 
T2 vs. T3 
-3.44 
(1.9) 0.0714 
1.08 
(1.7) 0.5261 
-1.96 
(1.75) 0.2622 
2.8 
(1.55) 0.0725 
-0.78 
(1.56) 
0.615
6 
-1.54 
(1.37
) 
0.262
3 
-1.35 
(1.52
) 
0.375
2 
-2.4 
(1.42
) 
0.092
5 
T2 vs. T4 
-18.55 
(1.98) <.0001 
-16.93 
(1.79) <.0001 
-8.33 
(1.83) <.0001 
0.29 
(1.62) 0.8591 
-4.05 
(1.64) 
0.014
3 
-3.59 
(1.43
) 
0.012
3 
-3.92 
(1.6) 
0.014
6 
-6.35 
(1.49
) 
<.000
1 
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Table 4-36. Multivariate model results investigating predictors of PedsQL-Cancer domain scores in HL 
 
Pain and Hurt Nausea 
Procedural 
Anxiety 
Treatment 
Anxiety Cancer Worry 
Cognitive 
Problems 
Perceived 
Physical 
Appearance 
Communica-
tion 
Factor 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P B (SE) P 
Age 
(Child vs. 
Teen) . . 
-20.94 
(3.93) 
<.000
1 . 
6.62 
(3.75) 0.0782 
6.92 
(2.87) 0.0165  .  . 
Gender 
(Male vs. 
Female) 
7.28 
(2.6) 0.0054 . 
9.33 
(3.12) 0.0029 . 
4.35 
(2.98) 0.1445  . 
12.53 
(2.55) 
<.000
1  . 
Ethnicity 
(Other vs. 
White)            . 
-4.97 
(3) 0.0981  . 
Radiation 
(Yes vs. 
No) . 
7.03 
(4.25) 0.0993 . . .  .  . 
-5.88 
(3.3) 
0.075
7 
Time . . . . .  .  .  . 
T2 vs. T3 
-3.5 
(1.9) 0.0665 . . 
2.8 
(1.55) 0.0725 .  .  . 
-2.38 
(1.42) 
0.094
6 
T2 vs. T4 
-18.69 
(1.98) 
<.000
1 
-16.86 
(1.79) 
<.000
1 
-8.46 
(1.82) 
<.000
1 . 
-4.07 
(1.65) 0.0138 
-3.57 
(1.43) 0.0129 
-4.08 
(1.59) 0.0110 
-6.36 
(1.49) 
<.000
1 
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Melanoma 
 
 Only a univariate analysis was performed on the melanoma group considering the 
small sample size that did not support conducting a multivariate analysis. This analysis 
identified age, gender, race, and time as predictors of HRQOL domains in children with 
Melanoma. Females reported significantly lower physical HRQOL scores (p=.0295), 
white children reported higher physical HRQOL scores (p=.0498) than children from 
other races (Table 4-37). 
 
On the PedsQL-cancer module symptoms, age, gender, and race were impacted 
different symptoms of cancer treatment. Adolescents reported higher social functioning 
scores than children (p=.0798). As for cancer-related symptoms, children reported a 
significantly lower procedural anxiety scores, indicating higher symptom burden 
(p=.0171), while adolescents reported lower cancer worry score (p=.0943).  
 
Females reported significantly lower pain and hurt (p=.0082), nausea (p=.0065), 
and treatment anxiety (p=.0223 scores, indicating higher symptom burden in females. 
Cancer-related symptoms including cognitive problems, perceived physical appearance, 
and communication had no predictors of HRQOL identified (Table 4-38). 
 
 
Osteosarcoma 
 
While children with OS reported the lowest HRQOL across all diagnostic groups. 
The analysis of factors that were significantly correlated with these low HRQOL scores 
resulted in few findings. A univariate model to identify predictors of the PedsQL-Generic 
domain scores identified time as the only significant predictor of HRQOL on the 
PedsQL-Generic scale in children with OS (Table 4-39).  
 
A multivariate analysis reported the same significant effect (p<.0001) of time (T1 
vs. T4) on all HRQOL domains in children with OS (Table 4-40). T4 scores were 
significantly higher than T1 scores. Other factors considered in this analysis, including 
age, gender, and ethnicity, were not significantly correlated with HRQOL in children 
with OS. 
 
On the PedsQL-Cancer module, age, race, type of surgery and time were 
significant predictors of HRQOL in children with OS on the univariate analysis   
(Table 4-41). However, on the multivariate analysis, time was the only significant 
predictor of cancer-related symptoms in children with OS (Table 4-42).  
 
Children reported significantly higher cancer-symptom scores (p<0.05) on all 
cancer-related symptoms on the PedsQL-cancer scale at the end of treatment (T4) in 
comparison to the beginning of treatment (T1). All other factors included in this analysis 
were not correlated with cancer-related symptoms in children with OS. 
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Table 4-37. Univariate model results investigating predictors of PedsQL-Generic domain scores for melanoma 
 
 Physical Functioning Emotional Functioning 
Social 
Functioning 
School 
Functioning Total Score 
Factor B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P 
Age (Child 
vs. Teen) 7.37 (5.36) 0.1743 -0.74 (6.38) 0.9087 -15.66 (8.78) 0.0798 -3.95 (9.97) 0.6939 -1.78 (5.86) 0.7618 
Gender 
(Male vs. 
Female) 10.82 (4.84) 0.0295 5.55 (6.15) 0.3710 4.18 (9.16) 0.6496 9.7 (9.65) 0.3200 8.55 (5.45) 0.1223 
Ethnicity 
(Other vs. 
White) -11.43 (5.7) 0.0498 1.17 (6.94) 0.8661 9.44 (9.82) 0.3402 2.65 (11.1) 0.8127 -2.21 (6.32) 0.7275 
Time           
T1 vs. T2 2.2 (4.51) 0.6277 -9.73 (4.87) 0.0511 -0.43 (3.3) 0.8977 -1.37 (5.74) 0.8129 -2.43 (3.27) 0.4611 
T1 vs. T3 -2.81 (4.97) 0.5745 -8.75 (5.38) 0.1098 -6.71 (3.69) 0.0748 -5.59 (6) 0.3566 -6.27 (3.64) 0.0904 
T1 vs. T4 -5.01 (5.07) 0.3278 -5.67 (5.49) 0.3064 -4.02 (3.77) 0.2919 -2.63 (6.35) 0.6807 -4.94 (3.71) 0.1888 
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Table 4-38. Univariate model results investigating predictors of PedsQL-Cancer domain scores for melanoma 
 
Pain and Hurt Nausea 
Procedural 
Anxiety 
Treatment 
Anxiety Cancer Worry 
Cognitive 
Problems 
Perceived 
Physical 
Appearance 
Communica-
tion 
Factor B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P 
Age 
(Child 
vs. 
Teen) 
5.43 
(8.45) 0.5251 
10.29 
(6.25) 0.1093 
-25.54 
(10.15
) 0.0171 
3.51 
(5.38) 0.5184 
15.4 
(8.93) 0.0943 
9.78 
(9.01) 0.2861 
-1.91 
(11.87
) 0.8735 
-3.06 
(9.75) 
0.75
57 
Gender 
(Male 
vs. 
Female) 
19.75 
(6.97) 0.0082 
15.51 
(5.33) 0.0065 
12.19 
(11.18
) 0.2836 
11.48 
(4.78) 0.0223 
11.44 
(8.83) 0.2043 
6.03 
(8.92) 0.5036 
4.33 
(11.57
) 0.7109 
-5.85 
(9.47) 
0.54
10 
Ethnicit
y (Other 
vs. 
White) 
-22.47 
(7.99) 0.0086 
-12.44 
(7.17) 0.0923 
2.95 
(12.71
) 0.8179 
-6.34 
(5.93) 0.2927 
-16.52 
(9.86) 0.1036 
-12.69 
(9.77) 0.2032 
-1.77 
(12.69
) 0.8899 
7.28 
(10.38
) 
0.48
82 
Time                 
T2 vs. 
T3 
-3.48 
(4.21) 0.4154 
-8.91 
(5.53) 0.1180 
1.43 
(6.67) 0.8320 
1.8 
(4.16) 0.6685 
-1.78 
(5.86) 0.7635 
1.1 
(4.93) 0.8243 
2.01 
(3.4) 0.5588 
-2.91 
(4.5) 
0.52
37 
T2 vs. 
T4 
-3.76 
(4.42) 0.4032 
-15.12 
(5.53) 0.0104 
-2.03 
(6.67) 0.7634 
-2.36 
(4.16) 0.5752 
-0.41 
(5.86) 0.9452 
0.51 
(4.93) 0.9177 
4.44 
(3.4) 0.2008 
2.45 
(4.5) 
0.58
99 
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Table 4-39. Univariate model results investigating predictors of PedsQL-Generic domain scores in OS 
 
  Physical Functioning Emotional Functioning Social Functioning School Functioning Total Score 
Factor B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P 
Age (Child vs. 
Teen) 5.22 (3.45) 0.1318 2.6 (3.37) 0.4416 -3.56 (2.52) 0.1590 -0.63 (3.54) 0.8588 2.16 (2.62) 0.4096 
Gender (Male 
vs. Female) 0.55 (3.49) 0.8754 3.77 (3.35) 0.2610 0.84 (2.54) 0.7405 -0.51 (3.53) 0.8861 1.15 (2.62) 0.6621 
Ethnicity (Other 
vs. White) -4 (3.66) 0.2753 -4.13 (3.54) 0.2444 -4.27 (2.65) 0.1081 2.36 (3.72) 0.5260 -3 (2.75) 0.2764 
Surgery 
(Amputation vs. 
Limb Salvage) 3.91 (4.12) 0.3432 -2.55 (4) 0.5240 2.84 (3.02) 0.3474 4.42 (4.17) 0.2907 2.29 (3.12) 0.4628 
Time <.0001 <.0001 0.1760 0.0010 <.0001 
T1 vs. T2 -5.05 (2.76) 0.0679 -6.65 (2.16) 0.0023 -2.12 (1.87) 0.2583 -5.53 (2.62) 0.0360 -4.39 (1.73) 0.0116 
T1 vs. T3 -2.08 (2.86) 0.4672 -9.37 (2.25) <.0001 2.27 (1.94) 0.2427 -3.67 (2.61) 0.1622 -3.22 (1.79) 0.0735 
T1 vs. T4 -16.09 (2.92) <.0001 -17.12 (2.31) <.0001 0.28 (1.99) 0.8874 -10.64 (2.64) <.0001 -11.57 (1.83) <.0001 
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Table 4-40. Multivariate model results investigating predictors of PedsQL-Generic domain scores in OS 
 
Physical Functioning Emotional Functioning Social Functioning School Functioning Total Score 
Factor B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P 
Time . . . . . 
T1 vs. T2 -5.05 (2.76) 0.0679 -6.65 (2.16) 0.0023 -6.65 (2.16) 0.0023 -5.53 (2.62) 0.0360 -4.39 (1.73) 0.0116 
T1 vs. T4 -16.09 (2.92) <.0001 -17.12 (2.31) <.0001 -17.12 (2.31) <.0001 -10.64 (2.64) <.0001 -11.57 (1.83) <.0001 
T1 vs. T3 . -9.37 (2.25) <.0001 -9.37 (2.25) <.0001 . -3.22 (1.79) 0.0735 
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Table 4-41. Univariate model results investigating predictors of PedsQL-Cancer domain scores in OS 
 
 Pain and Hurt Nausea 
Procedural 
Anxiety 
Treatment 
Anxiety 
Cancer 
Worry 
Cognitive 
Problems 
Perceived 
Physical 
Appearance 
Communica-
tion 
Factor 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P B (SE) P 
Age (Child 
vs. Teen) 
8.87 
(3.44) 
0.010
4 
-1.08 
(3.22) 
0.736
8 
-21.27 
(4.74) 
<.000
1 
-2.01 
(2.99) 
0.502
8 
9.95 
(4.67) 
0.034
1 
-0.93 
(2.96) 
0.753
2 
-2.03 
(3.42) 
0.552
7 
-10.6 
(3.26) 
0.001
3 
Gender 
(Male vs. 
Female) 
3.35 
(3.51) 
0.341
0 
2.69 
(3.2) 
0.402
1 
7.92 
(5.07) 
0.119
6 
1.49 
(2.98) 
0.617
2 
2.85 
(4.76) 
0.549
3 
0.19 
(2.96) 
0.949
6 
5.71 
(3.37) 
0.090
7 
1.28 
(3.41) 
0.706
9 
Ethnicity 
(Other vs. 
White) 
-5.26 
(3.68) 
0.154
5 
-5.77 
(3.36) 
0.087
0 
4.19 
(5.37) 
0.436
0 
0.14 
(3.15) 
0.964
4 1.5 (5) 
0.764
3 
-1.3 
(3.11) 
0.675
4 
-5.08 
(3.55) 
0.154
2 
-4.44 
(3.56) 
0.213
3 
Surgery 
(Amputation 
vs. Salvage) 
6.23 
(4.18) 
0.137
4 
7.22 
(3.78) 
0.057
7 
-7.6 
(5.99) 
0.205
4 
-7.07 
(3.53) 
0.046
1 
-3.94 
(5.62) 
0.483
7 
1.13 
(3.5) 
0.747
7 
1.99 
(4.06) 
0.623
9 
-3.22 
(4.01) 
0.423
2 
Time <.000
1 
<.000
1 
<.000
1 
<.000
1 
<.000
1  
0.019
1  
0.046
9  
0.000
7 
T1 vs. T2 -24.08 
(2.99) 
<.000
1 
16.44 
(2.86) 
<.000
1 
-13.66 
(2.64) 
<.000
1 
-12.37 
(2.6) 
<.000
1 
-6.32 
(2.73) 
0.021
2 
-2.3 
(1.87) 
0.218
8 
-1.36 
(2.54) 
0.593
3 
-3.85 
(2.52) 
0.126
8 
T1 vs. T3 -20.3 
(3.12) 
<.000
1 
18.06 
(2.98) 
<.000
1 
-15.3 
(2.76) 
<.000
1 
-14.93 
(2.71) 
<.000
1 
-13.33 
(2.84) 
<.000
1 
-3.91 
(1.95) 
0.046
1 
-5.1 
(2.64) 
0.054
5 
-7.99 
(2.61) 
0.002
4 
T1 vs. T4 -18.91 
(3.2) 
<.000
1 
-7.7 
(3.08) 
0.013
1 
-19.34 
(2.85) 
<.000
1 
-15.3 
(2.78) 
<.000
1 
-19.48 
(2.92) 
<.000
1 
-6.17 
(2) 
0.002
3 
-6.74 
(2.71) 
0.013
6 
-10.4 
(2.69) 
0.000
1 
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Table 4-42. Multivariate model results investigating predictors of PedsQL-Cancer domain scores in OS 
 
  
Pain and Hurt Nausea 
Procedural 
Anxiety 
Treatment 
Anxiety Cancer Worry 
Cognitive 
Problems 
Perceived 
Physical 
Appearance 
Communica-
tion 
Factor  B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P 
Time . . . . .  .  .  . 
T1 vs. 
T2 
-4.39 
(1.73) 0.0116 
16.31 
(2.86) <.0001 
-13.61 
(2.63) <.0001 
-12.31 
(2.6) <.0001 
-6.35 
(2.73) 0.0208  .  . 
-8.05 
(2.61) 
0.00
22 
T1 vs. 
T3 
-3.22 
(1.79) 0.0735 
17.86 
(2.98) <.0001 
-15.3 
(2.75) <.0001 
-14.8 
(2.72) <.0001 
-13.31 
(2.84) <.0001 
-3.91 
(1.95) 0.0461 
-5.13 
(2.64) 
0.052
9 
-3.77 
(2.51) 
0.13
49 
T1 vs. 
T4 
-11.57 
(1.83) <.0001 
-7.92 
(3.08) 0.0107 
-19.38 
(2.84) <.0001 
-15.23 
(2.78) <.0001 
-19.42 
(2.92) <.0001 
-6.17 
(2) 0.0023 
-6.82 
(2.71) 
0.012
5 
-10.47 
(2.69) 
0.00
01 
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Total Sample 
 
 A univariate model identified most variables as significant predictors of HRQOL 
on the PedsQL-Generic scale within the total sample across different HRQOL domains 
(Table 4-43). A multivariate analysis identified age, risk, diagnosis, and time in treatment 
as significant predictors (p<.05) of HRQOL domains in the total sample (Table 4-44). On 
the PedsQL-Cancer module, age, gender, race, risk, surgery, radiotherapy, diagnosis, and 
time were significant predictors of HRQOL in our total sample (Table 4-45). However, 
on the multivariate analysis, age, race, diagnosis, and time were significant (p<0.05) 
predictors of cancer-related symptoms (Table 4-46). Significantly higher cancer-
symptom scores (p<0.05) were reported on all cancer-related symptoms on the PedsQL-
Cancer scale at the end of treatment (T4) in comparison to the beginning of treatment 
(T1).  
 
? Research Question 3-2: What is the combined effect of cancer and treatment 
factors on the self-reported HRQOL of children undergoing curative cancer 
treatment in each diagnostic group? 
 
To assess the combined effect of cancer and treatment factors on HRQOL, we 
attempted to look for the best model to fit the different variables on each HRQOL domain 
and cancer-related symptom in our analysis. Since we utilized a mixed linear model to 
identify predictors of HRQOL changes over time, the most feasible method to look for 
model fit is using the Akaike information criterion (AIC). To examine AIC values, lower 
values indicate better model fit. Table 4-47 represents the AIC values for the HRQOL 
domains, while Table 4-48 represents the AIC values for cancer-related symptoms. 
 
 The AIC values represent the best fit models for each separate HRQOL domain 
and for the total HRQOL as well. The best fit model for each domain was the following: 
 
? Physical functioning: The AML diagnostic group (age*time).  
? Emotional functioning: The AML group (risk*time).  
? Social functioning: The AML group (risk*time). 
? School functioning: The AML group (ethnicity*risk*time). 
? Total HRQOL score: The AML group (risk*time). 
 
As for cancer-related symptoms, the best fit model for each score was the 
following: 
 
? Pain and hurt: The AML diagnostic group (time). 
? Nausea: The AML diagnostic group (age*time). 
? Procedural anxiety: The AML diagnostic group (age*risk*time). 
? Treatment anxiety: The AML diagnostic group (risk*time). 
? Cancer worry: The AML diagnostic group (risk*time). 
? Cognitive problems: The AML diagnostic group (risk). 
? Perceived risk appearance: The AML diagnostic group (time). 
? Communication: The OS diagnostic group (age*time). 
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Table 4-43. Univariate model results investigating predictors of PedsQL-Generic domain scores in the total sample 
 
  Physical Functioning Emotional Functioning Social Functioning School Functioning Total Score 
Factor  B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P 
Age (Child vs. 
Teen) 
3.96 (1.48) 0.0076 1.02 (1.24) 0.4127 -6.09 (1) <.0001 0.41 (1.3) 0.7526 0.52 (1.05) 0.6171 
Gender (Male vs. 
Female) 
3.84 (1.5) 0.0107 5.76 (1.24) <.0001 -0.13 (1.04) 0.9039 1.32 (1.31) 0.3122 2.91 (1.06) 0.0061 
Ethnicity (Other 
vs. White) 
-2.25 (1.74) 0.1969 -0.83 (1.45) 0.5669 -0.9 (1.2) 0.4506 1.01 (1.51) 0.5044 -1.06 (1.23) 0.3893 
Risk   0.0152   0.0431   0.4752   0.1998   0.0934 
High vs. Low -5.68 (2.09) 0.0068 -4.14 (1.85) 0.0254 1.66 (1.47) 0.2597 -3.34 (1.9) 0.0796 -3.3 (1.51) 0.0296 
High vs. 
Intermediate 
-1.51 (1.9) 0.4273 -3.79 (1.68) 0.0247 1.41 (1.34) 0.2947 -2.37 (1.75) 0.1745 -1.7 (1.37) 0.2167 
Surgery (Yes vs. 
No) 
-20.41 (1.86) <.0001 -5.81 (1.68) 0.0005 -7.47 (1.36) <.0001 -1.99 (1.76) 0.2570 -10.9 (1.36) <.0001 
Radiotherapy 
(Yes vs. No) 
10.4 (1.55) <.0001 1.41 (1.33) 0.2898 7.8 (1.06) <.0001 2.64 (1.37) 0.0549 6.25 (1.1) <.0001 
Diagnosis   <.0001   0.0005   <.0001   0.1017   <.0001 
ALL vs. AML 5 (2.33) 0.0318 4.76 (2.13) 0.0258 -5.47 (1.68) 0.0012 -3.62 (2.27) 0.1108 1.13 (1.71) 0.5077 
ALL vs. HL -6.11 (1.63) 0.0002 0.85 (1.5) 0.5694 -8.45 (1.18) <.0001 -3.71 (1.56) 0.0180 -4.46 (1.21) 0.0002 
ALL vs. MEL -10.35 (3.84) 0.0071 -5 (3.52) 0.1555 -5.11 (2.77) 0.0656 -4.01 (3.73) 0.2826 -6.5 (2.84) 0.0221 
ALL vs. OS 18.04 (2.05) <.0001 6.63 (1.88) 0.0004 2.88 (1.48) 0.0514 -0.29 (1.97) 0.8826 8.87 (1.51) <.0001 
Time   <.0001   <.0001   0.0012   <.0001   <.0001 
T1 vs. T2 -2.32 (0.97) 0.0165 -4.54 (0.86) <.0001 -0.48 (0.73) 0.5150 -0.37 (1.04) 0.7196 -2.02 (0.66) 0.0021 
T1 vs. T3 -2.48 (1.02) 0.0150 -5.45 (0.91) <.0001 0.31 (0.77) 0.6822 -1.11 (1.07) 0.2995 -2.13 (0.69) 0.0020 
T1 vs. T4 -11.34 (1.06) <.0001 -10.92 (0.94) <.0001 -2.68 (0.8) 0.0008 -6.11 (1.1) <.0001 -8.22 (0.72) <.0001 
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Table 4-44. Multivariate model results investigating predictors of PedsQL-Generic domain scores in the total sample 
 
  Physical Functioning Emotional Functioning Social Functioning School Functioning Total Score 
Factor  B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P 
Age (Child vs. Teen) 7.13 (1.65) <.0001   .  -3.96 (1.07) 0.0002   .    .  
Risk Group   .    .    .    .    .  
High vs. Low -9.46 (2.23) <.0001 -3.69 (1.96) 0.0596   .  -6.31 (2.16) 0.0036 -6.47 (1.65) <.0001 
Diagnosis   .    .    .    .    .  
ALL vs. AML 0.79 (2.31) 0.7332 2.61 (2.11) 0.2171 -4.85 (1.68) 0.0041   .    .  
ALL vs. HL -7.08 (3.43) 0.0394   .  -5.1 (2.51) 0.0422 -3.59 (3.19) 0.2608 -3.24 (2.48) 0.1919 
ALL vs. MEL . (.) .    .  -3.85 (2.77) 0.1643   .  . (.) .  
ALL vs. OS . (.) .  . (.) .  . (.) .    .  . (.) .  
Time   .    .    .    .    .  
T1 vs. T2 -1.8 (1.04) 0.0833 -3.82 (0.95) <.0001   .    .  -1.41 (0.72) 0.0513 
T1 vs. T3 -2.2 (1.1) 0.0450 -4.41 (1) <.0001   .    .  -1.55 (0.76) 0.0422 
T1 vs. T4 -10.13 (1.15) <.0001 -9.67 (1.05) <.0001 -2.65 (0.8) 0.0009 -5.18 (1.23) <.0001 -7.41 (0.79) <.0001 
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Table 4-45. Univariate model results investigating predictors of PedsQL-Cancer in the total sample 
 
  
Pain and Hurt Nausea 
Procedural 
Anxiety 
Treatment 
Anxiety Cancer Worry 
Cognitive 
Problems 
Perceived 
Physical 
Appearance 
Communica-
tion 
Factor  
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
Age (Child 
vs. Teen) 
6.8 
(1.52) 
<.000
1 
3.74 
(1.35) 0.0057 
-17.61 
(1.84) 
<.000
1 
-0.97 
(1.28) 0.4471 
8.21 
(1.68) 
<.000
1 
2 
(1.31) 0.1259 
1.76 
(1.51) 0.2456 
-5.02 
(1.32) 
0.000
1 
Gender 
(Male vs. 
Female) 
4.79 
(1.53) 0.0018 
2.99 
(1.36) 0.0278 
6.77 
(1.95) 0.0005 
2.88 
(1.27) 0.0238 
7.21 
(1.7) 
<.000
1 
0.76 
(1.31) 0.5625 
9.05 
(1.48) 
<.000
1 
1.61 
(1.33) 
0.229
0 
Ethnicity 
(Other vs. 
White) 
-4.89 
(1.78) 0.0061 
-1.45 
(1.58) 0.3570 
1.84 
(2.26) 0.4164 
-1.43 
(1.48) 0.3343 
2.67 
(1.98) 0.1780 
-2.09 
(1.51) 0.1661 
-4.35 
(1.75) 0.0129 
-1.35 
(1.54) 
0.380
5 
Risk 0.1365 0.3021 0.5396 0.3828 0.0134  0.0441  0.6311  
0.573
2 
High vs. 
Low 
-3.27 
(2.44) 0.1810 
-2.99 
(2.1) 0.1552 
3.18 
(3.01) 0.2915 
-2.81 
(2.04) 0.1691 
-7.07 
(2.51) 0.0050 
-2.39 
(2.05) 0.2430 
-2.01 
(2.37) 0.3962 
0.8 
(2.04) 
0.696
2 
High vs. 
Intermediat
e 
0.68 
(2.24) 0.7595 
-2.64 
(1.92) 0.1711 
1.06 
(2.75) 0.6998 
-1.36 
(1.87) 0.4672 
-5.55 
(2.29) 0.0155 
1.89 
(1.87) 0.3126 
-0.38 
(2.16) 0.8588 
-0.96 
(1.87) 
0.607
4 
Surgery 
(Yes vs. 
N0) 
-4.9 
(1.99) 0.0138 
-7.01 
(1.73) 
<.000
1 
0.88 
(2.57) 0.7307 
-1.79 
(1.66) 0.2799 
-10.07 
(2.21) 
<.000
1 
-0.64 
(1.71) 0.7101 
-0.94 
(1.98) 0.6372 
-2.23 
(1.73) 
0.198
0 
Radiothera
py (Yes vs. 
No) 
1.82 
(1.68) 0.2783 
-0.39 
(1.48) 0.7948 
7.03 
(2.11) 0.0009 
-1.37 
(1.39) 0.3219 
-2.72 
(1.85) 0.1432 
1.62 
(1.42) 0.2517 
0.39 
(1.64) 0.8109 
3.53 
(1.44) 
0.014
6 
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Table 4-45. (Continued) 
 
  
Pain and Hurt Nausea 
Procedural 
Anxiety 
Treatment 
Anxiety Cancer Worry 
Cognitive 
Problems 
Perceived 
Physical 
Appearance 
Communica-
tion 
Factor  
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
B 
(SE) P 
Diagnosis 0.0330 
<.000
1 0.0067 0.1431 
<.000
1  0.0805  0.8796  0.2209 
ALL vs. 
AML 
-0.86 
(2.81) 0.7586 
4.09 
(2.42) 0.0914 
2.73 
(3.47) 0.4318 
1.48 
(2.3) 0.5199 
5.68 
(2.96) 0.0553 
-4.52 
(2.32) 0.0515 
-2.54 
(2.71) 0.3497 
-1.43 
(2.41) 0.5529 
ALL vs. 
HL 
-1.23 
(1.84) 0.5031 
3.93 
(1.59) 0.0135 
-7.41 
(2.34) 0.0016 
3.09 
(1.53) 0.0432 
7.99 
(2) 
<.000
1 
-3.62 
(1.57) 0.0210 
-0.19 
(1.82) 0.9179 
-3.1 
(1.6) 
0.0528 
 
ALL vs. 
MEL 
-9.46 
(4.53) 0.0371 
-10.98 
(3.86) 0.0045 
-5.78 
(5.6) 0.3018 
-3.08 
(3.69) 0.4050 
-2.87 
(4.79) 0.5482 
-6.3 
(3.75) 0.0930 
0.51 
(4.38) 0.9067 
-3.59 
(3.86) 0.3519 
ALL vs. 
OS 
3.94 
(2.2) 0.0742 
8.66 
(1.9) 
<.000
1 
-3.84 
(2.84) 0.1760 
3.12 
(1.84) 0.0907 
13.96 
(2.43) 
<.000
1 
-1.66 
(1.9) 0.3811 
0.57 
(2.21) 0.7963 
0.66 
(1.92) 0.7334 
Time 
<.000
1 
<.000
1 
<.000
1 
<.000
1 
<.000
1  0.0102  0.0160  
<.000
1 
T1 vs. T2 
-11.03 
(1.56) 
<.000
1 
11.49 
(1.29) 
<.000
1 
-12.12 
(1.45) 
<.000
1 
-7.02 
(1.18) 
<.000
1 
-2.76 
(1.3) 0.0341 
-1.33 
(1.07) 0.2131 
-0.42 
(1.27) 0.7406 
-2.48 
(1.25) 0.0483 
T1 vs. T3 
-8.42 
(1.61) 
<.000
1 
9.69 
(1.34) 
<.000
1 
-16.35 
(1.5) 
<.000
1 
-8.08 
(1.22) 
<.000
1 
-5.42 
(1.34) 
<.000
1 
-2.48 
(1.1) 0.0251 
-0.94 
(1.32) 0.4751 
-5.44 
(1.3) 
<.000
1 
T1 vs. T4 
-15.24 
(1.65) 
<.000
1 
-3.94 
(1.37) 0.0040 
-21.84 
(1.53) 
<.000
1 
-9.84 
(1.25) 
<.000
1 
-10.16 
(1.37) 
<.000
1 
-3.48 
(1.13) 0.0020 
-3.53 
(1.35) 0.0089 
-8.59 
(1.32) 
<.000
1 
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Table 4-46. Multivariate model results investigating predictors of PedsQL-Cancer scores in the total sample 
 
  
Pain and Hurt Nausea 
Procedural 
Anxiety 
Treatment 
Anxiety Cancer Worry 
Cognitive 
Problems 
Perceived 
Physical 
Appearance 
Communica-
tion 
 Factor B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P B (SE) P 
Age 
(Child vs. 
Teen) 
8.39 
(1.65) <.0001 
2.45 
(1.46) 0.0930 
-18.64 
(2.03) <.0001 . 
4.68 
(2.05) 0.0228 
4.68 
(2.05) 0.0228  . 
-4.94 
(1.47) 0.0008 
Ethnicity 
(Other vs. 
White) 
-4.68 
(1.74) 0.0072 . . . .  . 
-4.23 
(1.7) 0.0130  . 
Risk 
Group . . . . .  .  .  . 
High vs. 
Low . . . . 
-2.47 
(2.7) 0.3600 
-2.47 
(2.7) 0.3600  .  . 
Diagnosis . . . . .  .  .  . 
ALL vs. 
AML . 
-0.55 
(2.42) 0.8198 . . 
3.15 
(2.91) 0.2798 
-4.32 
(2.34) 0.0656  .  . 
ALL vs. 
HL . 
0.06 
(1.79) 0.9725 
9 
(5.25) 0.0865 
5.4 
(1.58) 0.0006 
4.43 
(2.36) 0.0602 
4.43 
(2.36) 0.0602  .  . 
ALL vs. 
MEL 
-9.13 
(4.43) 0.0395 
-14.6 
(3.85) 0.0002 . . . 
-5.87 
(3.76) 0.1188  .  . 
ALL vs. 
OS . (.) . . (.) . . 
2.88 
(1.84) 0.1190 . (.) .  .  .  . 
Time . . . . .    .   
T1 vs. T2 -11.07 
(1.61) <.0001 
12.11 
(1.33) <.0001 
-12.26 
(1.47) <.0001 
-7.77 
(1.21) <.0001 
-0.61 
(1.55) 0.6957 
-0.61 
(1.55) 0.6957  . 
-2.09 
(1.29) 0.1063 
T1 vs. T3 -8.56 
(1.66) <.0001 
10.23 
(1.37) <.0001 
-16.46 
(1.52) <.0001 
-8.93 
(1.25) <.0001 
-2.45 
(1.59) 0.1236 
-2.01 
(1.13) 0.0742     
T1 vs. T4 -15.3 
(1.69) <.0001 
-3.39 
(1.4) 0.0155 
-21.99 
(1.55) <.0001 
-10.65 
(1.27) <.0001 
-7.06 
(1.62) <.0001 
-7.06 
(1.62) <.0001 
-3.85 
(1.34) 0.0043 
-8.26 
(1.35) 
<.000
1 
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Table 4-47. Model fit AIC values for PedsQL-Generic HRQOL domain scores 
 
 Diagnosis 
 ALL AML HL OS 
Domain Model AIC Model AIC Model AIC Model AIC 
Physical 
age*gender*race* 
risk*time 6387.8 age*time 2010.6 
age*gender*risk* 
time 6975.9 time 3472.6 
Emotional gender*risk*time 6292.6 risk*time 1949.7 gender*time 6969.4 time 3316.3 
Social   risk*time 1769.3 age*time 6445.2   
School age*risk 5568 race*risk*time 1610.8 gender*time 6445.2 time 2874.5 
Total 
age*gender*race* 
risk*time 5962.2 risk*time 1808.3 gender*time 5832 time 3156.6 
 
ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; HL: Hodgkin lymphoma; OS: osteosarcoma. 
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Table 4-48. Model fit AIC values for PedsQL-Cancer symptoms 
 
 Diagnosis 
 ALL AML HL OS 
Domain Model AIC Model AIC Model AIC Model AIC 
Pain and Hurt age*gender*race*risk*time 6685.8 time 1369.5 gender*time 5282.7 age*time 3156.6 
Nausea age*gender*race*risk*time 6685.8 age*time 1309.7 radiation*time 5161.6 race*surgery*time 3397.3 
Procedural 
Anxiety age*gender*time 6716.4 age*risk*time 1388.7 age*gender*time 5267.6 time 5092.5 
Treatment 
Anxiety age*race*time 6261.5 risk*time 1291.9 time 5092.5 surgery*time 3348.2 
Cancer Worry gender*risk*time 6427.1 risk*time 1308.2 age*gender*time 5143.3 age*time 3450.9 
Cognitive 
Problems age*risk 6278.1 risk 1230.4 age*time 4958.2 time 3187.8 
Perceived 
Physical 
Appearance gender 6586.7 time 1297.1 gender*race*time 5087.9 gender*time 3375.8 
Communication age*time 6516.9   risk*time 4981.6 age*time 3332.9 
 
ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; HL: Hodgkin lymphoma; OS: osteosarcoma. 
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CHAPTER 5.    DISCUSSION 
 
 
Our review of the literature suggests that this study represents the largest 
longitudinal study of HRQOL in children with cancer. This study has also identified 
many longitudinal trends in HRQOL that were not previously reported and demonstrates 
the differences in HRQOL between children under curative treatment and childhood 
cancer survivors and highlights the need to separate and make this distinction in future 
HRQOL research. The study has also identified new sets of symptoms that are most 
concerning to children through their treatment. The findings in this study will further 
improve research by identifying symptoms that are of most concern to children with 
cancer.  
 
The longitudinal trends of change in HRQOL have been poorly understood in 
many of the disease groups included in our study. Our study helps address some of the 
limitations that have been identified with longitudinal trends of HRQOL over time in 
children with cancer. Our study findings point to the dynamic nature of HRQOL in 
children with cancer as they go on through treatment. It also points to the need for 
specific interventions at certain times in treatment to achieve the highest impact on 
HRQOL of children with cancer. In addition, many factors that have been extensively 
measured in previous studies proved no effect, while other factors proved to be of high 
correlation to HRQOL in our sample. 
 
Our findings also identify certain characteristics that define patients with 
likelihood of lower HRQOL in general. Patients who are non-white, female, younger in 
age, on a higher risk arm of treatment have higher risk of developing lower HRQOL. 
Also, patients who are new to treatment report the lowest HRQOL. 
 
 
Aim 1 
 
Aim 1 was to identify longitudinal trends in HRQOL change in diagnostic groups 
of children undergoing curative cancer treatment.  
 
HRQOL varied across diagnostic groups and over time with a consistent trend of 
changing HRQOL over time in all diagnostic groups. Regardless of the diagnostic group, 
children reported poor HRQOL at the beginning of treatment (T1) followed by a decrease 
in HRQOL as children received cancer treatments (T2), improved HRQOL at later time 
points (T3) and a higher level in comparison to previous time points at the end of 
treatment (T4). Higher HRQOL scores on the PedsQL-Generic and PedsQL-Cancer 
indicated better outcomes and fewer problems with HRQOL domains, while lower 
HRQOL indicated more problems and worse HRQOL on these domains. While little 
information is provided by the available literature on the change in HRQOL over time in 
children undergoing active cancer treatment, our findings that demonstrate a dynamic 
change in HRQOL in response to time in treatment with improving HRQOL at the end of 
treatment are generally supported by previous literature.13,46,48,49  
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Another consistent finding across all diagnostic groups was the observation that 
social functioning remained the highest scoring domain throughout the entire treatment 
period. These results may be explained by the uniquely supportive environment and 
resources children being treated for cancer experience at SJCRH. Considering the nature 
of the hospital and the facilities that are not generally available at most treating hospitals, 
social functioning scores may not be as high in other institutions as was reported in our 
sample. Other factors may also support the high social functioning scores including the 
support children receive from their parents and family, and their community and school.  
 
Our subgroup analysis found that children with ALL presented with among the 
lowest HRQOL at the beginning of treatment that continuously improved throughout 
treatment. Children with ALL also had the longest duration of treatment among all the 
diagnostic groups (120-146 weeks) with the first data collection occurring at day 40 of 
chemotherapy. This likely explains the particularly low HRQOL at T1 for children with 
ALL considering the side effects experienced by the time the first HRQOL scores were 
collected. It is also of note that of the cancer-related symptoms, children with ALL also 
reported low scores for procedural anxiety, which can be explained by the younger age of 
these children in compared to the other diagnostic groups. 
 
 Children with AML reported low emotional functioning, a trend that was 
observed in other diagnostic groups as well. However, emotional functioning scores 
improved steadily and rapidly throughout treatment, eventually reached high scores at the 
end of treatment that were comparable to HRQOL in normal populations. As for 
symptoms, nausea was the lowest scoring (most troublesome) symptom early in 
treatment; however, at the end of treatment, pain and hurt symptoms was the one most 
troublesome, followed by cancer worry. Children with AML have about a 15% percent 
chance of developing a refractory or recurrent AML. They also have a high risk of 
developing multiple complications, which may explain the burden of thinking about the 
recurrence reflected in the cancer worry scores. 
 
 Children with HL reported comparable trends as to those reported across all 
diagnostic groups with high social functioning scores and lower emotional functioning 
scores at the beginning of treatment that improved steadily throughout treatment. Similar 
to the children with AML, they also had low physical functioning scores during treatment 
and at the end of treatment. Nausea was the most troublesome cancer-related symptom 
that displayed abrupt improvement especially at the end of treatment. However, the most 
troublesome symptom at the end of treatment was cancer worry. 
 
One understudied group of patients is children with melanoma. Our review did 
not identify any previous studies that measured HRQOL outcomes in children with 
melanoma. Melanoma is typically an adult onset disease, thus, little information exists on 
the HRQOL of life in children with melanoma. Children with melanoma also receive 
different treatments than other childhood cancer groups. The use of biological response 
modifiers like Interferon-α in melanoma have been reported to affect adults with 
melanoma.33 However, our small group of children with melanoma generally reported the 
highest HRQL outcomes across diagnostic groups at all time-points. These responses 
 100 
provide an insight into the general tolerance of melanoma treatment in adolescents with 
cancer (15 out of 23 participants in the melanoma group were adolescents). It can also be 
the result of different outcomes and symptoms of melanoma treatment (skin changes) that 
were not recorded or measured using our instruments.  
 
The lowest HRQOL scores across all domains and symptoms were reported 
among children and adolescents with osteosarcoma (OS). While HRQOL improved 
abruptly over time in children with osteosarcoma, it remained well below the score of 80 
which is considered to represent an average HRQOL score for a healthy child. The lower 
HRQOL score for children with osteosarcoma has been previously reported.48 Children 
with OS undergo considerable and extensive therapies including extensive surgery and 
chemotherapy. These treatments impact HRQOL during treatment and may explain the 
change in HRQOL over time in children with osteosarcoma. It is also of note that even at 
the end of treatment; the OS group reported lower HRQOL scores than the other groups 
included in this study. This trend of lower HRQOL may be explained to an extent by 
some of the moderating factors that were included in this study, most specifically surgical 
intervention in the form of limb amputation or limb-sparing procedures. These surgical 
interventions can be severe and result in multiple complications and may include 
permanent loss of limb and physical function that affect the child’s physical and 
emotional functioning early in treatment and into survivorship. Previous studies have 
found children who underwent either limb sparing or amputation reported no significant 
differences between either procedures in terms of HRQOL outcomes.79 Our analysis of 
HRQOL in children with osteosarcoma found similar results, with no noted differences in 
HRQOL between children on the two surgical procedures. However, this outcome has 
been reported to change as children with osteosarcoma progress into survivorship, with 
evidence suggesting limb-sparing procedures offer higher HRQOL outcomes for 
survivors of lower-limb osteosarcoma in comparison to survivors with amputations.80 
The effect of surgery during osteosarcoma treatment can be especially significant in 
adolescents who have lower self-image secondary to these procedures.3,81,82 
 
 
Aim 2 
 
Aim 2 was to identify the differences in HRQOL among different diagnostic 
groups of children undergoing curative cancer treatment. 
 
Across diagnostic groups and over time, multiple variations in self-reported 
HRQOL were observed. These variations were captured through the different domains 
that were measured using the PedsQL-Generic and PedsQL-Cancer scales. While some of 
the variations over time reflected a consistent trend of change across all diagnostic 
groups, other domain scores reflected specific issues with a particular diagnostic group in 
comparison to the other groups.  
 
 A noticeable low scoring domain across all diagnostic groups over time was the 
physical functioning domain. However, certain groups, children with osteosarcoma in 
particular, reported significantly lower physical functioning scores than other groups. 
 101 
This could be inferred to be a result of the intensive therapies that children with 
osteosarcoma receive. However, physical functioning significantly increased by the end 
of treatment (for T4) for all diagnostic groups with the exception of melanoma. 
Improvement likely reflects the decreased effects of intensive treatments as children 
approach the end of their treatment. The importance of physical functioning as a domain 
of HRQOL has been extensively covered in literature;13,74,83,84 however, our study points 
to the considerably low physical functioning scores for children with osteosarcoma, in 
particular; a trend that relates to severe pain and limited mobility in children with 
osteosarcoma.15,51 This trend also points to the need to assess and support interventions 
that may enhance physical activity, control pain, and improve physical functioning and 
mobility for these children.84  
 
 Emotional functioning was relatively higher than other domains throughout 
treatment. It was lowest in children with osteosarcoma and highest in children with 
melanoma at the beginning of treatment (T1). At the end of treatment (T4), children with 
AML reported the highest emotional functioning scores, while children with 
osteosarcoma reported the poorest emotional functioning score throughout treatment.  
However, in all diagnostic groups except for children with melanoma, emotional 
functioning improved significantly at the end of treatment in comparison to the beginning 
of treatment. Children with melanoma reported a non-significant decrease in their 
emotional functioning scores at the end of treatment (T4) in comparison to the previous 
time points in treatment (T2,T3). Across all diagnostic groups, children with AML 
achieve the highest score increase in emotional HRQOL, adding 19 points at the end of 
treatment (T4) in comparison to the beginning of treatment (T1). This significant increase 
may reflect the emotional burden that children with AML experience at the beginning of 
their treatments and the support they receive from their families and care professionals 
throughout their treatment. It could also be due to the attrition of children with higher risk 
disease who may have relapsed or progressed and thus taken off the study. HRQOL data 
on these children were not included in this study.  
 
 Social functioning domain scores were reported as the highest HRQOL domain 
scores over time and across all diagnostic groups. The lowest social functioning score at 
the beginning of treatment (T1) was for children with osteosarcoma, while the highest T1 
score was for children with Hodgkin lymphoma. At the end of treatment (T4), children 
with osteosarcoma maintain the lowest social functioning score while children with AML 
report the highest scores. However, social functioning does not improve significantly 
over time in all diagnostic groups expect for children with Hodgkin lymphoma. This 
observation may reflect the consistent support from the family, community, and institute 
that children receive throughout their treatment.  
 
 In general, school functioning scores steadily increased over time across 
diagnostic groups. However, children with osteosarcoma reported the lowest school 
HRQOL scores across all diagnostic groups at T1 and T3. Only two groups, Hodgkin 
lymphoma and osteosarcoma, reported a significant increase in school functioning at the 
end of treatment (T4) in comparison to the beginning of treatment (T1). School 
functioning has been identified as a significant factor that affects HRQOL in children 
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with cancer. School attendance was correlated with higher HRQOL in children 
undergoing cancer treatment.57 Children undergoing curative cancer treatment, however, 
may find it difficult to maintain a regular attendance at school, which may explain the 
low school functioning scores. Hospital-based schooling programs may offer help for 
children to keep pace with their healthy peers at home, but such programs can be argued 
to support the social functioning domain rather than school functioning considering the 
wording of school functioning items on the PedsQL-Generic scales. Items related to 
school functioning in this scale include statements as “I miss school because of not 
feeling well” and “I miss school to go to the doctor or hospital”. Such items do not 
identify hospital-based schooling as a viable alternative to school and may thus lead to 
the lower school functioning scores as children do not identify their attendance at a 
hospital-based school program as a viable alternative to regular schooling. 
 
 Since cancer-related symptoms at the beginning of treatment were collected from 
only children with ALL and osteosarcoma, we should take care about drawing 
conclusions on the cancer-related symptom scores at the beginning of treatment. 
However, because most diagnostic groups generally report similar trends of change in 
cancer-related symptoms over the remaining time points, it is possible to draw inferences 
from the information on the two groups in regard to symptom scores. In general, the 
children in all diagnostic groups reported gradually increasing scores for cancer-related 
symptoms, with varying degrees of improvement at the end of treatment in comparison to 
the beginning of treatment for different diagnostic groups. This observation implies 
HRQOL trends at the beginning of treatment (T1) in the groups that did not report 
symptoms at T1 (i.e., Hodgkin lymphoma, AML, melanoma) that are relatively similar to 
the groups that did report symptoms (i.e., ALL, osteosarcoma).  
 
Pain and hurt was one of the most problematic cancer-related symptoms at the 
beginning of treatment and only three disease groups (AML, Hodgkin lymphoma, and 
osteosarcoma) reported significant improvement in pain and hurt scores. Children with 
melanoma and ALL reported no significant changes in pain and hurt scores at the end of 
treatment (T4) in comparison to the beginning of treatment. Children with ALL reported 
consistently low (poorer) pain and hurt scores that did not improve through their 
treatment, which also indicates substantial pain that is not relieved in children with ALL. 
The osteosarcoma group experienced the most significant improvement on pain and hurt 
scores following T1 before surgery, experienced a worsening in pain and hurt following 
surgery at T3, then improved at T4. This is likely a result of the improvement in pain and 
hurt following recovery from surgery after T3. However, even at the end of treatment 
(T4), children with osteosarcoma reported the second to lowest pain and hurt scores, 
indicating that while there was a substantial improvement, children with osteosarcoma 
experienced substantial pain even at the end of treatment (T4). Pain and hurt symptoms 
are widely reported and measured in children with cancer.82,85–87 The correlation of pain 
and HRQOL in children with cancer have also been identified previously.85 This study, 
however, adds new understanding to the variation in pain and hurt symptoms across 
different diagnostic groups and helps to identify groups with more severe pain symptoms, 
namely children with osteosarcoma and children with ALL. It also identifies other groups 
 103 
that may experience less pain symptoms, allowing researchers to identify target 
diagnostic groups for future intervention research.  
 
 The lowest symptom scores reported over time and across diagnostic groups were 
related to nausea. Nausea was also a symptom that significantly improved at the end of 
treatment (T4) in comparison to the beginning of treatment (T1) in all diagnostic groups 
except for children with ALL. In children with ALL, nausea decreases significantly at T2 
but did not recover to the baseline score at T1 even at the end of treatment (T4). While 
the experience of nausea and vomiting early in treatment is directly related to 
chemotherapy, the complaint of nausea even at the end of treatment in children with ALL 
and osteosarcoma can be explained by the experience of anticipatory nausea and 
vomiting. Anticipatory nausea and vomiting is a commonly studied phenomenon in adult 
cancers.88,89 Recently, more attention to this phenomenon in the field of pediatric 
oncology led to a set of guidelines to the management of anticipatory nausea and 
vomiting in children with cancer.90 However, little information is available on the 
prevalence and significance of this issue in children with cancer. Our study helps to 
identify a potential target population of children with ALL to measure this phenomenon 
and to design and implement future interventions to control anticipatory nausea and 
vomiting in children with cancer. 
 
 Procedural anxiety continuously improved over time in all diagnostic groups 
except for children with melanoma. In addition, all diagnostic groups except for children 
with melanoma reported a significant improvement (fewer problems) in their procedural 
anxiety scores at the end of treatment (T4) in comparison to the beginning of treatment 
(T1). Children with melanoma presented with a different trend than the other diagnostic 
groups included in this study. They reported a non-significant worsening (decreased 
scores) in their procedural anxiety scores at the end of treatment (T4) in comparison to 
the first time reported (T2). Children with melanoma also report more procedural anxiety 
at the end of treatment (T4) across all diagnostic groups. This particular trend in children 
with melanoma may require further examination into aspects of their treatment that may 
result in more procedural anxiety even towards the end of their treatment.  
 
 Treatment anxiety on the PedsQL-Cancer module was a reflection of three items: 
‘I get scared when I’m waiting to see the doctor’, ‘I get scared when I have to go to the 
doctor’, and ‘I get scared when I have to go to the hospital’. In general, children across all 
groups reported high scores (fewer problems) on this symptom. However, only 2 groups 
reported a significant improvement in treatment anxiety at the end of treatment (T4) in 
comparison to the beginning of treatment, namely children with ALL and children with 
osteosarcoma. However, this significance may be due to the availability of an additional 
time-point at the beginning of treatment for these two groups while other groups had no 
report on these symptoms at the same time-point. Additionally, across all diagnostic 
groups and all time points, children with osteosarcoma reported the lowest treatment 
anxiety scores, indicating more problems, at the beginning of treatment (T1). This 
observation may again be related to the significant effects of surgery on children with 
osteosarcoma early in treatment. Treatment anxiety has been previously reported as a 
factor affecting HRQOL in children with cancer,91 especially in adolescents.92 This 
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relationship of treatment anxiety with the adolescent age groups may explain the low 
treatment anxiety scores in children with osteosarcoma and Hodgkin lymphoma, two 
groups that tend to have a higher percentage of adolescents. 
 
 Cancer worry scores were lowest, indicating higher symptom burden, across 
diagnostic groups and over time in children with osteosarcoma at the beginning of 
treatment (T1). However, cancer worry scores improved in all diagnostic groups overall 
and significantly at the end of treatment (T4) in children with ALL, Hodgkin lymphoma, 
and osteosarcoma. Furthermore, cancer worry scores in children with osteosarcoma 
improved significantly at T2 in comparison to T1, indicating that the decreased cancer 
worry score at the beginning of treatment (T1) may be also related to the acute surgical 
resection that children with osteosarcoma undergo early in treatment. 
 
 Cognitive problems were stable over time except in children with Hodgkin 
lymphoma and osteosarcoma, where these outcomes improved significantly. The 
significant improvement in cognitive problems in children with Hodgkin lymphoma can 
be attributed to the effects of radiotherapy early in treatment. However, in all diagnostic 
groups, changes in cognitive problem scores were limited to a range of 5 points, a 
relatively narrow range in comparison to other symptoms measured in this study. This 
finding may be related to the long term nature of treatment effects on cognition and 
impact on children undergoing curative cancer treatment. It also may be a reflection of 
the continuous hospitalization of children that may lead to delayed assessment and 
recognition of cognitive problems outside of a school setting. 
 
 Perceived physical appearance was also a relatively stable domain that reflected 
continuous improvement over time, with the exception of children with melanoma who 
reported a non-significant decrease (worse symptoms) in these scores at the end of 
treatment (T4). This particular observation in children with melanoma may reflect a 
significant impact of treatments that may encompass issues beyond the domain of 
perceived physical appearance. It also calls for more research into this important trend in 
this group. Body image and perceived physical appearance have been previously 
identified as areas of concern in children with cancer, specifically in adolescents.93,94 Our 
study identified similar patterns of lower perceived physical appearance scores in 
adolescents and females. It also identifies children with melanoma, mainly composed of 
adolescents, as a group that may require further intervention and research into the 
perceived body image and physical appearance during and following treatment. We 
found no previous studies that attempted to measure and identify issues related to 
HRQOL or physical appearance in children with melanoma. This trend can be also 
related to the lower sample size which may result in inconsistent patterns of HRQOL 
change in children with melanoma.  
 
 Communication was also a relatively high and generally stable domain over time 
and across diagnostic groups. A significant increase in communication scores at the end 
of treatment (T4) in comparison to the beginning of treatment was found in children with 
ALL, Hodgkin lymphoma, and osteosarcoma. As was the case with other domains, the 
poorest communication scores across diagnostic groups and over time was for children 
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with osteosarcoma at the beginning of treatment (T1). This consistent trend of poorer 
scores for children with osteosarcoma at T1 may reflect the significant impact that a 
major surgical procedure has on HRQOL aspects and domains that extend beyond the 
physical functioning domain. 
 
 
Aim 3 
 
Aim 3 was to identify correlates with HRQOL of children undergoing curative 
cancer treatment over time within each diagnostic group. 
 
Consistent with our theoretical framework, multiple factors were identified as 
affecting the HRQOL in children across diagnostic groups and over time in treatment. 
These factors included time, diagnosis, age, gender, race, risk group, and surgery. Our 
study identified children who are females, non-white, older, on higher risk treatment, and 
early in treatment as the most vulnerable for lower HRQOL during treatment. The 
identification of vulnerable groups who are at most risk for poor HRQOL can help guide 
development of interventions targeting these population groups at an ideal time in 
treatment to achieve the highest potential benefit. 
 
 
Cancer Factors 
 
Factors associated with HRQOL were most often related to cancer diagnosis and 
cancer treatment. However, our review of literature found half the studies that measured 
cancer diagnoses found no effect on HRQOL, while the remaining studies varied widely 
in identifying specific diagnostic groups correlated with lower HRQOL. Some studies 
identified children with ALL as having a lower HRQOL while others linked solid 
tumors13 and osteosarcoma with the lowest HRQOL.15 This variation among studies is 
most likely attributed to lower sample sizes and different collection times in these studies. 
Our study specifically identified children in the osteosarcoma diagnostic group as 
reporting lower HRQOL.  
 
Cancer risk group or disease stage has been previously explored to identify 
treatment groups’ lower HRQOL.13 Patients assigned to higher risk groups have been 
associated with higher intensity treatments and poorer outcomes, which correlates with a 
lower HRQOL. Thus, cancer risk group is a known factor that affects HRQOL in children 
with cancer. This study identified diagnostic groups in which assigned higher risk groups 
were correlated with lower HRQOL, namely, children with ALL and HL. While our 
study found risk group to be an important determinant of HRQOL in children with 
cancer, our review found only one study that identified a significantly negative effect of 
risk on HRQOL.50  
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Treatment Factors 
 
Type of Treatment. No differences were found in HRQOL for surgical versus 
radiotherapy treatment. These findings are likely related to the small number of patients 
within our sample who received these treatments. Only children treated for OS had a 
surgical procedure and only children with HL received radiotherapy. In our review, the 
majority of studies that assessed the effect of treatment type measured HRQOL in a 
single diagnostic group, making it difficult to draw comparisons of the effect of treatment 
type on a heterogeneous sample of children with cancer. In general, radiotherapy was 
found to be the most common treatment affecting HRQOL in children7,53,95 and was 
exclusively measured in children with brain tumors. However, in our sample of children 
with HL there was no difference in HRQOL reported by those who received radiotherapy 
compared to those who did not. Radiotherapy for children with HL is widely varied based 
on the location and extent of disease. This variation in radiotherapy dose and location 
may result in less than definitive findings on the effect of radiotherapy on HRQOL in our 
sample. While our univariate analysis found children who received surgery reported 
lower HRQOL than children who did not receive any surgery, this finding did not hold up 
in the multivariate analysis and is further complicated by the fact that only the OS 
diagnostic group received surgical treatment. 
 
Time in Treatment. Time is perhaps one of the least understood factors affecting 
HRQOL in children undergoing curative cancer treatment. Most studies in our review 
assessed HRQOL in a cross-sectional manner at varying time points, making it difficult 
to draw conclusions on the change in HRQOL over time.39,40,50For example, some 
researchers measured HRQOL at the time of diagnosis15,16 whereas others chose a time 
point that was important for the particular diagnostic group under study.46,50,56 The 
variability in treatment modality, intensity, and timing among diagnostic groups also 
makes it difficult to draw comparisons or make assumptions regarding HRQOL across 
diagnoses. Our findings point to the importance of time in treatment as a significant 
variable affecting HRQOL in children undergoing curative cancer treatment and to the 
dynamic nature of HRQOL, calling for the need to likewise monitor HRQOL in a 
dynamic fashion whether in clinical settings or research trials. The results of our study 
further emphasize the need for future research that targets the most vulnerable 
populations at the time of their lowest HRQOL; which as our study found, differs for 
HRQOL domains, cancer-related symptoms, and by diagnostic group. The identification 
of these time-points may allow researcher to implement interventions at ideal time-points 
to achieve the highest potential benefit. 
 
While we believe a large degree of the variation in HRQOL over time can be 
explained by the symptom experience of children, other factors should be considered and 
evaluated in future studies. These factors include the qualitative experiences of children 
throughout their cancer experience, including domains that address the meaning of illness 
and cancer worry. These domains may prove to have a significant effect on the HRQOL 
in children later in treatment as they, their families, and their clinical care providers learn 
how to manage their symptoms and develop different perspectives of the cancer 
experience based on their unique experiences and the growth they underwent during this 
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experience.96 These domains form a framework that can help researchers understand the 
changing trajectory of HRQOL in children with cancer which would also benefit from the 
use of qualitative approaches that would enable deeper exploration of the children’s 
views of themselves and their lives in the context of the cancer illness experience.  
 
 
Symptoms 
 
Symptoms of cancer and cancer treatment have been recognized as driving the 
cancer treatment experience.97,98 This association was also reported in our study. 
Symptoms captured through the PedsQL-Cancer module demonstrate the degree to which 
children’s HRQOL experience is influenced throughout their cancer treatment. Nausea, 
pain, and painful procedures (procedural anxiety) were the most problematic symptoms 
across most diagnostic groups. These symptom experiences are generally related to the 
physical aspects of cancer treatment. These experiences were also reflected on the 
PedsQL-Generic module, where the physical domain was the worst domain of HRQOL. 
 
Nausea has been constantly reported as an important factor affecting the well-
being and HRQOL in children under cancer treatment for more than 2 decades of 
research on cancer symptoms in children.88,97 Nausea was specifically a troubling 
symptom for our study. In most diagnostic groups in our study, nausea symptom scores 
decreased significantly, indicating worse symptoms, during treatment and in some 
diagnostic groups did not recover to baseline scores at the end of treatment. This 
particularly troubling symptom for children undergoing cancer treatment may require 
innovative and timely interventions that extend beyond the scope of pharmaceutical 
interventions.90 Explanations of this finding include anticipatory nausea and vomiting, 
and non-compliance with nausea and vomiting treatment regimens. However, this 
particular symptom requires more attention from clinicians and researchers to identify 
possible cause and interventions to alleviate this experience in children undergoing 
curative cancer treatment.  
 
 
Child Factors 
 
Age was identified as a significant factor affecting HRQOL in our study. This 
finding is in contrast to many HRQOL studies that were identified in our literature 
review. Of the 16 studies that analyzed age in our review, 5 found lower HRQOL in 
adolescents (ages 13-18) compared to children (ages 5-12), an observation that was 
supported in our study. However, our study found variability in patient reported HRQOL 
across domains and symptoms according to age. Adolescents reported significantly lower 
HRQOL scores, except for social functioning and procedural anxiety, while children 
(ages 5-12) reported significantly lower scores on those domains. The variable effect age 
has on HRQOL makes it imperative that that this important factor be considered in 
studies examining HRQL in children undergoing cancer treatment. 
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Our study also identified significant differences between gender and patient 
reported HRQOL. Females reported significantly lower HRQOL than males across all 
diagnostic groups. While gender was a strong predictor of HRQOL in our study and is 
widely reported in HRQOL literature, only one quarter of studies in our review that 
measured gender identified this variable as a determinant of HRQOL in children with 
cancer.  
 
Ethnicity was significant in the ALL and OS diagnostic groups and only in the 
univariate analysis for the emotional and social domains. These findings should take into 
consideration the high ratio of white patients in comparison to other ethnic groups in our 
study. This trend seems to be consistent with our review of studies on HRQOL in 
children under curative cancer treatment;7,39,45 of which only one identified race as a 
significant factor affecting HRQOL in children with cancer.45 Figure 5-1 presents a 
modified theoretical framework that incorporates the results of our findings. In this 
framework, race was the only factor that was not supported by our study findings. 
 
 
Recommendations and Implications 
 
The findings from our study pose practical, theoretical, policy, and research 
implications on the field of HRQOL research in children with cancer.  
 
 
Research Implications 
 
This study provided evidence on the dynamic nature of HRQOL change in 
children undergoing curative cancer treatment. However, further research is needed into 
the impact of particular treatment modalities that were not supported by our study. While 
radiation therapy has been identified as an important factor affecting HRQOL in children 
with cancer, our study did not find a significant impact of radiation on the HRQOL of our 
sample. This may have been due to methodological and sample size considerations. The 
findings from this study also justify the need to devise and implement effective 
interventions to control and manage troublesome symptoms in children with cancer. 
 
 
Practice Implications 
 
A significant finding from our study was the identification of nausea as the most 
troublesome symptom in children undergoing curative treatment for cancer. This stands 
in contrast to clinical perceptions of nausea control using anti-emetic medications. Our 
study suggests that the subjective experience of nausea is not controlled despite the 
rigorous use of anti-emetics in pediatric oncology, or that protocols to address nausea and 
vomiting in children with cancer are not effectively implemented or followed. It also 
suggests that anti-emetic drugs are more effective in controlling the objective experience 
of vomiting, while playing a lesser role in controlling the subjective experience of 
nausea. This gap between clinicians’ perceptions of nausea control using anti-emetics and  
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Figure 5-1. Modified conceptual model of HRQOL in children with cancer 
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children’s perception of continuous nausea symptoms require an effort from researchers 
to identify effective interventions to control nausea. It also calls for educating clinicians 
on the need to use integrative therapies that can effectively control nausea in children in 
addition to the routine use of anti-emetics. Our review criteria for interventions to 
improve HRQOL did not identify interventions that may help alleviate nausea in children 
with cancer. However, older studies and literature from adult oncology have identified 
possible interventions to help alleviate nausea that may be applicable for children with 
cancer. These interventions include behavioral, non-pharmacologic, and other supportive 
measures intended to decrease the effect of nausea on children with cancer.99–103 
 
The findings of this study also support the need for a dynamic collection process 
of HRQOL in children undergoing curative cancer treatments. Our study identified the 
longitudinal nature of HRQOL outcomes over time in children with cancer. This finding 
supports the need for a dynamic process of HRQOL data collection that ensures prompt 
action from clinicians in response to HRQOL problems that may arise in children while 
undergoing cancer treatments. Many issues still impede a dynamic process of collecting, 
and promptly managing HRQOL issues and symptoms in children with cancer. These 
issues include the practicality and feasibility of collecting data during or prior to patients 
visits, the identification of significantly low HRQOL scores, and the integration of 
HRQOL outcomes into the medical record of patients. The current design of most 
HRQOL instruments in children with cancer requires researchers to go through multiple 
steps to generate a score for a child. These steps include reverse scoring the items and 
generating an average score for each domain separately in addition to a total average, and 
finally comparing the collected HRQOL scores to previous HRQOL reports to identify 
significant changes. Such lengthy process is time-prohibitive for clinicians, and poses a 
barrier to wider use of HRQOL outcomes in clinical decision making. Multiple steps 
have been proposed and implemented in order to address the prompt collection and 
reporting of HRQOL data. These steps include the use of electronic data collection 
methods (tablets, smart phones, computer portals). The use of such electronic data 
collection methods allow for the prompt collection of HRQOL, the comparison of 
HRQOL data collected to previous data reported by the same patient, and the prompt 
notification of any significant changes in HRQOL to the clinician before meeting the 
patient.  This would allow for prompt interventions by clinicians to address problems in 
HRQOL. 
 
Pain and hurt is another important symptom that was correlated with lower 
HRQOL and an important factor to be controlled for in these children. Related to the 
experience of pain was the experience of procedural anxiety. Many interventions can be 
introduced to alleviate the effects of painful procedures and as a result lead to better 
HRQOL for children undergoing cancer treatment. Such interventions include creative 
imagery, relaxation, and cognitive behavioral training.97,100,104 This study helps identify 
critical times in children’s treatment trajectory, early at the beginning of treatment and 
during periods of intensified treatments, where such interventions may prove to be 
helpful and effective in controlling cancer pain. 
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This study also identified low scores (more problems) of procedural anxiety in 
children (ages 5-12) with cancer. This finding calls for clinicians to take a more active 
role in better management and communication regarding painful and intensive procedures 
not just with the family, but also with children themselves. 
 
Future interventions by clinicians and researchers may be crucial to improve 
HRQOL outcomes in children with cancer. The identification of the persistent nausea and 
pain and hurt, in addition to procedural anxiety in children (ages 5-12) provide further 
evidence to support the need for more extensive and targeted interventions to address 
these symptoms in clinical settings and to communicate with patients regarding the 
expectations from these experiences. It can also help guide development of specific 
interventions to improve HRQOL at specific time points during treatment for specific 
diagnostic groups. Such targeted interventions would yield the highest impact on 
HRQOL for each respective diagnostic group.  
 
 
Theoretical Implications 
 
 Our conceptual framework was sufficient to identify the factors that are important 
for HRQOL in children with cancer. In this study, we have presented child factors as a 
separate domain of HRQOL in children with cancer, including gender and age. The 
findings from our study support the notion of designating child factors as a separate 
domain that affects HRQOL in a moderating capacity. The findings from this study also 
support the future use of our conceptual model in HRQOL research in children with 
cancer and possibly other chronic conditions as well. 
 
 
Policy Implications 
 
This study also presents the need for institutional policies to collect HRQOL 
outcomes as an important measure of the illness experience of children undergoing 
curative cancer treatment, and the need for a dynamic data collection policies that ensures 
children report their HRQOL consistently over time throughout their treatment, and that 
these outcomes are considered in the clinical decision making process.  
 
These policies can be achieved through institutional commitment and with the 
help of modern technological advances to collect HRQOL data and other patient-reported 
outcomes during routine clinic visits. It also may include policies to encourage clinicians 
to discuss HRQOL outcomes during clinic visits and devise plans to control these 
outcomes. Furthermore, effective institutional policies to manage and control subjective 
experiences like nausea, pain and hurt, and procedural anxiety are needed to improve 
children’s HRQOL. 
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Limitations 
 
Results of our study should be considered in the context of several factors that 
may limit their validity. These limitations include methodological, measurement, and 
conceptual aspects surrounding the conduct of the study. 
 
 
Methodological Limitations 
 
An important limitation was related to the utilization of multiple treatment 
modalities and intensities used to treat diagnostic groups and even within the same 
diagnostic groups for different risk stages. The wide variation of treatments and 
intensities may have affected the comparisons between diagnostic groups in this study. In 
addition, the variations in durations of treatment regimens across diagnostic groups, 
ranging from few months to few years, may have affected studying findings. The 
combination of varying treatments and duration of treatments presented a significant 
impediment to quantifying and comparing the change in HRQOL over time within and 
across diagnostic groups as well as the trajectories of HRQOL over time. As a result, it 
may be difficult, within the boundaries of our study, to distinguish between the effects of 
treatment factors, and the effect of diagnosis on HRQOL. 
 
Additional methodological issues including the attrition of subjects as they 
progressed through treatment, or as they were lost to follow-up may also have affected 
our understanding of the change in HRQOL during the trajectory of treatment.24,105 Based 
on our experience, a considerable fraction of this attrition is due to disease relapse or 
progression. Thus, the results of HRQOL data at the end of treatment may best reflect the 
experience of healthier and better responding patients who were able to successfully 
complete treatment on their primary regimen.  
 
“Response shift” or the changing standard for HRQOL that is believed to often 
occur when individuals are faced with life-threatening conditions is another factor that 
may have influenced our study findings. Although design and statistical approaches exist 
to control for this issue,106 these approaches would have been beyond the scope of the 
current study. 
 
Response set by the child may have also affected our results, meaning that young 
children tend to respond in a consistent way, regardless of the question.107 This can 
include responding with the intent to please the interviewer, or answering questions they 
do not understand in order to appear competent. Some children also show a tendency to 
provide repetitive responses, or to report extreme responses to questionnaires, especially 
in measurement scales that use the same scaling system for all items.108 This study 
involved previously collected data, which did not allow us to address these address these 
methodological issues. However, the data were originally collected by experienced 
research nurses trained to recognize common child response sets and guide the child and 
parent to carefully examine their responses to avoid such patterns. 
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A final confounding methodological issue was related to the optional participation 
in this study. This could have resulted in loss of patients who were experiencing lower 
HRQOL than their peers who agreed to participate. However, data indicated that most 
patients who were eligible to participate in the study did in fact consent and participate. 
The study did not include any invasive measures and posed no potential harm to the 
patients. 
 
 
Measurement Limitations 
 
HRQOL instruments are categorized as generic, disease-specific, or modular. 
Generic measures allow for comparisons between different groups of children, such as 
between children with cancer and children in the general population. Usually, population 
norms are available to facilitate the interpretation of results. These measures are 
generalizable, but may not adequately address symptoms important to patients with 
cancer, and may not be responsive to disease-specific interventions. In contrast, disease-
specific tools are more likely to be responsive to disease-related changes in HRQOL but 
do not facilitate comparisons between children with and without cancer. Several 
instruments have been developed and proposed for assessing HRQOL in children with 
cancer.66,71,72,109,110 Our study utilized the most frequently used generic and cancer-
specific instrument in childhood cancer studies. However, these instruments as with all 
other HRQOL instruments fail to measure many domains that affect HRQOL in 
particular diagnostic groups or for particular types of treatments.111,112 While we tried to 
achieve a better measurement of HRQOL in our sample by using both generic and 
cancer-specific modules, the variation in disease status and treatment modalities makes it 
difficult to draw conclusions on the differences between diagnostic groups of childhood 
cancer, or between children with cancer and the normal population of children.105,113 
Additionally, there is a lack of consistency and number of domains included in different 
instruments.24,66,114 These limitations can lead to questioning the relevancy of the final 
outcome measures to the actual HRQOL of patients;115 thus, presenting a challenge to our 
interpretations of the data and comparisons between disease groups. This limitation may 
be of importance to one particular group in our study, children with melanoma. Children 
with melanoma are treated with novel treatments that result in symptoms of skin scarring 
and malformation, which may have attributed to their decreasing perceived physical 
appearance scores over time. Children with cancer commonly experience symptoms that 
are not assessed by the HRQOL measures used in this research. This may have resulted in 
an incomplete picture of symptoms, symptom burden, and other aspects of the cancer 
experience that can affect HRQOL in children with cancer. 
 
 
Conceptual Limitations 
 
An important limitation to our understanding of HRQOL lies in the lack of a 
consensus on a conceptual framework to guide the understanding and study.24 This is an 
issue that can explain the wide variation in items and domains that are included in 
HRQOL scales. This lack of conceptual clarity which may have affected the validity of 
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findings could be explained in part by the differences in defining HRQOL, as an 
expression of functional abilities and performance,116 or as a measure of values and 
preferences,22,112,117 with more studies in the field of childhood cancer approaching it as a 
function of perception.66 While many models have been proposed for HRQOL in the 
adult oncology population, a literature search provided no evidence of a HRQOL model 
in the childhood cancer population. This study has attempted to design and utilize a 
conceptual model that adapts adult and pediatric frameworks while maintaining the 
emphasis on the perception of the child as a force that largely affects the final outcome of 
HRQOL in children with cancer. This conceptual framework was built to be compatible 
with the instruments that have been used in to monitor HRQOL in this clinical 
population. We believe that our revised conceptual framework was successful in 
identifying relevant factors of HRQOL in children with cancer and should be 
incorporated by researchers to address the conceptual and theoretical limitations of 
HRQOL research.  
 
 
Conclusion 
 
HRQOL is a dynamic phenomenon that requires close attention by the research 
and the clinical care community. Close, long-term follow-up and longitudinal research 
are needed to monitor the trends and changes that new treatment modalities and regimens 
offer to the general illness experience of children with cancer. This will allow clinicians 
and researchers to provide timely and effective interventions to address and improve 
HRQOL issues and symptoms in children undergoing curative cancer treatment.  
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APPENDIX A.  PEDSQL MODULES AND SCORING 
 
 
? The PedsQL-Generic Core Scale age-specific modules are available on the 
following link: 
 
http://www.proqolid.org/content/download/11861/176794/version/1/file/RC_Peds
QL-4.0-Core-All_AU4.0_eng-USori.pdf 
 
? The PedsQL-Cancer Scale age-specific modules are available on the following 
link: 
 
http://www.proqolid.org/content/download/11814/176655/version/1/file/RC_Peds
QL-3.0-Cancer-All_AU3.0_eng-USori.pdf 
 
? The scoring manual for the PedsQL-Generic and PedsQL-Cancer scales is 
available on the following link: 
 
http://www.pedsql.org/PedsQL-Scoring.pdf 
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APPENDIX B. IRB APPROVALS 
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APPENDIX C. PEDSQL USER-AGREEMENT 
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